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The small molecule 5-hydroxytryptamine (5-HT) is best known as a 
neurotransmitter, yet it has many other functions. 5-HT has been found in many areas 
of the body and plays a role in many physiological and pathophysiological 
mechanisms. The 5-HT molecule acts both as a ligand for the 5-HT receptor family, 
comprised mainly of G protein-coupled receptors (GPCRs), and as a metabolic 
precursor of melatonin. The 5-HT1B receptor, currently a pharmacological target for 
treating migraines and cluster headaches, has been heavily studied, and its structure 
has been elucidated. However, the N-terminus of the receptor, which was truncated to 
obtain the receptor's crystal structure, was thought to be noncontributing to the ligand's 
action on the receptor. In this thesis, I showed that for the human 5-HT1B receptor, the 
N-terminus's glycans modulated the potency of 5-HT by over 20 fold, potentially via a 
fly-casting-like mechanism. The N-terminus captures 5-HT from the surrounding 
environment and relocates it closer to the receptor's binding site. 
Additionally, it was shown that this is a property of the primary amine functional 
group of 5-HT. The potencies of other agonists, sumatriptan and dihydroergotamine, 
were not affected by the removal of the N-terminal glycans of the receptor. While this 
receptor was hypothesized to be located in the human myoblast, it was not found in 
this work. However, the other 5-HT linked receptors 5-HT2A and 5-HT2B, along with the 
5-HT transporter SERT, were found to be expressed in immortalized human myoblast 
by Western blot analysis. In conjunction with a proliferation assay and a proteomic 
profiler assay, it was shown that 5-HT is involved in increasing myoblast numbers in 
culture over time. The proteomic profiler further hinted that proliferation might be 
triggered via the MAP kinase, the mTOR, or the Wnt pathways. It is clear from this 
work that 5-HT is involved in the skeletal muscle's metabolism, warranting further 
study. Together these works, on the 5-HT1B receptor and the identification of the 5-HT 
pathway in human skeletal muscle, provide information that can lead to the generation 
of more specific pharmacologics, lead to better treatments in skeletal muscle injuries, 





Abbreviation Full Name 
5-HIAA  5-hydroxyindoleacetic acid 
5-HT  5-hydroxytryptamine; Serotonin 
5-HTP  5-hydroxy-L-tryptophan; Oxitriptan 
5-MIAA  5-methoxyindoleacetic acid 
AADC  L-amino acid decarboxylase 
AANAT  aralkylamine N-acetyltransferase 
AC  adenylate cyclase 
AChE  acetylcholinesterase 
ADHD  attention deficit hyperactivity disorder 
AKT  RAC-alpha serine/threonine-protein kinase 
ALDH2  aldehyde dehydrogenase 
ALS  amyotrophic lateral sclerosis 
AOFA  amine oxidase [flavin-containing] A 
AOFB  amine oxidase [flavin-containing] B 
AOXA  aldehyde oxidase 
ARR  arrestins 
ASMT  acetylserotonin O-methyltransferase 
cADP  cyclic adenosine diphosphate 
cAMP  cyclic adenosine monophosphate 
cAMPK α2  5'AMP-activated protein kinase subunit alpha 2 
CD11c  integrin alpha X 
CD86  cluster of differentiation 86 
CGenFF CHARMM general force field 
CHARMM chemistry at Harvard macromolecular mechanics 
CP1A1  cytochrome P450 1A1 
CP1A2  cytochrome P450 1A2 
CP1B1  cytochrome P450 1B1 
CREB  cyclic AMP-responsive element binding protein 
CYPIID6  cytochrome P450 2D6 
CV collective variables 
DAG  diacylglycerol 
DAMP damage-associated pattern 
DHE dihydroergotamine 
DM double mutant 
DMDF damage-myofiber-derived-factor 
ERK1/2  mitogen-activated protein kinase 3 /1 
ERK5  mitogen-activated protein kinase 7 
FDA The United States Food and Drug Administration 
FGF fibroblast growth factor 
FOXO4  forkhead box protein O4 
G-protein guanine nucleotide-binding protein 
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Abbreviation Full Name 
GAPS GTPase accelerating proteins 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
GENCI grand équipement national de calcul intensif 
GID  gastrointestinal disorders 
GPCR  G protein-coupled receptor 
GRK  G protein-coupled receptor kinase 
GSK-3α/β  glycogen synthase kinase-3 alpha/beta 
GTP guanosine triphosphate 
HGF hepatocyte growth factor 
HIAL  5-hydroxyindoleacetaldehyde 
HPC high performance computing 
Hsp27  heat-shock protein beta 1 
I23O2  indoleamine 2,3-dioxygenase 2 
IDPR intrinsically disordered protein region 
IDRIS Institut du développement et des ressources en informatique scientifique 
IGF-1 insulin-like growth factor I 
IL-6  interleukin 6 
IL-17  interleukin 17 
INMT  indolethylamine N-methyltransferase 
IP3  inositol 1,4,5-triphosphate 
IPF  idiopathic pulmonary fibrosis 
JAK janus kinase 
LB  lysogeny broth 
LCK  lymphocyte-specific protein tyrosine kinase 
LEF  lymphoid enhancer-binding factor 
LGICs  ligand-gated ion channels 
LINCS linear constraint solver 
LYN  lck/yes novel tyrosine kinase 
MAT monoamine transporters 
MD molecular dynamics 
MDD  major depression disorder 
MetaD metadynamics 
MEK5  dual specificity mitogen-activated protein kinase 5 
MPO  myeloperoxidase 
mTORC1  mammalian target of rapamycin complex 1 
Myf-5 myogenic factor 5 
Myf-6 myogenic factor 6 
MYOD  myoblast determination protein 
MYOG myogenin 
NDD  neurodegenerative disorders 
p70S6K  ribosomal protein S6 kinase beta-1 
Pax-3 paired box protein 3 
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Abbreviation Full Name 
Pax-7 paired box protein 7 
PbMetaD parallel bias metadynamics 
PFA  para-formaldehyde 
PFK  6-phosphofructo-1-kinase 
PIP2  phosphatidylinositol 4,5-bisphosphate 
PKC  protein kinase C 
PLCβ  phospholipase C, beta 
PLCδ1  phospholipase C, delta 1 
PLP  pyridoxal 5’-phosphate 
PMAT  plasma membrane monoamine transporter 
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
PRAS40  proline-rich Akt substrate of 40 kDa 
PSP  progressive supranuclear palsy 
Rab-3A  ras-related protein 3A 
Rab-4  ras-related protein 4 
Rab-27  ras-related protein 27 
RGS regulator of G protein signaling 
Rgyr radius of gyration 
RhoA  ras homolog gene family, member A 
RPS6  ribosomal protein S6 
RT  room temperature 
SC satellite cell 
SERT  serotonin transporter 
SM  skeletal muscle cell growth medium 
SNAT  serotonin N-acetyltransferase 
SOM Self-organizing map 
Spry-1 protein sprouty homolog 1 
STAT  signal transducer and activator of transcription 
STAT  signal transducer and activator of transcription 
SUM sumatriptan 
TAS2 taste receptor type 2 
TCF  transcription factor 
TIP3P transferable intermolecular potential with 3 points 
TPH1  tryptophan hydroxylase 1 
TPH2  tryptophan hydroxylase 2 
VMAT  vesicular monoamine transporter 









The small monoamine 5-hydroxytryptamine (5-HT) is best known as the 
neurotransmitter serotonin. However, 5-HT is involved in many physiological 
processes, from bacteria to mammals. Receptors and other proteins involved in 5-HT 
biological processes are often targeted for pharmaceutical intervention. Infamously, 
serotonin-reuptake inhibitors (SSRI) are used to treat depression and other psychiatric 
pathologies. Additionally, the serotonin receptors are targeted to treat other conditions 
such as migraines, obesity, and constipation. 
 
Unpublished data from the Experimental Neuropathology Unit at the Institut 
Pasteur, where the experimental data for this thesis was performed, indicated that 
treatment of mice with the SSRI inhibitor fluoxetine increased post-lesional skeletal 
muscle regeneration efficiency. It was hypothesized that an increased amount of 
extracellular 5-hydroxy tryptamine (5-HT) in muscle was responsible for these 
observations. Hence, an investigation into the 5-HT receptors present in murine 
muscle was instigated. Data from qPCR experiments indicated active transcription of 
the gene coding for the 5-HT1B receptor in the tissue. The expression of the receptor 
was confirmed via Western blotting of whole murine skeletal muscle. It was observed 
in the Western blot that the bands for 5-HT1B presented broad and were running at a 
higher molecular weight than theorized. We gathered that the higher running of the 
bands might be linked with post-translation modifications of proteins. Specifically, 
glycosylation has been identified to cause bands to run higher than expected.  
 
From our observations, we began to question whether 5-HT is involved in 
human skeletal muscle regeneration and whether the glycosylation of the N-terminus 
of the 5-HT1B receptor has functional importance. We theorized several 5-HT1B 
receptor versions were present in this tissue due to the band's thickness on the western 
blot. Knowing that the N-linked glycosylation of a protein is dependent on the cell 
expressing the protein, we wondered if there was a significant variation of this receptor 
present in the tissue in our sample as there were multiple cell types present. 
Additionally, if the variations were present, we wondered if there were functional 
differences between the glycotypes. To get answers to these questions, we 
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investigated 5-HT in muscle proliferation and the function of the PTMs in the 5-HT1B. 
To get a molecular view of the interactions of 5-HT with 5-HT1B, we carried out in silico 
modeling of the interaction of the PTMs and specific domains of the 5-HT1B receptor 
with its ligands. The modeling was performed in the Structural Bioinformatics Unit at 
the Institut Pasteur. 
 
1.1 Historical perspective 
 
1.1.1 Discovery of Serotonin 
 
5-hydroxytryptamine (5-HT), serotonin, is an indole with an ethylamine at the 
three position and a hydroxide group at the five position (Figure 1.1). The compound 
5-HT is ubiquitous and has been found in Bacteria1, Eukaryota2, and proposed to exist 
in Archaea3. The high rate of conservation of 5-HT and its multi-functionality reflect its 
importance in life. The closer to metazoans one goes along the evolutionary tree, the 
more complex and ingrained the role of 5-HT becomes. A large amount of information 
is known about the role of 5-HT in humans. However, there is still much more to be 
discovered, including its involvement in human physiology or pathology. 
 
 
Figure 1.1. IUPAC Naming and numbering of serotonin. 5-hydroxytryptamine illustrated at 
physiological pH. 
 
5-HT was first discovered in 1937 by Vittorio Erspamer4. Erspamer purified 5-
HT, which he named "enteramine," from enterochromaffin cells. In 1948 the name 
"serotonin" was coined by Rapport et al. after they isolated a vasoconstricting 
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compound, 5-HT, from beef serum5. It was not until 1952 that Erspamer demonstrated 
that both enteramine and serotonin were the same molecule6. The following year in 
1953, 5-HT was discovered in the mammalian brain7. In 1954 5-HT was identified as 
the causative agent of the symptoms of carcinoid syndrome8. With the pinpointing of 
5-HT as the pathological agent, the work to determine how it functions mechanistically 
began.  
 
1.1.2 Discovery of 5-HT Receptors 
 
In 1957 two pharmacologically distinct 5-HT receptors were identified by 
Gaddum and Picarelli in the ileum of Guinea Pigs9. They termed the receptors as the 
M receptor and the D receptor. The names stem from one of the receptors being 
blocked by dibenzyline (the D receptor) and the other receptor by morphine (the M 
receptor). Today these two receptors are named 5-HT2 and 5-HT3, respectively. 
Gaddum and Picarrelli's discovery proceeded in the 1960s with the localization of 5-
HT receptors in rodents' brains. With the development of radio ligand binding assays, 
other areas of localization of 5-HT within the brain were demonstrated. In 1979 
Peroutka et al. showed that the brain had two separate 5-HT receptors and termed 
them as the 5-HT1 and 5-HT2 receptors. 
It took until 1984 for the first 5-HT receptor gene 5-HT1A to be cloned and 
identified. The identification of the 5-HT1A gene was followed by the identification of 
multiple 5-HT receptors throughout the 1990s, with the most recent being discovered 
in 2003. While the cloning of the specific receptors' genes did elucidate most of the 5-
HT receptors, it was not a straightforward process. The 5-HT1B receptor was initially 
thought to be only present in rodents. Due to its similarity in amino acid content (97 % 
shared) and a closely shared pharmacological profile (with the drugs available at the 
time) with the human 5-HT1D receptor, it was thought that the rodent 5-HT1B receptor 
was a homolog of the human 5-HT1Dβ receptor. At the time, it was believed that two 
subtypes of the human 5-HT1D receptor existed, 5-HT1Dα and 5-HT1Dβ. It was not until 
the rodent 5-HT1D gene was cloned that it was realized that 5-HT1Dβ was indeed a 
distinct receptor10. 
Eighteen receptors have been identified in the mouse or human genome and grouped 
by sequential homology into seven 5-HT family subtypes. The chronological discovery 
of the receptors' human genes except for the murine 5-HT5B gene, which is not found 
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in humans, can be found in Table 1.1. As the receptors' function was elucidated, some 
of the receptors were renamed to be grouped into the appropriate subfamily. As the 
receptors began to be identified, the work into defining their pharmacological profiles 
and their mechanistic actions started, and they continue to this day.  
 
Receptor Year Cloned Notes 
5-HT1A 198711,12  
5-HT1B 199213,14 Initially named 5-HT1Dβ 
5-HT1D 199115 Initially named 5-HT1Dα 
5-HT1E 199216 Not found in mice 
5-HT1F 199317  
5-HT2A 199018  
5-HT2B 199219 Initially named 5-HT2F 
5-HT2C 198820 Initially named 5-HT1C 
5-HT3A 199521  
5-HT3B 199922  
5-HT3C 200323  
5-HT3D 200323  
5-HT3E 200323  
5-HT4 199524  
5-HT5A 199425  
5-HT5B 199326 Not found in Humans 
5-HT6 199327–29  
5-HT7 199330–32  
 
Table 1.1. Chronological discovery of the 5-HT receptors genes. All of the genes are 






To better understand 5-HT receptors, one needs to understand the G-protein coupled 
receptor (GPCR) superfamily. All 5-HT receptors, except 5-HT3, belong to this 
superfamily. The GPCR superfamily contains over 70033 different receptors in humans 
alone and has been estimated to account for about 5 % of the human genome34. 
GPCRs are involved in multiple genetic diseases and cancers, Alzheimer's disease, 
atherosclerosis, neurodegeneration35, and others. The GPCR family is the largest 
pharmaceutical intervention target, with ~35 % of drugs on the market acting on a 
GPCR. All GPCRs fundamentally have seven transmembrane alpha-helices with an 
extracellular N-terminus and an intracellular C-terminus. Their structural similarities 
stem from an ancient common ancestor. 
 
1.2.1 GPCRs in nature 
 
GPCRs are found in most eukaryotic organisms, which can be attributed to the 
receptor's ancient origins. Even in bacteria, rhodopsin-like seven-transmembrane 
proteins are used to harvest energy from light and fix carbon36. In eukaryotes, the 
GPCR superfamily has evolved into five families. Each is structurally distinct from one 
other. Classically, all known GPCRs families are organized into six classes (A-F or 1-
6). The classes and their subfamilies names are listed in Table 1.2 below: 
Traditional Class Family Name 
A (1) Rhodopsin-like 
B (2) Secretin receptor family 
C (3) Metabotropic glutamate receptors 
D (4) Fungal mating pheromone receptors 
E (5) Cyclic AMP receptors 
F (6) Frizzled / Smoothened 
 
Table 1.2. Traditional Classification of GPCR families. GPCRs can be categorized into six 
different Classes A-F. 
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The GPCRs have been re-organized in vertebrates using the GRAFS 
(glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin) classification system37. 
The GPCRs are further subdivided within each of the GPCR classes into subfamilies.  
 
1.2.2 Structural and functional diversification 
 
The differentiation of GPCRs has been broad over time and is utilized by the 
human body to perform many functions. Each class of GPCR has a distinct functional 
mechanism. The rhodopsin class is the largest GPCR family containing 19 subfamilies, 
with most GPCR falling in this subfamily. This family also exists in the GRAFS 
organizational scheme as "R." The rhodopsin-like subfamilies vary significantly in what 
the receptors sense. The stimulating agent for the receptors are broad and include 
photons, lipids, peptides, stretch, and small molecules. Although they sense various 
ligands, all of the rhodopsin-like GPCR are similar in amino acid sequence38.  
The Class B or secretin family is the second most stratified GPCR family with 
three subfamilies. Secretin GPCRs respond to peptide hormones of the glucagon 
family. The B1 subfamily is composed of receptors recognizing traditional hormones 
such as glucagon and secretin. The B1 subfamily constitutes the secreting class in 
GRAFS. The "S," the B2 subfamily, is also known as the adhesion GPCRs and are 
characterized by an autocatalytic adhesion domain in their N-termini39. In the GRAFS 
system, this subfamily is considered a separate class and represents the "A," which 
stands for adhesion. The final subfamily, B3, consists of GPCRs found only in 
invertebrates.  
Going further, class C consists of metabotropic glutamate receptors involved in 
neurotransmissions. The mammalian receptors are deeper organized into three 
groups, 1-3. Glutamate receptors are the "G" family in the GRAFS hierarchy. The D 
class GPCRs, the fungal mating pheromone receptors, and the E class, the cyclic amp 
receptors, contain only a few members and are not found in human beings37. The final 
class, class F, consists of the Frizzled related receptors. This class comprises 11 
receptors, which are integrated into three main pathways involving the Wnt β-catenin, 
the calcium pathway, and the planar cell polarity pathway40. In the GRAFs 
organizational scheme, the Frizzle receptors are joined by the taster receptor type 2 
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(Tas2), from class A, to form the "F" in the acronym. The GRAFS classification scheme 
can be visualized in Table 1.3 below. 
 
GRAFS Class Family Name Traditional Class 
G Glutamate C 
R Rhodopsin A 
A Adhesion / Cyclic AMP receptors B2 / E 
F Frizzled / Taste-2 F / A 
S Secretin B1 / B3 
 
Table 1.3. GRAFS Classification of GPCR families. A more recently proposed scheme to 
categories the GPCRs of vertebrates.  
 
1.2.3 GPCRs in the human body  
 
GPCRs are found in many different forms and throughout the human body. 
GPCRs are involved in the body's ability to observe the outside world. Rhodopsin 
GPCRs in the retina allow for photons to be detected in the eyes. Taste and olfactory 
receptors on the tongue detect small molecules. Sensory neurons use glutamate 
GPCRs to communicate with each other41. In the cochlea, Frizzled GPCRs are used 
to maintain the polarity of hair cells for hearing42. The GPCRs diversity is reflected by 
the comprehensive utilization of them in the human body. The expansiveness of 




Figure 1.2. Phylogenetic tree of human GPCRs. The phylogenetic tree of the human GPCRs 
according to the GRAFS system. The families are color-coded, and the number of receptors 
in each family is displayed in parentheses after the family name. The gene names of the 
receptors are labeled in grey. The Rhodopsin subfamilies are labeled α, β, γ, and δ. Four 
examples represent the 422 olfactory receptors. The red star marks the 5-HT1B receptor. The 




1.2.4 Pharmaceutical targeting 
 
 Due to their wide dispersal throughout the body, the involvement of GPCR in 
disease and disease prevention is not surprising. The GPCR superfamily is the most 
pharmaceutically targeted receptor type. One hundred thirty-four of GPCRs are 
targeted by an estimated 700 approved drugs44. Over 200 non-olfactory GPCRs have 
not yet been pharmacologically targeted despite being potential therapeutic targets. 
Thus it's likely that the number of drugs acting on GPCRs will increase45. Examples of 
drugs that target most of the GPCRs can be seen in Table 2 in Annex I. 
 
1.2.5 Intercommunication/signal cross-talk 
 
 The structural similarities between GPCRs cause drugs to cross-talk with 
GPCRs of various subfamilies. Cross-talk is a significant concern during drug 
development and can potentially cause serious side effects. While a ligands' lack of 
specificity is a source for cross-talk, other factors must be considered when dealing 
with GPCRs, as cross-talk in GPCRs does not stop with the ligand of the GPCR. 
GPCRs have been reported to dimerize both in a homogenous and heterogeneous46 
fashion. While in vivo dimerization is still disputed47, synergistic effects from cross-talk 
between receptors and their interacting partners, for which heterodimerization is a 
likely explanation, have been reported48,49. GPCRs have also been known to indirectly 
interact with other types of receptors, especially tyrosine kinase receptors50. Cross-talk 
can also occur in the lower levels of the secondary messenger cascades that are 
triggered by GPCRs. The signals can amplify or inhibit the cascade either through 
direct inhibition on the activated enzymes51 or by regulating the GPCRs availability at 
the plasma membrane52. Cross-talk in GPCRs is poorly understood and can be very 
complex. However, due to GPCRs clinical and pharmacological significance, GPCR 
cross-talk is an area that needs further exploration. 
 
1.2.6 Relationships with arrestin/ GIRK /Spatial-temporal relation 
 
 In the canonical pathway, the GPCR is activated by its ligand or activating 
stimulus, driving the receptor to favor the active conformational state. The active state 
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of the receptor recruits the G protein complex. The receptor acts as a guanine 
nucleotide exchange factor (GEF), promoting the release of GDP and the binding of 
GTP to the Gα subunit of the G protein-GPCR complex. Upon GTP binding, the Gα 
and Gβγ subunits dissociate. The G protein subunits go on to activate secondary 
messenger pathways. The cytosolic domain of the GPCR is recognized by a G protein-
coupled receptor kinase (GRK), which phosphorylates the domain. The 
phosphorylated domain is identified by β-arrestins and, with adapter proteins’ help, 
initiate clathrin-based endocytoses. Thereby deactivating the receptor and recycling or 
destroying it. It is important to note that several canonical pathway variations have 
been observed, which differ based on the exact GPCR and G proteins involved in the 
pathway. 
 
1.2.7 G proteins 
 
 The guanine nucleotide-binding proteins (G proteins) in the GPCR complexes 
constitute a heterotrimeric protein complex that propagates secondary messengers 
upon activation. The G proteins consist of alpha, beta, and a gamma subunit. Each of 
the subunits have diversified over time and are found as various paralogs with different 
functions. To date, in humans, there are four families of Gα subunits made up of 18 
unique proteins, 5 Gβ subunits, and 12 Gγ subunits53. Additionally to the G protein 
subunits, another superfamily of G proteins exists. The small G-protein superfamily, 
monomeric GTPases, bind to and hydrolyze guanosine triphosphate (GTP) to 
guanosine diphosphate (GDP). The superfamily comprises the five families Arf, Rab, 
Ran, Ras, and Rho, consisting of over 150 members54. 
 The G protein subunits propagate a GTPase cycle. When dormant, the Gα 
subunit is bound to a GDP, the Gβγ complex, and in some instances with a GPCR. 
When a ligand or other activating stimulus activates the GPCR conformation, it acts as 
a guanine nucleotide exchange factor and promotes the Gα subunit to release the GDP. 
With the release of GDP, the binding pocket in Gα binds to GTP, which has a higher 
intercellular concentration than GDP55. The binding causes a major conformational 
shift in the switch I and switch II regions of Gα56, causing Gα to disassociate from the 
Gβγ complex and the GPCR. The separated G protein complexes regulate different 
secondary messengers such as cyclic AMP, IP3, and Ca2+. The Gα protein bound to 
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GTP is considered to be in its active state and binds to other proteins based on the 
particular Gα subtype. For example, GSα –GTP binds to adenylyl cyclase. The Gα 
subunit hydrolyzes the GTP to GDP, deactivating the subunit. The kinetics of 
hydrolyzation are impacted by proteins termed GAPS, GTPase accelerating proteins, 
which are a type of RGS, regulator of G protein signaling. GAPSs have been 
demonstrated to accelerate the hydrolysis of GTP to GDP by more than 103 times57. 
After the Gα subunit is rebound to GDP after hydrolyzation, the subunit rebinds to the 





1.2.8 Structural features of GPCRs 
 
 
Figure 1.3. A GPCR with various domains highlighted. The 5-HT1B receptor in blue nested in 
a field of lipids in tan by heteroatom coloring. The extracellular N-terminus is highlighted in 
cyan, and the intracellular C-terminus is marked in purple. The extracellular loops are colored 
in pink and intracellular loops are colored in dark green. Theoretical glycans on the N-terminus 
are colored in green by heteroatom coloring. 
 
Although a wide variety of GPCRs exist, the receptors maintain some standard 
features. GPCRs have seven transmembrane alpha-helices with three extracellular 
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and three intracellular loops. Generally, the N-terminus is extracellular, and the C-
terminus is intracellular. The receptors sit in the plasma membrane in a barrel shape, 
with the barrel's top being the entrance site to the active site (Figure 1.3). Each of the 
receptor's domains can be involved in the function of the GPCR, allowing for significant 
variation in the receptor's function.  
The extracellular loops and the N-terminus may play a role in the ligand's access 
to the active site. The N-terminus can have multiple functions. Including being a ligand-
binding site (as in the class C GPCRs), it can have an autoproteolytic site, acts as a 
dimerization site, or be involved in plasma membrane targeting. The extracellular loops 
may affect ligand-receptor interaction through electrostatics, regulate ligand access, or 
change the geometry of the seven-transmembrane barrel58. The intracellular loops are 
involved in binding arrestins, G-proteins, kinases, and scaffolding proteins59. The C-
terminus is heavily involved in the regulation of GPCRs. The C-terminus is involved in 
binding to the G protein heterotrimer, contains the target sites for GRKs and 
subsequent arrestins, and includes an area that anchors the lipid into the plasma 
membrane60. Many of the functions of these regions mentioned above are due to post-




The mechanosensation of GPCR is another of the many sensing mechanisms 
of these receptors. The observation of the direct involvement of GPCRs with 
mechanosensation is a recent development. Two receptor domains have been 
identified: the N-terminus61 and helix 8 near the C-terminus of the receptor62. The 
glycans attached to the β2 androgen receptor's N-terminus have been shown to sense 
traction forces and trigger β-arrestin signaling. Traction sense was confirmed when a 
chimera of the angiotensin II receptor, with a β2 adrenoreceptor N-terminus, was 
activated by traction force61. On the other end of GPCRs helix 8, a short alpha-helix 
between transmembrane helix 7 and the C-terminus has been shown to act as the 
receptors' mechanosensory region. In gain of function experiments, the addition of 
helix 8 from the mechanosensitive histamine H1 receptor to mechano-insensitive 
gonadotropin-releasing hormone receptor conferred agonist independent 
mechanosensing abilities. The helix, which lies on the intracellular side of the 
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membrane, was shown to be crucial to the sensing of force, as point mutations 
breaking the helical motif dampened mechanosensation. Through these experiments, 
it was suggested that helix 8 might act as constant force spring62. However, further 
work would need to be performed to confirm this theory. Mechanosensation appears 
to be another one of the many inputs GPCRs recognize and demonstrates that areas 
outside of the active site can stimulate the receptor. 
 
1.2.10 Intrinsically disordered protein regions 
 
While GPCRs are known for their seven-transmembrane helical structure, they 
also contain domains that do not have an ordered structure. In general, the intrinsically 
disordered protein region (IDPR) can be classified into the following five types of fold 
segments: foldons, unfoldons, non-foldons, semi-foldons, and inducible foldons. The 
IDPR can, respectively, spontaneously fold, unfold with an interacting partner, remain 
unfolded, maintained in a semi-folded state, or fold with an interacting binding 
partner63. These foldons are mostly observed in GPCRs in the non-transmembrane 
segments of the receptors. The IDPRs of GPCRs vary between the families of GPCR. 
They are primarily found in the N-terminus, intercellular loop 3, and the C-terminus of 
GPCRs64. At the familial level, the different GPCR IDPR patterns appear to reflect the 
variation of each GPCR family's overall structure. 
For the R or the rhodopsin family of GPCRs, the terminal residues and the loops 
between the transmembrane helices are generally unordered, except for helix 8. The 
extracellular loops, in general, have been associated with ligand binding and receptor 
activation. In comparison, the intracellular loops interact with the G-proteins and other 
GPCR binding partners65. The N-terminus IDPR is generally glycosylated with 
unverified consequences, and its involvement with ligand binding is unclear. The third 
intracellular loop that varies in length is usually an IDPR and a phosphorylation site. 
G-proteins and other kinases recognize the phosphorylated IDPR sites. The C-
terminus is palmitoylated, anchoring the C-terminus to the membrane and creating a 
4th intracellular loop. The 4th intracellular loop can also be phosphorylated. The C-
terminus IDPR region is recognized by β-arrestin and G proteins. The IDPRs of GPCRs 
allows multiple binding partners to interact with GPCRs in the receptors' various states. 
Unfortunately, the knowledge of IDPRs of GPCRs are only at the beginning of being 
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studied, and more work is needed to understand the roles of IDPR in GPCR signaling 
fully. 
 
1.2.11 Post-translational modifications of GPCRs 
 
GPCRs contain multiple PTMs of various types and with different functions. The 
receptors are glycosylated, phosphorylated, lipidated, and ubiquitinated (Figure 1.4). 
While some of the functions of the PTMs of GPCRs have been determined, many are 
still not understood. It is known that phosphorylation of the intracellular loops and the 
C-terminus is involved in recruiting binding partners of GPCRs. β-arrestins are one of 
these binding partners that recognize the multiple phosphorylation sites of the GPCR. 
The multiple phosphorylations of GPCRs have been said to occur in patterns with 
different functions and labeled by the term "phospho-barcoding." Based on the 
phospho-barcode, the GPCR-β-arrestin complex will be favored in a particular 
conformation leading to one of several outcomes66. The complex can desensitize and 
internalize the receptor or act as a scaffold for other kinase cascades such as the Raf-
MEK-ERK or ASK-MKK4/7-JNK complexes67. Due to phosphorylation leading to the 
desensitization and internalization of the receptors, these sites act as input points for 
other pathways to regulate GPCR activity68. Once internalized, the GPCRs may be 
adorned with another PTM, ubiquitin, leading to trafficking and the receptor's 
degradation. In addition to ubiquitination and phosphorylation, other PTMs also have 
diverse effects on GPCRs. 
The lipidation of GPCRs is predominately seen in the C-terminus of the 
receptors. Typically, the C-terminus is palmitoylated at a cysteine via a thioester bond. 
GPCRs have also been shown to be palmitoylated in the intracellular loops of the 
receptor69. The function of palmitoylation has been theorized to be two-fold. 
Palmitoylation has been suggested to be involved in receptor trafficking, and due to its 
transient nature, in signaling69,70. The signaling mechanism of GPCRs may stem from 
an induced tertiary shape. The palmitoylation of the C-terminus anchors the 
intracellular tail to the membrane, creating a fourth intracellular loop71. This fourth 
intracellular loop may be recognized by kinases that, in turn, phosphorylate the C-
terminus, leading to β-arrestin signaling.  
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 The effects of glycosylation on GPCRs are less well understood. Glycosylation 
has been observed to occur on the extracellular domains of GPCRs. The N-terminus 
and the extracellular loops, usually the second extracellular loop, can both be 
glycosylated. The purpose of the extracellular loops' glycosylation has been theorized 
to stabilize it and orient it away from the entrance to the binding pocket58. The function 
of glycosylation of the N-terminus has been studied more extensively. Removal of the 
glycosylation site in the N-terminus caused reduce surface expression in several 
GPCRs. These include the β2 adrenoceptor, angiotensin II type 1 receptor, and the 
melanocortin 2 receptor72. Additionally, N-terminus glycosylation's role is involved in 
the dimerization of β2 adrenoceptor73. While some knowledge has been acquired about 





Figure 1.4. Post-translational modification sites of GPCR. An example of post-translational 
modification was found on a Rhodopsin α GPCR. The N-terminus is often glycosylated, circled 
in red, and the C-terminus is mostly palmitoylated, circled in green. The third intracellular loop 
(ICL3) and the C-terminus are sites for phosphorylation and ubiquitination, in magenta and 
blue dashed oval. Extracellular loops are labeled as ECL, transmembrane helices are labeled 
TM, and intracellular loops are labeled ICL. 
 
1.3 5-HT Receptors  
 
 The receptors of 5-HT are composed of two different protein families; the G 
protein-coupled receptors (GPCRs) and the ligand-gated ion channels (LGICs). All of 
the subfamilies of the 5-HT receptors are GPCRs except the 5-HT3 family, which are 
LGICs. As to date, not counting isoforms, there are seventeen known 5-HT receptors 
in humans, twelve are GPCRs, and five are LGICs. All of the 5-HT receptors are found 
on the plasma membrane, and some have been found on the mitochondrial 
22 
 
membrane74. While named and grouped due to their response to 5-HT, the GPCRs 
and the LGICs receptors are very different. 
 
1.3.1 GPCRs - G protein-coupled receptors 
 
 The 5-HT GPCRs subclass GPCRA19 is composed of the 5-HT1, 5-HT2, and 5-
HT4-7 receptors. All of the GPCRA19 receptors follow a canonical pathway. Which 
canonical pathway the receptors follow is based on which G protein complex interacts 
with the specific receptor. The 5-HT1 and 5-HT5 receptors, coupled to the Gαi protein, 
inhibit adenylyl cyclase (AC) when the receptors are activated. For the 5-HT2 
subfamily, which interacts with the Gαq/11 G protein complex, phospholipase C beta 
(PLCβ) is stimulated during receptor agitation. The remaining subfamilies of the 5-HT 
receptors, 5-HT4-7, interact with the GαS protein, which leads to AC activation when the 
receptors bind to 5-HT. An example of the GPCR canonical action is illustrated in 
Figure 1.5A. Aside from their canonical functions, the 5-HT GPCRs also have some 
non-canonical functions.  
The non-canonical G protein signaling has been observed to act via β-arrestin 
recruitment. The recruitment of the β-arrestin proteins to GPCRs has been shown to 
lead to the desensitization75 and internalization of the receptors76. When the 5-HT 
GPCRs bind 5-HT and conform to the receptor's active conformation, GPCR kinases 
recognize the 5-HT GPCR and phosphorylate the receptor. The phosphorylated form 
of the 5-HT GPCR is identified and complexed by β-arrestin 1 or β-arrestin 2. The 
arrestins sterically block G proteins from binding to the 5-HT GPCR77. The 5-HT GPCR 
- β-arrestin complex can be recognized by clathrins, which have a high affinity towards 
the beta-arrestin76 complex, leading to the receptors' internalization via clathrin-
mediated endocytosis. Once internalized, the receptors are delivered to the sorting 
endosome. In the endosome, they are either further transported to the lysosome for 
destruction or end up back in the plasma membrane via the recycling endosome78 
(Figure 1.5B). Clathrin-mediated endocytosis is not the only way the receptors are 
internalized. Caveolae and dynamin-mediated endocytosis have also been described 
as an internalization mechanism of 5-HT receptors79. Internalization of the receptors is 
just one of the aspects which govern receptors surface density and may vary based 






Figure 1.5. Activation of 5-HT GPCRs canonical and non-canonical pathways. 
The canonical pathway (A): ① 5-HT binds to the 5-HT GPCR and induces a conformational 
change in the receptor (the exact conformational change is unknown, the structure of a ligand 
unbound 5-HT GPCR has not been solved). The G protein complex displaces the guanosine 
diphosphate (GDP). ② The G protein complex binds guanosine triphosphate (GTP) at the 
alpha subunit. ③ the G protein receptor complex dissociates. ④ The G protein alpha subunit 
binds to adenylate cyclase (AC). The formation of cyclic adenine monophosphate (cAMP) from 
adenine triphosphate (ATP) is catalyzed. The non-canonical pathway (B): ① and ② are the 
same as in A. After the G protein receptor complex dissociates ③, the GRK phosphatase 
recognizes the GPCR. ④ The G protein-coupled receptor kinase (GRK) phosphorylates the 
GPCR. The arrestins (ARR) recognize and bind the phosphorylated GPCR. ⑤ Along with 
adapter protein 2 (AP2), clathrins and other factors initiate clathrin-mediated endocytosis. ⑥ 
The clathrin coat sheds and ⑦ receptors are shuttled to the recycling endosome via the early 
endosome for further sorting. The receptors are ⑧ returned to the plasma membrane, after 
dephosphorylation and ligand removal, from the early or recycling endosomes. The receptor 
is alternatively ⑨ degraded in the lysosomes via the late endosome. 
 
In addition to internalization, the receptors' synthesis and degradation into the 
receptor surface density at the plasma membrane. Unfortunately, not much has been 
done in identifying the dynamics of the synthesis or degradation of the human 5-HT 
GPCRs. In rats, a limited amount of work has shown that the 5-HT GPCR surface 
density varies between 5-HT1A, 5-HT1B, and 5-HT2A. It was uncovered that the steady-
state of the surface density of the 5-HT GPCRs are governed by different total kinetic 
rates of synthesis and degradation. Additionally, it was discovered that this variation in 
rates is more significant between 5-HT receptor families than within interfamily 
subtypes80. Further work on the kinetics of the 5-HT receptors is needed to understand 
the overall function of 5-HT in the body. While kinetics differ, the similarity in the 
functions of the 5-HT GPCRs stems from their comparable tertiary structures. 
All 5-HT GPCRs have the same general structure. Additionally, the receptors 
have several conserved structural motives that are a hallmark of GPCRs; they include 
the DRY, NPxxY, and P-I-F motifs. The DRY motif contains a salt bridge between the 
D and R residues, which is indicative of the resting state of the receptor, which is 
broken when the receptor is in the activated, ligand-bound conformation. The NPxxy 
motif acts as a lever on the transmembrane helices. It is responsible for the G protein's 
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engagement and disengagement to the ligand-free and ligand-bound conformation of 
the receptor81. Finally, the P-I-F motif located at the bottom of the binding pocket is 
involved in the transmembrane helices' conformational movement during the activation 
of the 5-HT GPCRs when the ligand binds82. These structural motifs are illustrated in 
Figure 1.6. The structural similarities between the receptors and their known self-
interactions make it none too surprising that the various receptors may interact. 
 
Figure 1.6. A GPCR G protein complex demonstrating the common GPCR structural 
motifs. 
A truncated (residues 45-385) version of human 5-HT1B (390 a.a.) bound to the agonist 
donitriptan (red) and bound to the mini Go complex consisting of the truncated G protein 
trimeric heterocomplex of a modified Gαo subunit, and unmodified Gβ and Gγ. The 5-HT1B 
protein is in cyan, the Gαo subunit is in green, the Gβ subunit is in purple, and the Gγ subunit is 
in grey. The conserved GPCR motifs DRY, P-I-F, and NPxxy are in yellow, blue, and magenta, 
respectively. Arrows indicating the general direction of the 5-HT1B extracellular N-terminus and 
intracellular C-terminus are in cyan. Part of a transmembrane helix of 5-HT1B has been hidden, 
seen as dashed cyan marks, to aid in the visualization of the conserved motifs. The figure was 




It has been reported that these receptors dimerize both homogeneously and 
heterogeneously84–86. Even dimerization with other non-5-HT GPCRs such as the 
dopamine 2 long-form receptor87 has been shown. These interactions can lead to the 
receptors' regulation and open up the broader question of the roles of receptor interplay 
in the GPCR pathways. Some work has indeed shown that the 5-HT GPCRs regulate 
each other. The 5-HT1B receptor, when agonized with receptor-specific agonist, has 
been shown to cause the internalization of the 5-HT2B receptors52.  
 
1.3.2 LGICs - Ligand-gated ion channels 
 
The 5-HT3 subfamily is the only subfamily of the receptors that are LGICs. They 
are structurally similar to the nicotinic acetylcholine receptors and bear no resemblance 
to the 5-HT GPCRs. Due to their structural composition, they are classified with the 
cation-selective Cys-loop receptor family. The 5-HT3 receptors require a pentameric 
superstructure for the receptor to function88. The receptors exist in an inhibited, active 
closed, active open, and two intermediate states89. At rest, the receptors' pore is 
closed, and when 5-HT binds to the active closed receptor, the channel conforms to 
the active open state. The active open channel allows monovalent cations, such as 
sodium and potassium, and some divalent cations to flux into the cell. The drug 
tropisetron, given as an anti-nausea medication, was shown to stabilize the inhibited 
conformation of the receptor89. The receptors are known to be desensitized to 
activation by calcium cations90and 5-HT91, but the mechanism behind this is unclear. 
The work to elucidate these receptors' mechanisms is ongoing but may require the 




Although most of the 5-HT GPCRs are structurally similar, they have structural 
variance, allowing for the synthesis of receptor-specific ligands. Due to the structural 
similarities, many compounds have cross-reactivity with several of the 5-HT receptors. 
It is important to note that inter-species variation between the homologs of the 5-HT 
receptors can cause ligand action to be different between the species. It has been 
clearly demonstrated that in the 5-HT1B, a single variation in residue 355 (351 in rats) 
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between the human (T) and the rat (N) version of 5-HT1B causes the difference in these 
receptors' pharmacological profile. When the human 5-HT1B receptor was point 
mutated at T355N, the receptor became drastically sensitive to propranolol and 
desensitized to sumatriptan92. The interspecies and intraspecies similarities of the 5-
HT receptors provide a challenge. Their similarities must be kept in mind when 
designing and testing novel therapeutics. Many agonists and antagonists of the 5-HT 
receptors have cross-reactivity between the 5-HT receptors and even with other 
GPCRs. A list of human 5-HT subtype-specific agonists and antagonists is presented 
in Table 1.4.  
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Receptor Agonist Antagonist 
5-HT1A F-1559993, LY29328494 Robalzotan10 
5-HT1B L-694,24710* SB-21664195 
5-HT1D L-694,24710* BRL-15,57296 
5-HT1E BRL 5444397* N.S.M 
5-HT1F LY-33437010 N.S.M 
5-HT2A DOI98* 5-I-R9115099 
5-HT2B BW-723C86100* RS‐127445101 
5-HT2C CP‐80910193, WAY‐163909102 RS-102221103 
5-HT3A-E SR 57227A104 Tropisetron104**
5-HT4 GR-113808105 SB-204070106 
5-HT5A N.S.M SB-699551107 
5-HT5B N.S.M N.S.M 
5-HT6 WAY-208466108 SB-258585109 
5-HT7 AS19110 N.S.M 
 
Table 1.4. Available specific human 5-HT subtype receptor molecules.  
* Cross-reactive with other 5-HT receptors 
** Cross-reactive with the 5-HT3 subfamily 
N.S.M - No specific molecule available 
 
1.3.4 The PTMs of 5-HT receptors 
 
For a broader review of the PTMs of GPCRs, see section 1.2.11. 
 
While the secondary structure of proteins plays a substantial role in the final 
three-dimensional protein structure, other factors also contribute. In particular, PTMs, 
a covalent modification of proteins occurring after translation, are being discovered as 
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having an ever-expanding role in proteins' function. PTMs come in various forms, such 
as acetylation, phosphorylation, glycosylation, lipidation, sumoylation, serotonylation, 
and many others. PTMs are known to be involved in multiple functions, for example 
protein folding, cellular signaling, protein stabilization, protein destruction, membrane 
anchoring, and others. PTMs have been described in several families of GPCRs. In 
particular, some work was performed elucidating the role of glycosylation of the N-
terminus of GPCRs111–113. The glycosylation at the receptors' N-terminus has been 
described as involved in regulating expression, protein folding, and conformational 
state stabilization114. Several 5-HT receptors are known to have PTMs. In particular, it 
is known that phosphorylation, glycosylation, and lipidation all occur in the 5-HT 
receptors. More specifically, it has been shown that glycosylation can be found in the 
extracellular N-terminus.  
 When comparing the N-terminus amino acid sequences of all of the known 5-
HT receptors, the presence of putative glycosylation sites is observed in all of the 5-
HTR subfamilies (Figure 1.7). Of interest is that glycosylation can provide a source of 
structural variation of the receptor. This variation is based on the glycosylation program 
of the cell that is expressing the gene. This point of difference may be exploitable in 
drug design and may open up designing tissue-specific pharmaceuticals. It also draws 























Figure 1.7. Alignment of the N-terminus of all known human 5-HT receptors. Theoretical 
N-glycosylation sites (N-X-S/T) are highlighted in yellow. 
 




 5-HT is synthesized throughout the body, with a vast majority of it being 
synthesized by the gut's enterochromaffin cells. The next highest 5-HT synthesizing 
cells are the brain's neurons, with the remainder of the total 5-HT being produced by a 
variety of cells throughout the body. 5-HT is biosynthesized from the essential amino 
acid L-tryptophan via a two-step process. L-tryptophan is catalytically hydroxylated at 
position 5, becoming 5-hydroxy-L-tryptophan (5-HTP) via a tryptophan hydroxylase 1 
or 2 TPH1/2 enzyme, a biopterin (BH4) co-factor, a ferrous ion, and an oxygen gas 
molecule (see Scheme 1.1). This first step of the pathway is the rate-limiting reaction 
of the biosynthesis of 5-HT. Although this is the rate-limiting step of the reaction 
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generally, the enzymatic activity of TPH-1 is known to not saturate under normal 
physiological conditions115. 5-HTP is catalyzed further by aromatic amino acid 





Scheme 1.1. Human biosynthesis of serotonin at physiological pH. The two-step catalysis 
of serotonin (5-HT) from L-tryptophan (A). In the first step, L-tryptophan is catalyzed to 5-
hydroxy-L-tryptophan (5-HTP) by tryptophan hydroxylase 1 or 2, the coenzyme 
tetrahydrobiopterin (BH4), an oxygen molecule, and a ferrous ion. This reaction also yields a 
water molecule and a quinoid dihydropterin (qBH2) molecule. In the second step, 5-HTP is 
catalyzed to 5-HT and a CO2 molecule by the aromatic amino acid decarboxylase (AADC) 
enzyme and the coenzyme pyrisoxalphophate (PLP). The coenzyme reaction in the TPH1/2 




5-HT is metabolized further in the human body, generating many other 
compounds. One of the metabolites includes the sleep hormone melatonin. Melatonin 
is synthesized from 5-HT via a two-step mechanism. The serotonin N-acetyl-
transferase enzyme (SNAT) acetylates 5-HT at the primary amine to make the N-acetyl 
serotonin intermediate. Next, the acetylserotonin O-methyltransferase enzyme 
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(ASMT) methylates the hydroxide at the 5 position of the intermediate to make 
melatonin. Melatonin can be further metabolized into formy-N-acetyl-5-
methoxykynurenamine, and 6-hydroxymelatonin (see Scheme 1.2).  
Besides melatonin, 5-HT is also metabolized into 5-hydroxyindoleacetaldehyde 
(HIAL), formyl-5-hydroxy-kynurenamine, and N-methylserotonin. HIAL, which is 
catalyzed from 5-HT by the monoamine oxidase A or B enzymes (MAOA and MAOB, 
respectively), is further metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by the 
aldehyde oxidase 1 or aldehyde dehydrogenase 2 enzymes. Further, 5-HIAA can be 
catalyzed by the acetylserotonin O-methyltransferase enzyme to 5-
methoxyindoleacetic acid (5-MIAA)116–118 (See Scheme 2). The metabolites of 5-HT 
can be used to monitor the 5-HT levels in the body to help with clinical diagnoses. For 
example, to check for excess 5-HT in the body, a biomarker of carcinoid tumors and 




As 5-HT is utilized throughout the body, the control of its synthesis is important. 
The stability of 5-HT varies based on where in the body the molecule is located. It has 
been shown that in rabbits, 5-HT is stable for up to two days in platelets, while in the 
brain, it is stable for minutes120. The variance in half-life, outside of metabolic activity, 
can be attributed to the storage of 5-HT into storage vesicles. In platelets, 5-HT is 
stored in acidified dense granules121, which stabilize and may aid in shielding 5-HT 
from oxidation. In the brain's neurons, 5-HT is stored in storage vesicles along with 
serotonin binding proteins (SBP). SBPs were originally thought to bind and protect 5-
HT and reduce the osmotic pressure within the vesicles122. However, work by Jimenez 
del Rio et al. brought into doubt the true functions of SBPs122, which remains 
unresolved. The low half-life of 5-HT in the brain can be attributed to the tight regulation 
of free 5-HT from 5-HT's neurotransmitter activities. This regulation is mainly 
metabolic, involving the reuptake, degradation, and synthesis of 5-HT. These three 
parameters governing the concentration of 5-HT throughout the body are themselves 
systematically regulated. 
The biosynthesis of 5-HT is regulated on multiple levels. Due to high interest in 
5-HT's as a neurotransmitter, the regulation of 5-HT biosynthesis is mostly limited to 
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the biosynthesis in neurons. The exception being the bacterial regulation in the gut-
brain axis signaling model115. Much of the biosynthesis regulation occurs around the 
first rate-limiting step of the biosynthesis pathway, the conversion of L-tryptophan to 5-
HTP. All parts of this reaction can be involved in the regulation of the biosynthesis of 
5-HT. Starting with the beginning reagent L-tryptophan, where higher concentrations 
of the amino acid yield greater amounts of the 5-HTP product123. It has been stated 
that the co-factor of the reaction BH4 is the limiting reagent in this part of the pathway. 
Increasing its concentration in vivo causes an increase in 5-HTP production124. Hence, 
the BH4 metabolism plays a critical role in the regulation of 5-HT synthesis. 
Additionally, it has been shown that O2 levels in neurons are below the saturation levels 
of this reaction125. This observation shows that O2 concentrations also play a role in 
the synthesis rates. Finally, the enzymes TPH1/2 (peripherally/ neuronally expressed) 






Scheme 1.2. The human biocatabolism of 5-HT at physiological pH. Enzymatic 
modifications to the reagents are highlighted in red. The alternative melatonin synthesis 
pathway modifications are highlighted in blue. The enzymes involved are the following: 
acetylcholinesterase (AChE); aldehyde dehydrogenase (ALDH2); amine oxidase [flavin-
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containing] A (AOFA); amine oxidase [flavin-containing] B (AOFB); aldehyde oxidase (AOXA); 
acetylserotonin O-methyltransferase (ASMT); cytochrome P450 1A1 (CP1A1); cytochrome 
P450 1A2 (CP1A2); cytochrome P450 1B1 (CP1B1); cytochrome P450 2D6 (CYPIID6) 
indoleamine 2,3-dioxygenase 2 (I23O2); indolethylamine N-methyltransferase (INMT); 
myeloperoxidase (MPO) serotonin N-acetyltransferase (SNAT). 
The TPH1/2 activities have been shown to be dependent on the ferric iron ion. 
If the ion is oxidized or lost, the TPH1/2 enzymes are reversibly inhibited. Interestingly, 
it is known that the TPH2 enzyme has a stronger affinity for ferric iron ions, which 
makes it less likely to be inactivated when compared to TPH1124. Thus, the iron 
metabolism can also play a regulatory role in the biosynthesis of 5-HT. The divergence 
of the hydrolases goes further in terms of regulation. TPH2, when phosphorylated at 
S19, has been shown to have an increase in the 5-HT production kinetics126,127. In 
contrast, phosphorylation in TPH1 leads to its ubiquitination and proteasomal 
degradation128. This goes along with the higher turnover of TPH1, which has a half-life 
of 15-60 minutes129 compared to the half-life of 2.5 days of TPH2130. Together all these 
factors play a role in regulating the synthesis of 5-HT. 
MAOA and MAOB mostly govern the degradation of 5-HT in the mitochondrial 
membranes. In the periphery, most 5-HT is degraded by the liver131, and most of the 
rest of the 5-HT is metabolized in the lungs132, while in the brain, 5-HT is directly 
degraded in the neurons. Thus, regulation of the MAOs impacts the degradation of 5-
HT. MAOs are regulated through endogenous inhibitors such as tribulins133, a naturally 
occurring indole derivative compound, and expression regulators such as vitamin D134. 
Outside of the synthesis and degradation of 5-HT, its trafficking also influences its 
regulation. 
At physiological pH, 5-HT is protonated, making it energetically unfavorable to 
pass through the lipid membrane's non-polar portion. To overcome this physical 
limitation, 5-HT is actively transported through membranes by monoamine transporters 
(MAT) such as the serotonin transporter (SERT), the plasma membrane monoamine 
transporter (PMAT), and the vesicular monoamine transporter (VMAT). The MATs 
have also been shown to be regulated135,136, adding another layer of regulation to the 
5-HT related pathways. MATs are regulated in multiple manners, including 5-HT 
regulating SERTs. In platelets, 5-HT covalently binds to Rab-4 under high cellular 5-
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HT concentrations. Serotonylation promotes the activation and binding of Rab-4 to 
SERT, inhibiting SERT trafficking to the plasma membrane to further 5-HT uptake135. 
All of the various regulation mechanisms that influence 5-HT levels reflect its broad 
application in the body and point to its critical role in normal physiological functions.  
1.5 Cellular Functions 
1.5.1 Receptor mediated actions 
At the cellular level, the function of 5-HT is both receptor and non-receptor-
mediated. The receptor-mediated response varies based on which 5-HT receptors are 
expressed by the cell. Once activated by the binding of 5-HT, the receptor undergoes 
a conformational change. This change causes an additional conformational shift in the 
bound G protein complexes. The conformational change increases the affinity to GTP 
on the G protein complex, causing the complex to disassociate once GTP binds and 
freeing the Gα subunit to interact with other proteins. Based on which Gα protein (Gαi,
Gq/11, or Gαs) was released by the active form of the 5-HT receptor, various secondary 
messenger cascades are activated. 
When 5-HT binds to any of the 5-HT1 or 5-HT5 subfamily receptors, it activates 
the Gαi adenylyl cyclase inhibiting cascade, which leads to a decrease of cAMP 
concentration within the cell by binding and inhibiting AC. The activation of Gαi has also 
been associated with an increase in inositol 1, 4, 5-trisphosphate (IP3) and 
diacylglycerol (DAG) formation. The increase stems from the cleavage of 
phosphatidylinositol 4,5-bisphosphate (PIP2) via Phospholipase C, delta 1 (PLCδ1) 137. 
5-HT5A has also been shown to decrease cyclic adenosine diphosphate (cADP) 
concentration by inhibiting ADP-ribosyl cyclase activity 138. Finally, the G protein-
coupled inwardly rectifying potassium channel (GIRK) has also been demonstrated to 
be activated by this family of 5-HT receptors139. 
The 5-HT2 subfamily of receptors releases the bound Gq/11 proteins in the active, 
ligand-bound conformation. The released Gq/11 protein binds and activates 
Phospholipase C, beta 1 (PLCβ1), thereby increasing IP3 and DAG production. The 5-
HT4-7 receptors, when activated, release the bound Gαs protein, which binds to AC, 
forming an active complex and initiating the production of cAMP. A summary of the 
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various pathways of the 5-HT receptors and their pathway modulations can be seen in 
Figure 1.8. 
Figure 1.8. The activation of the 5-HT receptors regulates secondary messenger 
pathways. Where 5-HTx is the 5-hydroxytryptamine receptor family. Once 5-HT binds to the 
receptor, it releases a Gα protein subunit, listed under the G-Protein categories heading, 
activating several pathways. Acronyms:  adenylate cyclase (AC);  ADP-ribosyl cyclase activity 
(ADPR); cyclic adenosine diphosphate (cADP); cyclic adenosine monophosphate (cAMP); 
diacylglycerol (DAG); G protein-coupled inwardly rectifying potassium channel (GIRK) 1,4,5-
trisphosphate (IP3); phospholipase C, beta (PLCβ); Phospholipase C, delta 1 (PLCδ1). * Not 
found in humans 
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1.5.2 Non-receptor mediated actions 
 
Apart from its receptor-mediated functions, 5-HT also has non-receptor-
mediated actions. These include serotonylation, radical scavenging, and modulating 
the melatonin metabolism. Within the last decade, the discovery of serotonylation, the 
transamination of 5-HT to a protein's glutamine residue, has evolved the view of the 
function of 5-HT. Serotonylation has been identified to be involved in a host of 
processes. Some of the proteins which have been discovered to be serotonylated 
include ras-related protein 4 (Rab-4) and ras homolog gene family, member A (RhoA) 
in platelet activation140, ras-related protein 3A (Rab-3A), and ras-related protein 27 
(Rab-27) in beta cells during insulin release141, and Rab-4 in neuronal SERT 
internalization. Aside from acting as a PTM, 5-HT has been shown to scavenge free 
radicals142 and along with its metabolite melatonin scavenging reactive species such 
as nitric oxide143. Finally, 5-HT, being a precursor for melatonin, has been identified as 
the rate-limiting compound in the biosynthesis pathway of melatonin144 and may 
regulate its biosynthesis. 
 
1.6 Physiological Properties 
 
1.6.1 5-HT Locations 
 
While 5-HT was originally isolated from the enterochromaffin cells in the gut, 
most of the research on 5-HT focused on its neurological properties. The classical 
understanding of 5-HT's physiological role in the body was based on its function in the 
brain and the gut. In the brain, 5-HT is highly involved in many processes. The 
synthesis of 5-HT mainly occurs in the neurons located in the raphe nucleus in the 
brainstem's midline. Most of the brain is innervated with serotonergic fibers, and 5-HT 
has been implicated in many behavioral disorders and other brain functions145. Due to 
its gross involvement in human behavior, the brain's 5-HT neurons constitute a 
significant pharmaceutical intervention target. Behavior linked to 5-HT signaling has 




In the gut, both the enterochromaffin cells and the enteric neurons synthesize 
5-HT via TPH1 and TPH2, respectively. Through knockout mice models, it was 
concluded that the 5-HT synthesized by the enterochromaffin cells, which synthesize 
a majority of the body's 5-HT, is most likely used as a hormone throughout the body 
and that the 5-HT made by the enteric neurons are involved in gut motility146. The gut 
has also been linked to being communicative with the brain. This relationship allows 
for inter-kingdom signaling, via 5-HT, where the gut microbiome directly communicates 
with the brain115. The newly uncovered and still poorly understood brain-gut 
relationship is another example of the growing understanding of 5-HT in physiology 
and pathophysiology. 
Outside of the brain and the gut, 5-HT has a broad range of functions throughout 
the body. Besides homeostatic physiological processes, 5-HT has been implicated in 
development and stem cell proliferation147. 5-HT signaling has been described in: the 
arteries, blood, bone, genitourinary tissues, heart, liver, lungs, mammary, and 
others145,146. While the multiple actions of 5-HT have been studied in many tissues 
throughout the body, not much is known about 5-HT's function in skeletal muscle. 
The role of 5-HT in skeletal muscle has been barely explored. What is known 
so far is that 5-HT has been identified in rat myoblasts, myotubes, and whole muscle. 
It was demonstrated in myotubes and whole muscle to regulate glucose uptake via 
GLUTs and the 5-HT2A receptor148. Further, it was shown that 5-HT, via the same 
receptor, modulates the activity of 6-phosphofructo-1-kinase (PFK) in skeletal 
muscle149 and the Janus Kinase (Jak)/ signal transducer and activator of transcription 
(STAT) pathway in myoblasts150. While the Jak/STAT pathways are implicated with 
proliferation and differentiation151, this has not been exhibited in skeletal muscle cells. 
Finally, there is minimal evidence present in the literature on the role of 5-HT in human 
skeletal muscles. Through its broad distribution throughout the body, it is clear that 5-





5-HT is present at the beginning of development as SERT152, TPH2146, and 5-
HT itself have been found in murine oocytes and two-cell embryos. 5-HT is critical in 
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determining the asymmetry of the embryo. In frog and chicken embryos, it has been 
shown that 5-HT is distributed in a concentration gradient throughout the 16 cell 
embryo153. The embryo cells are linked by gap junctions allowing the positively charged 
5-HT to travel throughout the embryo driven via an electrochemical gradient 
established by asymmetrically expressed cation expelling pumps. The variation in the 
5-HT concentration leads to left-right specific gene expression154.  
Further down the path in development, 5-HT has been closely associated with 
neuronal development. 5-HT has been linked to multiple facets of brain development. 
Development is driven starting with 5-HT neurons and then progressing with 5-HT 
target tissues' development once the 5-HT neurons have reached those tissues155. 
Outside of the brain, it has been shown, in mice, that 5-HT is crucial for heart 
development. Mice with a deficiency in 5-HT or mice lacking the 5-HT2B receptor 
showed congenital heart defects156. While some correlative evidence exists in humans 
between the 5-HT related genes and behavioral disorders, very little has been proven 
in how 5-HT affects human development. 
 
1.6.3 Signaling Classifications 
 
The broad scope of signaling of 5-HT, which can act as an autocrine, endocrine, 
or a paracrine, diversify and embellishes the function of this molecule. 5-HT is locally 
synthesized and used for auto/paracrine signaling in multiple organs and tissues. For 
example, 5-HT allows beta cells to inhibit the release of glucagon by alpha cells in the 
pancrease157. In the lung, it is used by pulmonary arterial endothelial cells to govern 
the growth of pulmonary arterial smooth muscle cells158, and it restrains milk production 
by acting on the mammary epithelial cells during lactation159. 5-HT also has major 
functions as an endocrine factor, such as in liver regenerations via the 5-HT2B 
receptor160, the regulation of homeostasis of the extracellular matrix of cardiac 
tissues161, and signal for T cell activation162. While the function of 5-HT can be divided 
into signaling categories, the reality of the action of this compound is more complicated. 
In many parts of the body, 5-HT acts on multiples axes, a local signal 
auto/paracrine signal, and a hormone. Platelets interact with 5-HT on multiple facets. 
Platelets use 5-HT as an autocrine to initiate the reuptake of 5-HT via the 5-HT2A 
receptor and release 5-HT as a paracrine when stimulated163. In the placenta, 5-HT 
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plays a critical hormonal role in the neuronal development of the fetus164 and acts as 
a paracrine involved in trophoblast maintenance. Overexposure to 5-HT causes 
trophoblast to go through apoptosis165. Finally, in smooth muscle cells, 5-HT induces 
cell migration and cytoskeleton reorganization via the 5-HT4 receptor166. While already 
extensive, the known way 5-HT functions and the depth of its utilization by the body is 




With its broad physiological action, it is not surprising that 5-HT and its receptors 
are involved in various pathophysiologies. 5-HT has been implicated in cancers, 
diabetes, fibrosis, gastrointestinal disorders, inflammation, obesity, osteoporosis, 
neurodegenerative diseases, and pulmonary disease. Generally, most pathologies can 
be linked to either overexpression or repression of 5-HT related proteins. A summary 
of examples can be found in Table 1.5 at the end of this section. 
 
1.7.1 Overexpression of 5-HT related components 
 
 Several cancers have been linked with the dysregulation of 5-HT related 
elements. Glioblastomas have been shown to grow in response to 5-HT7 receptor 
stimulation via interleukin 6 (IL-6) and Mitogen-activated protein kinase 3 /1 (ERK1/2) 
mediated proliferation167. Along with glioblastomas, hepatocellular cancer proliferation 
has also been linked with 5-HT. Starved hepatocellular cancer cell lines treated with 5-
HT showed increased proliferation, and mouse models where 5-HT signaling was 
inhibited showed tumor growth inhibition168. Additionally, patient samples from the 
same study revealed an increased expression of the 5-HT2B receptor, which stimulated 
proliferation through the upregulation of ribosomal protein S6 kinase beta-1 (p70S6K). 
The excess expression of 5-HT related proteins has been linked to other pathologies 
with overgrowth. 
 
 Several works demonstrated that conditions with excess proliferation such as 
valvulopathy, cardiac hypertrophy, and fibrosis were linked to the exuberant 
expression of 5-HT signaling components. In the heart, it was shown that valvulopathy 
was caused by the overexpression of the 5-HT2B receptor169. This pathology is 
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infamous for its discovery. Norfenfluramine is a metabolite of the weight loss 
medication fenfluramine/phentermine, which caused valvulopathies in patients via the 
5-HT2B receptor. It was promptly banned by the U.S. Food and Drug Administration 
(FDA), and now pharmaceuticals are screened for 5-HT2B activity. In another related 
cardiac pathology, overexpression of 5-HT2B was shown in mouse models to cause 
cardiac hypertrophy with increased cell number, cell size, and proliferation of 
mitochondria170. Besides the heart, excessive expression of 5-HT receptors has been 
linked to dermal, liver, and idiopathic lung fibrosis. The upregulation of the 5-HT2B 
receptor has been linked to all three171–173 of the mentioned fibrosis. The dermal 
fibrosis was shown to have a 5-HT2B receptor-mediated increase in the extracellular 
matrix expression observed via qPCR171. In liver fibrosis, it was shown that in rats with 
diseased livers, treatment with 5-HT2B antagonist stalled proliferation and increased 
the rate of apoptosis in the liver172. Finally, in idiopathic lung fibrosis, quantitative 
western blotting showed an increase in AKT signaling, mediated by 5-HT2B, which was 
abated by chronic exercise173. Aside from pathologies involving proliferative 
dysregulation, pathologies involving inflammation have also been implicated with 
stimulus from excess 5-HT. 
 
 Pathologies involving inflammation: irritable bowel syndrome (IBS), Crohn’s 
disease, and neuroinflammation have been correlated with an increase in 5-HT 
receptors. In IBS, which has been linked with inflammation174, postprandial plasma 5-
HT levels were identified to be elevated in IBS with diarrhea174. Additionally, 
antagonizing the 5-HT3 receptors counters the IBS pathology175. In Crohn’s disease, 
an increase in the 5-HT7 receptor expression in integrin alpha X (CD11c) and cluster 
of differentiation 86 (CD86) positive dendritic cells was seen in both a mouse model of 
colitis and in samples of inflamed intestines from patients176. The same receptor, 5-
HT7, is expressed in microglial cells outside of the gut. This receptor is believed to drive 
inflammation from experiments that showed that it increased the release of the pro-
inflammatory cytokine IL-6 after antagnization177. While the overexpression of 5-HT 
related proteins is involved in several inflammatory pathologies, it has also been shown 
to occur in various other diseases. 
 
 Outside of driving cancers, proliferation, and inflammation, positive miss-
regulation of 5-HT has been seen in many other pathophysiologies. 5-HT has been 
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implicated in osteoporosis, progressive supranuclear palsy, and pulmonary 
hypertension. 5-HT has been proposed to be linked via the 5-HT1B receptor178, 
inhibiting osteoblast bone formation in osteoporosis. The active 5-HT1B receptor 
prevents the activation of the transcription factor CREB via the hampering of cAMP 
synthesis. In the neurodegenerative disease, progressive supranuclear palsy, 
overexpression of the 5-HT2A receptor179 was seen in the brain’s substantia nigra 
region, which is involved in movement. Finally, in pulmonary hypertension, the 5-HT2B 
receptor is overexpressed in pulmonary arteries stimulating elastase production and 
remodeling156.  
 
1.7.2 Repression of 5-HT related components 
 
 It is clear that 5-HT is involved in many pathologies. The overexpression of 5-
HT components can have a variety of effects. However, the impact of miss-regulation 
of the 5-HT signaling pathways is not limited to overexpression; its repression also 
plays a role in many pathologies. Several pathologies exhibit repression of 5-HT linked 
elements. Repression of 5-HT related proteins has been reported in cancer. A study 
on patient samples of ovarian tumors showed increased repression of the 5-HT2B 
receptor with the dissemination of ovarian cancer180. Besides cancers, reports of 
repression of 5-HT affiliated entities were observed in inflammatory and gut diseases. 
In rheumatoid arthritis, a TPH1 knockout mouse model showed an increase in arthritic 
markers, linked to a decrease in interleukin 17 (IL-17) and inhibition of T-regulatory 
cells181. These conditions were ameliorated ex vivo with the antagonism of the 5-HT2A 
and 5-HT2B receptors. In chronic constipation, agonism of the 5-HT4 receptor has been 
demonstrated to relieve this pathology182. The activated receptor initiates gut motility 
via the release of acetylcholine in the presynaptic cholinergic enteric neurons, causing 
the contraction of colonic longitudinal smooth muscles and relaxation of rectal circular 
smooth muscles. In diabetes, the 5-HT2C receptor stimulation was shown to better 
glucose tolerance and lower insulin concentrations in the plasma of diabetic mouse 
model183. A decrease in 5-HT receptors can be seen outside of inflammatory and gut-
related pathologies. 
 
 Repression of 5-HT signaling parts in neurons has been demonstrated in 
multiple neurogenic diseases. In both Alzheimer’s disease and amyotrophic lateral 
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sclerosis (ALS), the 5-HT1A receptor was shown to be expressed in lower cell densities 
in positron emission tomography (PET) scans of the brains of patients exhibiting these 
pathologies184,185. In both diseases, the raphe nuclei showed a decrease in this 
receptor. There was also a marked decrease in the binding potential of a 5-HT1A 
marker in the hippocampal region for Alzheimer’s patients. In contrast, ALS patients 
exhibited a marked decrease in receptor density in the cortex. In behavioral conditions 
such as ADHD, genetic studies have linked a deleterious mutant of the 5-HT2A receptor 
to this pathology186. Aside from ADHD, other behavioral conditions such as generalized 
anxiety disorder and major depressive disorder are believed to involve 5-HT. While 
several pathophysiological theories exist for these two diseases, the exact pathology 
has yet to be elucidated for either. Even so, these pathologies are treated with 
medications that alter the 5-HT distribution in the brain, with serotonin-specific 
reuptake inhibitors (SSRI) compounds being the primary treatment strategy. 
Neurological pathologies have been heavily linked with the under and overexpression 
of 5-HT components. However, much work remains to be done to understand the role 
of 5-HT in neurological pathologies. While covering a broad range of physiological 




Pathology Examples 5-HT entity implicated 
Cancer Glioblastoma; HCC; Prostate 5-HT7167; 5-HT2B168; 5-HT1A/B180 
Cardiomyopathy Valvulopathy; Hypertrophy 5-HT2B169; 5-HT2B170 
Diabetes Mellitus Neurohormonal dysregulation 5-HT2C183 
Fibrosis Dermal; Liver; Placenta 5-HT2B171; 5-HT2B172; SERT165 
GID IBS; Constipation; CD 5-HT3, SERT175; 5-HT4182; 5-HT7176 
Inflammation Neuroinflammation; AA 5-HT7177; 5-HT2A/B181 
Obesity Neurohormonal dysregulation 5-HT2C187 
Osteoporosis Neurohormonal dysregulation 5-HT1B188 
Mood disorders Anxiety; ADHD; MDD 
5-HT1A184,189; 5-HT1B,2A186,190; 
5-HT1A/B,2A-2C,3A,4,5,6,793 
NDD Alzheimer’s; ALS; PSP 5-HT1A/B184; 5-HT1A185; 5-HT2A179 
Pulmonary disease Pulmonary hypertension; IPF 5-HT2B156; 5-HT2B173 
 
Table 1.5. A table listing several 5-HT linked pathologies and the receptors implicated. 
AA - autoimmune arthritis; ADHD - attention deficit hyperactivity disorder; ALS - amyotrophic 
lateral sclerosis; CD - Crohn’s Disease; GID - gastrointestinal disorders; HCC - hepatocellular 
carcinoma IPF - idiopathic pulmonary fibrosis; MDD - major depression disorder; NDD - 
neurodegenerative disorders; PSP - progressive supranuclear palsy 
 
1.8 Pharmaceuticals targeting 5-HT receptors 
 
Although the 5-HT receptors are broadly implicated in many diseases, 
therapeutics that specifically target them are limited. Currently, only five out of the 
seventeen receptors have a therapeutic that specifically targets them (5-HT1A, 1B, 2C, 3, 
4). The 5-HT1 family has two major pharmacological targets, 5-HT1A and 5-HT1B. 
Buspirone, an azapirone family small molecule, is used in the treatment of GAD. The 
compound targets pre and postsynaptic neurons. There is evidence that it inhibits the 
presynaptic neurons in the raphe nuclei, repressing the firing of 5-HT neurons and 
halting 5-HT synthesis191. However, the exact mechanism by which buspirone treats 
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GAD is unknown. The other targeted 5-HT1 family receptor, 5-HT1B, is agonized to treat 
both migraines and cluster headaches. While the exact mechanism has not been 
proven for either, it is believed that, for migraines, agonized 5-HT1B receptors trigger 
vasoconstriction of painfully dilate cranial arteries192. In cluster headaches, it is thought 
that the agonists inhibit the activation of the trigeminovascular system193. Aside from 
the 5-HT1 subfamily of 5-HT receptors, other subfamilies are also targets for 
pharmacological intervention.  
The other 5-HT receptor families are pharmacologically targeted to modulate a 
variety of gastrointestinal dysfunctions grossly. The 5-HT2C receptor is agonized by the 
benzazepine class molecule, lorcaserin, to promote satiety in the treatment of 
obesity102. Lorcaserin agonizes the receptor in pro-opiomelanocortin neurons located 
in the arcuate nucleus stimulating them to excrete alpha-melanocortin-stimulating 
hormone. This hormone suppresses appetite by activating melanocortin-4 receptors of 
the neurons found in the paraventricular nucleus194. The 5-HT3 receptor, the only LGIC 
among the 5-HT receptors, is pharmacologically inhibited to prevent vomiting and 
nausea, mainly in conjunction with chemotherapy. The exact mechanism of action is 
unclear. However, it is believed to act on the 5-HT3 receptors located in the peripheral 
and central nervous system195. Finally, the 5-HT4 receptor is pharmacologically 
agonized with prucalopride, a benzofuran class compound, to alleviate chronic 
constipation. The agonist stimulates the receptor of enteric neurons controlling the long 
and circular smooth muscles of the colon, promoting spontaneous bowel 
movements196. A summary of the clinical compounds targeting 5-HT receptors can be 




Receptor Compound Class Examples Action Clinical Usage 







Migraine;            
Cluster headache 
5-HT2C Benzazepine Lorcaserin102 Agonist Promote satiety 
5-HT3 Setron Tropisetron89 Antagonist Antiemetic 
5-HT4 Benzofuran Prucalopride198 Agonist Chronic constipation 
 
Table 1.6. 5-HT receptors in medicine. Pharmaceuticals that are approved for medicinal 
use by the European Medicines Agency that target a 5-HT receptor. DHE is 
dihydroergotamine, and GAD is generalized anxiety disorder. 
 
While some of the receptors are already being targeted for certain pathologies, 
they may be involved in other, yet untreated, pathologies. For example, the 5-HT1B 
receptor has been linked to multiple pathologies other than migraines. Some of the 
pathologies include cancers199–201, degenerative movement disorders189,202, mood 
disorders203–206, and osteoporosis. 
With their involvement in multiple pathologies and pharmaceuticals that target 
this receptor, the 5-HT1B agonists present themselves as a good target for drug 
repurposing. However, the agonists on the market are not specific for the 5-HT1B 
receptor but have cross-reactivity with other 5-HT receptors, mainly of the 5-HT1 
subfamily. Cross-reactivity causes undesired effects and is a concern when designing 
therapeutic strategies. The ability to create therapeutics specific to one receptor 
subtype, or the niche of receptors expressed in a particular cell type, is critical in 
developing medications with low side effects. Understanding how the receptors vary 
from cell type to cell type by studying post-translational modifications that are 
functionally active in the receptors would make next-generation therapeutics hyper-
specific for receptors in specific cell types. Additionally, gaining a more profound 
knowledge of the presence and function of 5-HT receptors throughout the body, such 




1.9 Skeletal Muscles 
 
Skeletal muscles are one of the three muscle types that compose the muscular 
system found in invertebrates. Compared to the other muscle types, cardiac and 
smooth, skeletal muscle tissues are distinct in their appearance, molecular 
composition, and neurological control.  
Skeletal muscles have many functions in vertebrate organisms. The skeletal 
muscles contract providing the force in controlled locomotion and regulate the 
movement of substances in the other organismal tracts, such as the digestive tract. 
Additionally, they provide support to the structure of the organism and internal organs, 
stabilize joints, aid in thermoregulation through the generation of heat via ATP 
hydrolysis. Additionally, skeletal muscles protect by acting as a barrier to external 
forces, are a storage compartment for amino acids, and a source of emergency energy 
during starvation. 
 
1.9.1 Gross anatomy 
 
Skeletal muscles are fibrous organs connected to bones via tendons. The 
skeletal muscle is attached at the beginning of the organ by the proximal tendon named 
the “origin” and by the distal tendon termed the “insertion” at the end of the organ. The 
axis of force generation is a theoretical line drawn from the origin through the muscle 
to the insertion207. Skeletal muscles are categorized by their muscle architecture, which 
is defined by how the muscle fascicles lie in relation to the axis of force generation. 
The different muscle architectures allow for variations of force generations of fascicles 
of varying lengths.  
In humans, muscles are broadly categorized into being either longitudinal, 
pennate, or multipennate. Where longitudinal muscles have fascicles that are parallel 
to the axis of force generation, pennate muscles have fascicles that are at an angle 
not parallel to the axis (usually 1 ° to 30 ° from the axis). Multipennate muscles have 
fascicles that are at multiple angles non-parallel to the axis208. When the constituent 
fascicles of muscles are in line with the direction of the origin and insertion and the axis 
of force generation, as in longitudinal muscle architecture, the maximum force of the 
movement is produced when the fascicles contract207. Pennate and multipennate 
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muscles contain fascicles that are not aligned with the axis of force generation, yet 
they can generate more force than a comparable longitudinal muscle. The greater force 
is created by packing more, shorter fascicles in the same volume, thus increasing the 
physiological cross-sectional area, which overcomes the reduction of force from being 
off-angle with the axis of force generation209. Pennate muscle architecture allows for 
more compact muscles in areas where the size of longitudinally arranged fascicles 
would get in the way of the desired movement207. Muscle architecture is the grander 
layout of the highly organized composition of skeletal muscle anatomy. 
Skeletal muscles are composed of nested fibers, each enveloped by connective 
tissues (Figure 1.9). The skeletal muscle organ, enclosed by a layer of connective 
tissue called the epimysium, comprises multiple muscle fascicles. The muscle 
fascicles, encased by the perimysium connective tissue layer, are composed of muscle 
fibers and loose connective tissue. The loose connective tissue, the endomysium, 
packs the inter-muscle fiber space. The sarcolemma, a specialized plasma membrane 
coated with a glycocalyx, surrounds the muscle fibers. The muscle fibers are the 
contracting cells that compose muscle tissues and are made of multiple myofibrils. 
Each myofibril contains repeating units of sarcomeres, which are functionally 





Figure 1.9. The anatomical organization of skeletal muscle. Skeletal muscles are 
composed of myofibrils nested in sarcolemma encased muscle fibers. They are bundled into 
muscle fascicles surrounded by connective tissue, the endomysium, and encased by the 
perimysium. Muscle fascicles are grouped by the epimysium, making up the skeletal muscle 
organ. This figure is adapted from Betts et al. (2013) OpenStax “Anatomy and Physiology210 






1.9.2 Fiber types 
 
Muscle fibers have diversified to allow for different functions. Various 
transcription factors drive the diversification of fibers211. There have been numerous 
attempts at categorizing fiber types. However, there is no consensus. In general, there 
are three major ways to categorize the fibers either by their firing rate, their metabolism 
type, or by which myosin heavy chain is expressed in the fiber. The firing rate system 
splits the fibers into fast or slow-twitch fibers, and the metabolic system breaks fibers 
into oxidative or glycolytic. These ordering systems lead to the broad three fiber types: 
slow oxidative, fast oxidative, and fast glycolytic210. Due to the lack of specificity, this 
organizational system is often not used. 
 The most common classification system utilizes the isoforms of myosin heavy 
chain for identification. In this system, the labeling of slow-twitch fibers is type I, and 
fast-twitch fibers are either type IIa, IIb, or IIx. The metabolic profile of the fibers group 
type I and IIa as oxidative and IIb as glycolytic212. Type IIx fibers’ metabolic profile is 
dependent on their location213.  
There are a few complications with this naming system. The existent of 
heterogeneous fibers that express more than one form of myosin214 complicate the 
categorization. For example, under this system, the hybrid fiber types I/IIa, IIa/IIx, and 
IIb/IIx exist. Additionally, some fibers do not express any of these myosin isoforms and 
fall outside this classification system. These include embryonic, neonatal, head, and 
neck fibers214. Regardless of fibers’ typing, they play a role in muscle functionality and 
are linked to diseases such as obstructive pulmonary disease215, Ullrich disease216, 




Muscle fibers continue the organization pattern observed in the muscle organ 
and underlying tissues. Each muscle fiber is composed of several myofibrils encased 
in the sarcoplasmic reticulum. Each fiber is composed of linearly connected 
sarcomeres, which are the individual contracting units driving the entire muscle organ's 
force generation.  
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The structure of the sarcomeres is made up of an actin (thin) filament, a myosin 
(thick) filament, and a titin (elastic) filament, bound together between the Z-disc and 
the M-band. These structured elements are packed in parallel and responsible for 
skeletal and heart muscles' striated appearance. A sarcomere unit is defined by a Z-
disk (Z-line) on either end of it. A Z-disk is a protein complex that anchors parallel, 
running actin filaments. Myosin fibers are in the middle of the sarcomere, centered on 
the M-band protein complex, flanked by two actin filaments (one above and one below) 
on each end, and bound to two titin fibers which span from the M-band to the Z-discs218. 
The length of the myosin fiber, the heavy fiber, constitutes the A-zone. The 
myosin protein contains actin and ATP binding sites, which bind to the actin during 
contraction. The gap between the two parallel actin fibers and the length of the myosin 
is named the H-zone. The I-band is the area of the actin filament before the overlap 
with myosin to the Z-disk, from one sarcomere to the neighboring sarcomere. The 
regions of the sarcomere are visualized in Figure 1.10. 
 
 
Figure 1.10. Sarcomere structures. A) An electron micrograph section of muscle showing 
sarcomeres with their corresponding structural features. B) A schematic representation of the 
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electron micrograph of panel A with labeled components of the sarcomere. Adapted from 
Lange et al. 2020 
 
1.9.4 Molecular mechanism contraction 
 
A fundamental function of skeletal muscle is to generate force, which is utilized 
for conscious movement. Force in muscle tissue is produced by the controlled 
contraction of the sarcomeres of myofibrils. Motor neurons, which innervate skeletal 
muscle, propagate their action potentials by releasing acetylcholine into the 
neuromuscular junction. Acetylcholine binds to nicotinic acetylcholine receptors found 
on the sarcoplasm side of the neuromuscular junction, stabilizing the receptor's open 
conformation. The receptor's open conformation allows positively charged ions to 
transverse the sarcoplasm, instigating a flux of sodium ions to enter the cell, triggering 
the depolarization of the cell membrane potential.  
The membrane’s depolarization (Figure 1.11A) is conducted from the 
neuromuscular junction via T-tubules, which run transversely across the myofibrils. 
The-tubules are bordered by two terminal cisternae of the sarcoplasmic reticulum, 
forming the triad. At the triad membrane interfaces, the T-tubule membrane 
depolarization wave triggers dihydropyridine receptors to foster the opening of the 
ryanodine receptor on the sarcoplasmic reticulum membrane. The open ryanodine 
channels allow for a calcium ion flux from the sarcoplasmic reticulum into the 
cytoplasm219.  
As the released calcium ions reach the sarcomere, they bind to the protein 
troponin. The binding of calcium causes a conformational change, which initiates a 
secondary conformational change in the tropomyosin protein. The conformational 
change in tropomyosin exposes the myosin head binding site on the actin filaments, 
allowing for the formation of a cross-bridge between the two filaments. The myosin 
heads release a phosphate ion upon actin binding and undergo a conformational 
change (head movement), which contracts the sarcomere. With the conformational 
change, an ATP binding site is exposed. The binding of ATP releases the myosin head 





Figure 1.11. Mechanics of muscle contraction. Panels are displaying the relay of signal 
conductance from the neuromuscular junction to the sarcomere. After the neuron releases the 
neurotransmitter acetylcholine (ACh), ① ACh diffuses to the sarcolemma, where it binds the 
nicotinic acetylcholine receptor (nAChR). The binding of ACh causes the receptor’s channel to 
open, allowing a flux of sodium ions to enter the cell, initiating the action potential (A.P.) in the 
muscle cell. The sodium ion flux causes a reduction in negative electric potential, which is 
sensed by voltage-gated potassium channels (K+), ATP-sensitive potassium channel (K+ATP), 
and chloride channels (Cl-). The channels open and further propagate the A.P. down the T-
tubule ②. The voltage change is sensed by the dihydropyridine receptor (DHPR), which is 
mechanically linked to the ryanodine receptor (RyR) located on the sarcoplasmic reticulum 
(S.R.) membrane. The change in voltage causes DHPR to open the RyR Channels releasing 
Ca2+ ions into the cytoplasm ③ where it diffuses to the sarcomere. ④ The calcium ATPases 
55 
 
(Ca2+ATPase) and sodium-potassium adenosine triphosphatases (Na+ / K+-ATPase) 
reestablish the concentration gradient in the S.R. and the cytoplasm, respectively. In panel B, 
Ca2+ ions bind to troponin, causing a conformational change on the protein that changes the 
shape of tropomyosin, exposing the myosin-binding site on actin ①. The myosin head 
attaches to the exposed actin-binding site ②. ATP is hydrolyzed to ADP and an inorganic 
phosphate ③ driving the power stroke, causing the myosin head to move, contracting the 
sarcomere by shifting the actin towards the middle of the sarcomere. ADP is released from the 
myosin head, now in its low energy state, vacating the binding pocket for ATP ④. ATP binds 
to the empty myosin head and releases the myosin head from the actin completing the power 




Adult skeletal muscles have regenerative properties. The ability of skeletal 
muscle tissues to regenerate comes from a resident population of stem cells called 
satellite cells (SC). The SCs reside beneath the basal lamina on top of the sarcolemma 
of myofibers in a quiescent state. Upon activation, SCs begin to proliferate, with a 
fraction of cells maintaining quiescence to replenish the SCs population and a fraction 
differentiating to regenerate muscle fibers. The population of SCs fated for muscle fiber 
regeneration begins to multiply and then differentiates twice more to first, myoblasts, 
and then again to myocytes, before fusing with existing muscle fibers220. 
The paired box protein controls the SCs and their differentiation cascade (Figure 
1.12) (Pax) and the myogenic regulator family (MRFs) transcription factors. Dormant 
SCs are regulated by Pax-7 (additionally Pax-3 in embryonic SCs). Upon SC activation, 
myoblast determination protein 1 (MyoD) is expressed, the concentration of the already 
expressed myogenic factor 5 (Myf-5) increases, the concentration of Sprouty1 (Spry-
1) decreases, and Pax-7 expression is maintained. Experimental knockout mice 
models have shown that MyoD and Myf5 are redundant, but at least one is required 
for skeletal muscle generation221. A fraction of the population of SCs re-expresses 
Spry-1, returning themselves into a quiescent state222. After differentiation from SC to 
myoblast, the expression of Pax7 decreases, the expression of MyoD and Myf-5 
continues, and the expression of myogenic factor 4 (MyoG) begins. As the myoblast 
goes further down the differentiation pathway, the expression of Pax-7 stops 
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altogether, MyoD and Myf-5 expression decreases, and MyoG expression increases 
in myocytes. Myocytes go on to fuse to form myotubes with the rise in myogenic factor 
6 (Myf-6). Once formed, the tubes mature to myofibers and express the genes of 
skeletal muscle such as myosin heavy chains223.  
 
 
Figure 1.12. Transcription factor cascade of determining satellite cells. Once activated, 
quiescent satellite cells reduce their Spry-1 levels and begin to proliferate and differentiate. A 
population of satellite cells maintain Pax-7 expression and return to quiescence by expressing 
Spry-1. As Myf-5 and MyoD levels increase, activated satellite cells differentiate to myoblast 
and continue to proliferate. Myoblasts continue down the path of determination and 
differentiate to myocytes as Myf-5 and MyoD levels fall and MyoG levels rise. As Myf-6 levels 
increase and MyoG levels taper-off, myocytes fuse to form myotubes. Finally, Myotubes 
mature to myofibers with the expression of myosin heavy chains. (Inspired by Morgan et al.224) 
Physiologically, muscle repair is triggered by damage to the muscle fibers 
causing the release of warning signals, called damage-associated molecular patterns 
(DAMPs), from disrupted cells and extracellular matrices. Leukocytes contained in the 
muscle tissues recognize the DAMPs and initiate the inflammatory response via 
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cytokine signaling. The Inflammatory response removes the damaged cells and debris 
along with activating quiescent SCs. The SCs are activated via released hepatic growth 
factor (HGF) and, recently discovered, by the damage-myofiber-derived-factor (DMDF) 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)225. The SCs are driven to 
proliferate via HGF, Insulin-like growth factor 1 (IGF-1), fibroblast growth factor (FGF), 
Interleukin 6 (Il-6), and others226. 
SCs can also-self-activate when sensing mechanical stretching in the muscle 
fiber. The stretch in the fibers causes the release of HGF from the extracellular matrix, 
and the SCs themselves sense the mechanical force and release HGF as an autocrine. 
HGF is recognized by the c-met receptors of SCs, initiating a cascade that leads to the 
expression of Myf5 and the inhibition of MyoD227. Upon reprogramming the SCs by the 
transcription factors, the SCs become metabolically activated, allowing them to 
proliferate once signaled by IGF-1 and FGF226. The SCs daughter cells continue to 
differentiate with some daughter cells re-entering quiescence via the expression of 
Spry1, which inhibits tyrosine kinase cascades stimulated by HGF, FGF, and IGF-1, 
replenishing the SC population in the muscle. 
As the SC differentiate into myoblasts, they continue proliferating under the 
stimulus of IGF-1 and begin to differentiate by MyoD regulation triggering the 
expression of the MyoG determination factor. Opposingly, myostatin acts as an 
inhibitor of myoblast proliferation, arresting the cells in the G1 stage of the cell cycle 
and inhibiting MyoD and MyoG expression228. Myostatin, in turn, is negatively 
regulated by follistatin, which binds and neutralizes myostatin229. As myoblasts 
determine into myocytes, MyoD triggers MyoG expression. The understanding of the 
fusion of myocytes into myotubes needs more work. However, it is known that Myf6 
are the master regulators that coordinated the protein complexes, which lead to the 
formation of the myofibers that constitute the skeletal muscle tissue221. 
The signaling that controls the differentiation and proliferation from SC to 
myofibers is primarily mediated by mytokines, the cytokines of the muscle. The 
mytokines are recognized by membrane receptors that are of various receptor types. 
The tyrosine kinase receptor family’s involvement has been studied the most, including 
HGF, IGF-1, and FGF-2. However, other receptor families are involved as well. Some 
GPCRs (CRFR2, β2-AR, Fzd7, and others) have been found to play a role as well. The 
role of the 5-HT GPCRs has been studied minimally. 
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2 Part I 
 
Data from the experimental neuropathology laboratory indicated that treatment 
of mice with the SSRI inhibitor fluoxetine increased muscle regeneration. It was 
hypothesized that the increased amount of 5-HT was responsible for the observation. 
An investigation into the possible role and the presence of 5-HT receptors in murine 
muscle was initiated.  
Both genetic and proteomic data showed traces of a 5-HT pathway. Data from 
qPCR experiments indicated that the 5-HT1B receptor was present in the tissue, and 
this was confirmed via Western blotting of whole murine muscle. It was observed in 
the Western blot that the bands for 5-HT1B presented broad and were running at a 
higher molecular weight than theorized. We gathered that the higher running of the 
bands might be linked with post-translation modifications of proteins. Specifically, 
glycosylation has been associated with causing bands to run higher than expected.  
From our observation, we began to question the existence and functional 
importance of glycosylation of this receptor. We wondered if and how glycosylation or 
other transient PTMs of the receptor affect the potency of ligands. To understand our 
line of questioning, we investigated the purpose of the PTMs in the 5-HT1B receptors.  
Below we show how a multipronged approach was utilized to answer the above 
questions. Bioinformatics was used to identify potential and possibly significant 5–HT1B 
PTMs. Biochemical methods were used to verify the existence of PTMs and probe for 
their efficacy on the ligands' potency. Finally, computational methods were employed 
to help us understand a potential mechanism of action of the PTMs.  
 
We identified that glycosylation does occur in the N-terminus of the receptor. 
The glycosylation has an effect on potency. The impact on potency is ligand-specific 
and is observed with the native ligand, 5-HT. The mechanism by which the N-terminus 
affects the potency is potentially attracting the ligand from the extracellular milieu and 
releasing it near the binding pocket. Thereby, the ligand's concentration near the 




2.1 Materials and Methods 
 
2.1.1 Bioinformatics on 5-HT1B 
 
2.1.1.1 Homology Alignment 
 
The protein amino acid sequences of eight species, including humans, were 
collected from UniProt 230. The sequences were truncated to the N-terminus of the 
receptor. The homology alignment was performed in UniProt using the Clustal Omega 
alignment algorithms231. Conserved areas of the N-terminus were identified and 
highlighted. 
 
2.1.1.2 Identifying potential phosphorylation sites  
 
 Sites for potential phosphorylation were identified using the NetPhos 3.1 
Server232 using the human 5-HT1B receptor's amino acid sequence. Serine, threonine, 
or tyrosine residues with a predicted score above 0.900 out of 1.000 were considered 
as likely phosphorylated. 
 
2.1.2 Creating the PRESTO-Tango mutant constructs 
 
The mutant constructs were made using the QuikChange Lightning Site-
Directed Mutagenesis Kit from Agilent Technologies (Santa Clara, CA, USA).  
 
2.1.2.1 Primer Design 
 
The primers were designed using the QuikChange Primer Design tool found 
online (https://www.agilent.com/store/primerDesignProgram.jsp) from Agilent 
Technologies. A set of primers were designed for the single point mutations of N24A, 
N32A, S34A, D129A, and C388A. The created primer sequences and their calculated 
melting points (Tm) can be found in Table 1 of Annex I. For the synthesis of the primers, 
0.01 mol of each primer was ordered from Eurofins Scientific (Luxembourg, 
Luxembourg) purified via salt-free purification, quality control checked by MALDI, and 
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diluted to a concentration of 100 µM. Once received, a tenfold dilution using distilled 
and deionized water (ddH2O) was made to a final volume of 100 µL of each primer to 
create a stock of the primers at working concentration. The primers were stored at 4 
°C for the short-term and -20 °C for the long-term. 
 
2.1.2.2 Generating and purifying the template plasma DNA 
 
The PRESTO-Tango HTR1B plasmid was ordered for the Addgene (Watertown, 
MA, USA) repository, Ref. 66405. The agarose stab was probed and streaked on a 
fresh, room temperature (RT), 100 µg/mL ampicillin lysogeny broth (LB) agar plate, 
and left to culture overnight in a 37 °C incubator. The following day an isolated colony 
was picked and used to inoculate a 5 mL LB media culture with 100 µg/mL ampicillin 
in a 14 mL round bottom flask. The inoculated culture was then incubated overnight in 
a shaker at 200 rpm and 37 °C. The following day 750 µL of the culture was mixed with 
the same volume of 50 % sterilized glycerol into a 2.0 mL cryogenic tube and stored 
at -80 °C to make the glycerol stock. The glycerol was prepared from ≥ 99 % pure 
glycerol, Ref. G5516 (Sigma-Aldrich, St. Louis, MO, USA), mixed with ddH2O and 
autoclaved. The remaining culture was centrifuged at 1789 x g for 10 minutes at 4 °C 
to pellet the bacteria.  
The LB media from the pelleted culture was gently decanted, and the tube was 
allowed to rest upside down on a paper towel. Using a QIAprep® Miniprep kit, Ref. 
27104, from Qiagen (Hilden, Germany), the DNA was purified from the bacteria. The 
cells were resuspended in 250 µL of pre-chilled (4 °C) P1 buffer via pipetting and 
moved to a 1.5 mL centrifuge tube. The cells were lysed by adding 250 µL of P2 buffer, 
and the tubes were inverted six times. After allowing the lysing reaction to occur for 5 
minutes, 350 µL of neutralizing buffer N3 was added to the tubes, and once again, the 
tubes were inverted six times. The solution was spun at 17,000 x g for 10 minutes at 
RT, and the supernatant was loaded onto a spin column.  
The spin-column was loaded by centrifuging the column and the lysate 
supernatant for 60 sec at 14,100 x g. The column was washed twice, once with 500 µL 
of PB buffer and once with 750 µL of PE buffer. A spin, as described previously, was 
performed after the addition of each wash buffer. After the final wash, a secondary spin 
was performed to dry the column’s membrane. To elute the DNA, the column was 
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moved to a clean 1.5 mL centrifuge tube, 30 µL of ddH2O was loaded on the column, 
and the column was allowed to rest for one minute at RT. After the minute, the same 
spin as previously was performed. After the spin, the collected volume was loaded 
again onto the membrane, and the last two steps were repeated. The DNA suspension 
was quality controlled and quantified using a NanoDrop spectrophotometer from 
ThermoFisher (Waltham, MA, USA). An absorption ratio of 260 nm over the 280 nm 
wavelengths of over 1.8 was assessed as pure DNA. 
 
2.1.2.3 Performing the mutagenesis reactions 
 
Using the QuikChange Lightning Site-Directed Mutagenesis Kit, a mutant for 
each point mutation was generated using the PRESTO-Tango HTR1B plasmid as a 
template. The mutagenesis was performed as per manufacturer instructions with some 
modifications. The PCR reactions were performed as half-reactions with a final volume 
of 25 µL. The mixes were made with 50 ng of HTR1B template DNA, 0.2 µM final 
concentration of primers, 0.5 µL of dNTPs, 2.5 µL of 10x buffer, 0.75 µL of 
QuickSolution reagent, and 0.5 µL Quick Change Lighting Enzyme brought up to final 
volume 25 µL with ddH2O. The PCR reaction was performed as instructed with an 
adjustment in the annealing temperature to 50 °C from 60 °C and an extension time of 
199 seconds. 
To remove the template after the PCR reaction, a Dpn I digest was performed 
on all PCR products for 20 minutes at 37 °C. The reaction was performed using 1 µL 
of the kit-supplied Dpn I enzyme. The enzyme recognizes methylated adenosines 
present in the template DNA and cleaves DNA after the methylated adenosine. 
Methylation of DNA occurs in the bacterium but not during the PCR reaction. This step 
destroys the template DNA and prevents the unwanted transformation of the template 
into the bacteria. This increases the probability of the mutated form of the plasmid 
being successfully transformed into the bacteria. 
The digested PCR products were transformed into XL10-Gold ultracompetent 
cells as per manufacturer instructions. LB broth was used instead of the NZY+ broth 
listed in the manufacturer’s instructions, and the supplied control reaction was not 
performed. The transformed cells were plated on RT 100 µg/mL ampicillin LB agar 
plates and incubated at 37 °C for 20 hours.  
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The following day, three colonies from each plate were identified and picked to 
inoculate a 5 mL LB media culture with 100 µg/mL ampicillin contained in a 14 mL 
round bottom flask for each colony. The cultures were incubated overnight in a shaker 
at 200 rpm and 37 °C. The next day, glycerol stocks were made, and the DNA was 
purified from each culture as described above using the QIAprep® Miniprep kit. The 
DNA was diluted to 100 ng/µL in ddH2O, and 15 µL of the sample was sent to Eurofins 
Scientific for sequencing using the common CMV Forward primer (5’–
CGCAAATGGGCGGTAGGCGTG–3’). Using the N24A mutated plasmid, the above 
procedure was repeated with the N32A primers to generate the N24A and N32A double 
mutant plasmid. 
 
2.1.2.4 Verification of expression of the mutated plasmids in the HTLA cells: 
additional Western blot information. 
 
To verify that the mutant constructs were expressed correctly in the HTLA cells, 
Western blot analysis was performed on plasmid transfected HTLA cells’ extracts. The 
HTLA cells are a derivative of HEK293 cells, reported as female233, which stably 
express a luciferase reporter, and a hybrid ß-arrestin2-TEV genes ad were gifted from 
Richard Axel’s laboratory. The HTLA cells were maintained in Dulbecco's Modified 
Eagle Medium Ref. 41965039 from ThermoFisher (Waltham, MA. USA) with 10 % 
Fetal Bovine Serum Ref. S1860 from Biowest (Nuaillé, FR), 100 U/mL Penicillin-
Streptomycin Ref. 15140 from Gibco (Waltham, MA. USA), 2 μg/mL Puromycin Ref. 
J67236 from Alfa Aesar (Haverhill, MA, USA) and 100 μg/mL Hygromycin B Ref. 
400052 from Millipore (Burlington, MA, USA).  
The cells were prepared the day before by seeding each of the wells of a 6 well 
culturing plate so that on the day of transfection, the wells were at 80 % confluency, 
about 8 x 105 cells. The transfections were performed using the TransIT-293 
transfection reagent Ref. MIR 2700 from Mirus Bio (Madison, WI, USA) per the 
manufacturer’s instructions in OptiMEM I medium Ref. 31985070 from Gibco. The cells 
were then placed in the incubator at 37 °C and 5 % CO2 for 48 hours. 
 The protein was harvested from the cells in the following manner. After 48 hours 
of transfection, the cells were washed in 0 °C Dulbecco's phosphate-buffered saline 
(DPBS) [composed of 2.7 mM KCl, 1.5 mM KH2PO4, 138 mM NaCl, and 8.1 mM 
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Na2HPO4 · 7H2O], scraped, and collected into a 1.5 mL centrifuge tube. Cells were 
spun down at 6,700 x g for 15 seconds. The supernatant was removed via pipetting. 
Cells were re-suspended in lysis buffer (20 mM Tris-HCl Ref. 3253 adjusted to pH 7.5, 
1 mM EDTA Ref. e5134, 1 % Triton X-100 Ref. T8787 from Sigma (St. Louis. MO, 
USA), with 150 mM NaCl Ref. 27810.295 from VWR (Radnor, PA, USA), and 1x 
cOmplete protease inhibitor cocktail Ref. 11873580001 from Roche (Basel, CH). The 
suspension was left to rest on 0 °C for 15 minutes. The suspension was then spun at 
21,000 x g for 15 min at 4 °C. The supernatant was finally collected for further 
processing. 
 
To determine the concentration of protein in the cell lysate, the amount of 
protein in the lysates, the protein suspensions were quantified using a Pierce BCA 
Protein Assay Kit Ref. 23227 from Thermo Fisher as per the manufacturer’s 
instructions. The 96 well plates were read on MultiSkan EX also from ThermoFisher 
at 570 nm. The data were analyzed using Microsoft Excel 2013 (Redmond, WA, USA) 
software.  
After quantifying the lysates' protein concentration, the samples were prepared 
using NuPAGE LDS Sample Buffer Ref. NP0007 and NuPAGE Sample Reducing 
Agent Ref. NP 0009 and brought to a final concentration of 1.7 mg/mL. SDS-PAGE 
separation was performed on a 1.0 mm 10 - well NuPAGE 4-12 % Bis-Tris gradient 
gel Ref. NP0321 in NuPAGE MES SDS Running Buffer Ref. NP0002 using the 
NuPAGE Novex system as per manufacturer’s instructions. All items were purchased 
from ThermoFisher.  
After HTLA cells were transfected, harvested for proteins, and separated by 
SDS PAGE, the gel was transferred to an activated PVDF membrane, Ref. 162-0184 
from BioRad (Hercules, CA, USA). The membrane was activated in a 100 % methanol, 
Ref. 10141720 from Fisher (Hampton, NH, USA) in a 50 mL conical centrifuge tube 
allowed to rotate on a tabletop rotator for 5 minutes. The membrane was gently 
transferred using flat-tipped tweezers to a Towbin buffer (10x Tris/Glycine Buffer Ref. 
1610771 from Bio-Rad (Hercules, CA, USA), and 20% pure ethanol in ddH2O) soaked 
piece of blotting filter paper which laid on top of a sponge. The membrane and filter 
paper were soaked with more buffer, and air bubbles trapped between the membrane 
and filter were removed using a Western blot roller. Afterward, the gel was gently 
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transferred on top of the membrane and washed with more buffer to remove the SDS-
PAGE transfer buffer and equilibrate the gel. Next, another piece of pre-wetted filter 
paper was placed on top of the gel. Air bubbles between the layers were removed 
using the roller, a sponge was placed on top, and the cassette was closed. The 
cassette was placed into the Western blot chamber, and an -20 °C ice pack and 4 °C 
chilled Towbin buffer were added to the chamber. The proteins were transferred by 
applying a constant 300 mA current to the chamber for 1 hour. 
After the protein transfer, the membrane was labeled with a ballpoint pen and 
placed in a 50 mL conical centrifuge tube using tweezers. The membrane was quickly 
washed three times with 30 mL of ddH2O and stained with 5 mL of Ponceau S, Ref. 
P7170 from Sigma, for 2 minutes. Staining was performed as the tube rotated on a 
MACSmix tube rotator from Miltenyi Biotec (Gladbach, Germany) at 16 rpm. After two 
minutes, the Ponceau S solution was removed, and the membrane was de-stained 
with 10 mL of ddH2O. The water was replaced several times until the protein bands 
were visible. The membrane was then imaged and returned to the tube for further 
destaining with 0.1 M NaOH, made by diluting 50 % NaOH Ref. 415413 from Sigma-
Aldrich in ddH2O. Afterward, the membrane was rinsed twice with 30 mL ddH2O and 
once with phosphate-buffered saline with TWEEN® 20 (PBS-T) to equilibrate the 
membrane. PBS-T consists of 1X DPBS and 0.05 % TWEEN® 20, Ref. P7949 from 
Sigma-Aldrich. 
After equilibrating the membrane, the PBS-T was removed, and 10 mL of 5 % 
Skim Milk in PBS-T was added to block the membrane. The tube was placed on the 
rotator and left to rotate for 40 minutes at 12 rpm. After the blocking of the membrane, 
the milk was removed, and 5 mL of the primary antibody anti-5-HT1B, Ref. MAB5858 
from R&D systems (Minneapolis, MN, USA) or 1:5000 anti-FLAG M2, Ref. F3165 from 
Sigma, antibodies in 5 % milk was added to the tube. The tube was put onto the rotator, 
set to 12 rpm, and was placed in the 4 °C refrigerator for overnight incubation. The 
next day, the primary antibody mix was collected and frozen, and the membrane was 
quickly rinsed with 30 mL of RT PBS-T. Following the quick rinse, three 10 mL PBS-T 
washes were performed in succession. For each wash, the membrane was washed for 
10 minutes at a time on the rotator set at 16 rpm. After the third wash, 5 mL of the 
secondary antibody, 1:10,000 anti-mouse-HRP Ref. 31430 from Invitrogen (Calsbad, 
CA, USA), in 5 % milk was added to the tube and left to rotate at 12 rpm for 30 minutes 
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at RT. Following the secondary antibody incubation, the milk was discarded and the 
identical wash procedure described after the primary incubation was performed. The 
membrane was then further processed for imaging. 
After the last wash, the membrane was gently removed with flat-tipped tweezers 
and placed on top of a clean paper towel to remove excess wash buffer. The 
membrane was then placed onto a plastic sheet, and 600 µL of FemtoWest, Ref. 34095 
from ThermoFisher, was distributed evenly over the membrane. The plastic sheet was 
then folded over the membrane spreading the FemtoWest over the entire membrane. 
Care was taken to remove any air bubbles between the sheets and the membrane. 
The plastic sheet with the membrane was then placed into a lightproof container and 
brought to a Gbox for imaging. The time between the FemtoWest incubation and 
imaging was 5-15 minutes. Once the Gbox was ready for imaging, the membrane was 
moved to a paper towel and excess Femto West was gently dabbed away from the 
membrane. The membrane was then inserted in between two dry plastic sheets and 
placed into the Gbox, from Syngene (Cambridge, UK), on top of a white background. 
The blot was imaged with the visual marker setting turned on and saved onto the lab 




2.1.3.1 Generating and purifying endotoxin-free plasmid DNA 
 
The PRESTO-Tango high throughput drug screening assay can be used to test 
for compound potency in any of the known human GPCRs234. Plasmids containing all 
of the GPCRs can be obtained from the Addgene depository either as a kit Ref. 
#1000000068, which contains all of the know GPCR receptors or on an individual 
basis. Once the stab containing the bacteria with the plasmid was obtained, or from 
the glycerol stock, an ampicillin (100 µg/mL) LB agar plate was streaked out with the 
bacteria. The plates were left to culture overnight at 37 °C in an incubator. The following 
day, a single colony was picked and used to inoculate 100 mL of LB media with 100 
µg/mL ampicillin. The culture was allowed to shake at 200 rpm at 37 °C overnight. The 
next day the culture was moved to two 50 mL conical centrifuge tubes and spun at 
2795 x g for 15 minutes at 4 °C. If the culture medium was clear with a tan-colored 
pellet on the bottom, the tubes were removed for endotoxin-free DNA extraction. If the 
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media was not clear, the tubes were centrifuged for another ten minutes at 2795 x g at 
4 °C. 
The endotoxin-free DNA purification was performed using a NucleoBond® Xtra 
Midi kit from Machery-Nagel GmbH & Co. (Düren, Germany). The LB media from the 
centrifuge tubes was gently decanted, and the tubes were placed upside down on a 
paper towel to collect any remaining LB media. The pellet from one of the centrifuge 
tubes was resuspended in 8 mL of buffer RES by stroking the bottom tip of the 50 mL 
conical centrifuge tube on a small centrifuge rack several times. Once resuspended, 
the solution was moved with a pipette boy and a serological pipette to the other 
centrifuge tube. The second pellet was resuspended in the same manner as described 
for the first pellet. The resuspended mix was then treated with 8 mL of buffer LYS for 
lysing, mixed by inverting the tube three to five times, and left at RT for five minutes. 
While waiting, the filter system was set up by installing the O shaped holder onto the 
filter tube and placing both on top of a 50 mL conical centrifuge tube held by a 
centrifuge tube rack. The 50 mL centrifuge tube was installed to collect the waste. The 
column tube filter was then equilibrated with 12 mL of equilibration buffer, buffer EQU, 
by slowly and evenly applying the buffer to the upper lip of the filter in a rotational 
manner. After the five minutes, to neutralize the lysing reaction, 8 mL of buffer NEU 
was added to the tube containing the lysate, and the tube was mixed by inverting it 
three to five times. After the neutralization, the lysate was loaded onto the top lip of the 
filter in a slow rotational manner. Once all of the liquid passed through the filter, 5 mL 
of buffer EQU was added to the filter in the same manner as the lysate was. Once the 
buffer EQU passed through the filter, the filter was raised out of the tube and gently 
handled, with gloved hands, to extract the remaining liquid into the column. The filter 
was discarded, and the 50 mL centrifuge tube for the waste was emptied at this point. 
The column was then washed by adding 8 mL of buffer WASH and allowing the buffer 
to run through the column. 
The column was then moved to a new clean 50 mL conical centrifuge, and then 
5 mL of elution buffer, buffer ELU, was added to the tube to elute the DNA. Once all of 
the buffer ran through the column, using a clean serological pipette, the collected buffer 
was placed back in the column and allowed to run through it a second time. After the 
elution, to precipitate the DNA 3.5 mL of RT 99.5 % isopropanol Ref. I9516, Sigma-
Aldrich was added to the eluted DNA, and the mix was evenly distributed into 2 mL 
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centrifuge tubes. The tubes were then spun at 17,000 x g for 30 minutes at 4 °C. After 
centrifugation, the supernatant was gently removed via pipetting. To wash and 
consolidate the DNA, 2 mL of 70 % ethanol (prepared from 99.9 % Ethanol Ref. 
10375842 from Fisher) was used to move the pellets from all of the 2.0 mL centrifuge 
tubes into a single 2.0 mL centrifuge tube. The single 2.0 mL centrifuge tube was then 
spun at 17,000 x g for five minutes at RT. The ethanol was gently removed from the 
tube by pipetting, and the pellet was allowed to air dry for 15 minutes. The DNA was 
resuspended by adding a 150 µL of ddH2O to the pellet and shaking the closed tube 
at 1100 rpm and 37 °C on a thermomixer for 30 minutes. The DNA suspension was 
qualified and quantified using a NanoDrop spectrophotometer using the same criteria 
as mentioned before. 
 
2.1.3.2 Performing PRESTO-Tango assays 
 
The PRESTO-Tango day experiments were performed over five days outlined 
in Figure 2.2. On the first day, the HTLA cells were seeded into 60 mm dishes to be 
transfected on the following day. In general, an 80 % to near confluent T75 flask of 
HTLA cells had around 1.2 x107 cells. After preparing the plates, the HTLA cell cultures 
in T75 flasks had their medium removed, were quickly washed with 5 mL of sterile RT 
DPBS, and had 2 mL of 0.05 % Trypsin added to them. The flask was then left to 
incubate for three to five minutes at 37 °C until most of the cells detached from the 
bottom of the flask. The trypsinization was quenched by adding 3 mL of DMEM with 
10 % FBS and 1% Pen-Strep (culture medium) to the flask. The cells were then 
transferred to a 15 mL conical centrifuge tube and spun down at 300 x g for 3 minutes. 
The supernatant was removed, and the cells were resuspended in 10 mL of culture 
medium. The cells were then counted using a KOVA® (Grove, CA, USA) Glasstic® 
Slide 10 with quantitative grid slide after diluting the cells 1:1 with trypan blue, Ref. 
P08-34100, from PAN-Biotech (Aidenbach, Germany). After counting 2 x 106 cells 
were placed into each of the 60 mm cell culture, Petri dishes and culture medium were 
added to bring up the final volume in each dish to 3.5 mL. The Petri dishes were left 
overnight in the incubator. This amount of cells lead to a confluence of 70-80 % after 
the overnight incubation, which allowed for good transfection efficiency. 
On the second day, the transfection was performed. All the reagents were 
allowed to warm up to RT before mixing them. The plasmid was incubated with 
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OptiMEM and the TransIT293 reagent and was left to sit at RT for 15-30 minutes. The 
medium was not changed before the transfection was performed. The mixes were 
evenly distributed into the medium of the appropriate dishes, and the dishes were tilted 
to facilitate mixing. The plates were then placed back into the incubator overnight. 
On the third day, to prepare for the assay, the clear bottom 96 well tissue-
cultured-treated plates, Ref. 3610 Corning, were treated with a 0.1 mg/mL poly-D-
lysine, Ref. P6407 from Sigma, in ddH2O. The plates were treated by, using aseptic 
technique, distributing 40 µL of RT poly-D-lysine solution per utilized well of the plate 
by transferring the solution from the reagent reservoirs to the plates with a 12-channel 
pipette. The plates were gently agitated to ensure that the bottom of each well was 
completely covered. The plates were allowed to sit in the solution for at least two 
minutes, after which the poly-D-lysine solution was removed and recovered for future 
use. The plates were then allowed to dry for at least ten minutes at RT. Coating the 
wells was critical for the assays as the cells would otherwise detach when changing 
the medium, making the assay unusable. 
After the coating, the Petri dishes were trypsinized and counted as described 
before, with some exceptions. After the trypsinization was quenched with the culture 
medium, the cells were washed with 10 mL of DPBS and resuspended in 10 mL of the 
5-HT free medium, Charcoal stripped Fetal Bovine Serum Ref. A3382101 from Gibco, 
for counting. The cells were diluted and mixed well into a reagent reservoir at a 
concentration of 50,000 cells per 150 µL (333 cells / µL). Using a 12 channel pipette, 
the cells were distributed to the plate’s wells. The layout of the plate for the ligand 
assays can be seen in Figure 2.1. It is important to note that when working with a 
GPCR known to have a slow turnover and an extracellular domain that is sensitive to 
trypsin cleavage, one must use an alternative method to detach the cells from the Petri 
dishes. This note was not a concern for 5-HT1B as the turnover for this protein is known 
to be very fast, and our data verified that this was not an issue. After the cells were 
transferred, the plates were placed back into the incubator to allow the cells to attach 




Figure 2.1. A Plate layout of a typical PRESTO-Tango experiment. Wild-Types are wells 
with cells transfected with the PRESTO-Tango HTR1B plasmid, and Double Mutants are wells 
with cells transfected with the N24A and N32A mutated PRESTO-Tango HTR1B plasmid. 
 
On the fourth day, the cells were dosed with the probing compound(s). The 
compound(s) were serially diluted into the 5-HT free medium right before being 
distributed to the cells. If the compounds were light-sensitive, the serial dilution was 
performed in low light conditions (by turning off the biosafety cabinet light fixture). Once 
the serial dilutions were ready, the wells were emptied of their culture medium by gentle 
pipetting. Care was taken to remove all of the media from the wells and avoid cross-
contaminations of cells and compound dosages. Cross-contamination avoidance was 
achieved using a fresh reagent reservoir and a new set of pipette tips for every dosage. 
If the drug was suspended in DMSO, the control cells with the plasmid were given an 
equal final DMSO concentration in their culture medium. For the two-hour dosing 
experiment, the dosed mediums were aspirated after the cells were incubated with 
them for two hours at 37 °C and 5 % CO2. Each well was gently washed with 150 μL 
of HBSS at 37 °C and fresh medium without drugs and warmed to 37 °C was added to 
each well. The cells were then placed in the incubator for at least 18 hours. This period 




The stock drugs were made with 5-hydroxytryptamine hydrochloride 
(Serotonin) Ref. H9523 and N,N-dimethyl-5-hydroxytryptamine (Bufotenine) in 
acetonitrile Ref. B-022 purchased from Merck. (5'α,10α)-9,10-Dihydro-12'-hydroxy-2'-
(1-methylethyl)-5'-(phenylmethyl)-ergotaman-3',6',18trione mesylate 
(dihydroergotamine) Ref. 0475, (RS)-1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-
2-propanol hydrochloride (propranolol) Ref. 0624, 1'-Methyl-5-[[2'-methyl-4'-(5-
methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-
f]indole-3,4'-piperidine hydrochloride (SB224289) Ref. 1221, and N-[3-[3-
(Dimethylamino)ethoxy]-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-
yl)-[1,1'-biphenyl]-4-carboxamide hydrochloride (SB216641) Ref. 1242 purchased 
from Tocris (Bristol, UK). 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-
methanesulfonamide (sumatriptan) Ref. A5294 purchased from Biotrend (Cologne, 
Germany). 3-(2-Aminoethyl)-N-methyl-1H-indole-5-methanesulfonamide 
(Didesmethyl sumatriptan) Ref. SC206590 purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA). Fluoxetine Ref.MS5120 purchased from Eli Lilly (Indianapolis, IN, 
USA), Dihydroergotamine, sumatriptan, didesmethyl sumatriptan, and SB224289 
were dissolved in DMSO to make stock solutions. Bufotenine was suspended in 
DMSO after evaporating the acetonitrile with a rotary evaporator. The serotonin, 
fluoxetine, propranolol, and SB216641 were dissolved in distilled and deionized H2O 
to make the stock solution. Stock drug solutions were kept at - 20 °C and protected 
from light.  
 
On the fifth day, the plates were assayed. The plates were removed from the 
incubator and allowed to cool to RT (about 15 minutes when left sitting at RT). While 
waiting for the plates to cool down, fresh assay medium was made with newly thawed 
or mixed brightGlo reagent. The assay medium consisted of HBSS Ref. 55037C from 
Sigma, 20 mM HEPES, and 5 % Bright-Glo Luciferase Assay Ref. E2610 from 
Promega (Madison, WI, USA). The illuminometer was turned on at this time to allow it 
to warm up. It was important to give the illuminometer at least 30 minutes to warm up 
before taking any readings. Care was taken to protect the mix from light by wrapping 
the storage container holding the plates with aluminum foil. Once ready, the medium 
from the plates was fully removed via pipetting, and 100 µL of assay medium was 
distributed to each cell containing well. The plates were sealed with film, shaken at 
1500 rpm for 30 seconds on a plate shaker, and left to sit in the dark for 20 minutes. 
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After the incubation period, the plates were ready for the illuminometer reading on the 
Centro LB 960 Microplate Luminometer from Berthold Technologies (Bad Wildbad, 
DE). Right before the illumination reading, the plates had their film gently removed. On 
the illuminometer, the plates were shaken for 30 seconds on the double orbital setting 
with a diameter setting of 0.1, and then the plates were read with a counting time of 
0.30 seconds. Once read, the plates were discarded, and the data were exported to 
Microsoft Excel and analyzed in GraphPad Prism 7 software (San Diego, CA, USA) 
and R version 3.4.1 (Vienna, Austria). 
 
 
Figure 2.2. A diagram displaying the typical protocol for a PRESTO-Tango experiment. 
HTLA cells are seeded in medium on day one of the experiments in Petri dishes and allowed 
to culture overnight at 37 °C and 5 % CO2. The following day the cells are transfected with the 
target receptor(s) and incubated overnight. On Day 3, the transfected cells are moved to L-
Lysine treated 96-well plates and rested overnight. The plates are dosed with the drugs on 
Day 4 and are allowed to incubate for a minimum of 18 hours. On Day 5, the cells are treated 
with BrightGlo and assayed with the plate reading illuminometer.  
 
2.1.3.3 Data Analysis 
 
The data was extracted from excel sheets into the Prism software package. In 
Prism, dose-response curves (standard or variable slope) were fitted with outlier 
elimination at a confidence interval of 95 % for all experimental replicates. The dosage-
response curves used the following equation: 
 
𝑦 = 𝑚𝑖𝑛 + 
𝑚𝑎𝑥 − 𝑚𝑖𝑛




Where y is the luminescence, min is the minimum luminescence signal, max is 
the maximum luminescence signal, EC50 is the ligand concentration at half of the 
maximum luminescence signal, x is the ligand concentration, and the Hillslope is the 
slope of the curve. The Hillslope was fixed at 1 for the standard dose-response curve 
and remained variable for the variable slope (four-parameter) dose-response curve. 
 
Model selection was based on the Extra sum-of-squares F test with a max p-
value of 0.05. All curves were individually analyzed for EC50 values, and the EC50 
values were analyzed for outliers using the ROUT method with a Q = 1 %. The 
subsequent values were each individually analyzed against the EC50 values of the non-
mutated form of 5-HT1B using a Mann–Whitney U test with a two-sided hypothesis. The 
p-values were determined without accounting for multiplicity. Data were represented 
as medians with interquartile ranges. In R, fold change was calculated as a median 
ratio, and p-values were determined by between groups permutation resampling. The 
p values were calculated using a two-sided hypothesis against the double mutant. 
Differences were considered statistically significant for p-values below 0.05, and 
multiplicity was adjusted using the false discovery rate method 
 
Due to the nature of the assay, the only reliable measure from these curves was 
the EC50 values, which indicated a change in potency between the mutants and the 
wild-type 5-HT1B receptor. Generally, from a dosage curve, one can extrude several 
parameters, including the efficacy, the potency, and the mode of action of the ligand. 
These values are determined by the maximum value of the curve, the location of the 
curve along the x-axis, and the slope, respectively. The expected changes for these 





Figure 2.3. Variations of dosage dependency curves. The right shift seen in the blue curve 
when compared to the red curve shows that the compound corresponding to the blue curve is 
less potent than the compound corresponding to the red curve. The molecule corresponding 
to the green curve had less efficacy (a lower maximum plateau) and had a different mechanism 
of action (different slope) than the other curves corresponding to the two other compounds. 
 
This limitation in PRESTO- Tango arises from the variability of the number of 
total receptors present in the assay. The fluctuations of the number of receptors stems 
from the true number of cells per well, the expression efficiency of the plasmid per 
transfection and per mutation, and the loss of cells when changing the medium. Due 
to these three factors, it was unreliable to look at the maximum efficacy of the 
compounds in the PRESTO-Tango assays. Hence, the study was focused on the 
potency of the drugs, which was quantified by looking at the EC50 values of each set 
of measurements. 
 
2.1.4 PNGase F digest of human 5-HT1B  
 
2.1.4.1 Generating 5-HT1B and PNGase F N-linked Glycosylation Digestion 
 
HTLA cells were seeded at a density of 6 x 106 cells in 8 mL of medium on 4 
separate 10 mm cell culture dishes. The cells were then incubated overnight at 37 °C 
and 5 % CO2. The following day the cells were transfected as in PRESTO-Tango 
experiment and allowed to incubate another day. The cells were then placed at 0 °C 
and washed with 5 mL of 0 °C DPBS after decanting the DMEM. Once the wash 
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medium was removed via decanting, 1 mL of 0 °C DPBS was added to the dish. The 
cells were gently scraped using a cell scraper and collected into a 0 °C chilled 1.5 mL 
centrifuge tube. The cells were briefly spun at 6,708 x g for 15 seconds to pellet the 
cells. The supernatant was then gently removed via decanting and pipetting. The cells 
were lysed using about 150 μL lysis buffer, the lysis buffer volume was adjusted based 
on the pellet size. The cells were resuspended in the buffer and rested at 0 °C for 20 
minutes. The tubes were then spun at 17,000 x g for 15 minutes at 4 °C. After 
centrifugation, the supernatant was collected, and the pellet was discarded. 1:10 
dilutions of the lysates were quantified using A BSA kit to determine the concentration 
of the cell lysates. 
The protein lysates were digested using Peptide -N-Glycosidase F (PNGase F) 
Ref. P0704L, purchased from NEB (Ipswich, MA, US), per manufactures instructions 
for denatured reaction conditions. Briefly, 200 µg of protein were denatured for 10 
minutes at 100 °C in glycoprotein denaturing buffer brought to a final volume of 100 µL 
with distilled and deionized water. 20 µL of Glycobuffer 2 (10x) and 10 % NP-40 with 
10 µL of PNGase F were added to the mix and incubated at 37 °C for one hour. 20 µL 
of NuPAGE LDS Sample Buffer was added to the digested sample before heating it 
for 5 minutes at 70 °C  
 
2.1.4.2 SDS-PAGE and Western blot 
 
The samples were prepared using NuPAGE LDS Sample Buffer and NuPAGE 
Sample Reducing Agent and brought to a final concentration of 1.7 mg/mL. SDS-
PAGE separation was performed on a 1.0 mm 10-well NuPAGE 4-12 % Bis-Tris 
gradient gel (Ref. NP0321) in NuPAGE MES SDS Running Buffer using the NuPAGE 
Novex system as per manufacturer’s instructions.  
The SDS-PAGE gels were transferred onto 20 µm pore PVDF membranes 
using a Criterion blotter from Bio-Rad as per the manufacturer’s instructions. The 
membranes were stained with Ponceau S for total protein transfer validation. After the 
Ponceau S destaining with distilled and deionized water, the membranes were blocked 
in 5 % skim milk for 40 minutes. The blots were incubated with either 1:5000 anti-FLAG 
M2 or 1:500 anti-GAPDH Ref. AF5718 from R&D systems in 5 % skim milk overnight 
at 4 °C. The secondary antibody incubations with 1:10,000 anti-mouse-HRP Ref. 
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31430 or 1:5,000 anti-goat-HRP Ref. 81-1620 purchased from Invitrogen conjugated 
antibodies in 5 % skim milk were performed for 30 minutes at room temperature. The 
blots were exposed with FemtoWest enhanced chemiluminescence as per the 
manufacturer’s instructions. The exposed membranes were imaged using Gbox 
imaging system. 
 
2.1.5 Molecular Dynamics Simulations of the 5-HT1B receptor 
 
The molecular dynamics (MD) simulations were performed utilizing the full-
length wild-type 5-HT1B receptor and a double mutant with an alanine substitution at 
residues N24 and N32. The receptors were placed into a simulated bilayer membrane 
composed of pure palmitoyl-oleoyl phosphatidylcholine (POPC) in the presence of 
either a single molecule of 5-hydroxytryptamine (5-HT), sumatriptan (SUM), 
dihydroergotamine (DHE), or no ligand. All of the simulations were at atomistic 
resolution and done using GROMACS 2020.4235 with the PLUMED 2.7236 plug-in. The 
simulation's sampling was enhanced, and the convergence of the simulation was 
accelerated using the metadynamics approach. The work was performed with the high 
performance computing (HPC) resources of the Institut du développement et des 
ressources en informatique scientifique (IDIRS) under the grant allocation 2020-
101592 given by the grand équipement national de calcul intensif (GENCI). 
 
2.1.5.1 Initial Models 
 
There are five know experimentally determined structures of the 5-HT1B 
receptor (Table 2.1). All of the structures are missing the N-terminal domain and have 
a thermostabilizing point mutation83 at L138W. The constructs used for X-ray 
crystallography structure determination were further modified by replacing intracellular 







PDB ID code Method Resolution (Å) Residues  Reference  
4IAQ X-ray  2.80 38-239 / 304-387  82 
4IAR X-ray 2.70 38-239 / 306-387 82 
5V54 X-ray 3.90 37-239 / 305-388 238 
7C61 X-ray 3.00 38-239 / 305-390 239 
6G79 Cryo-EM 3.78  45-240 / 305-385 83 
 
Table 2.1. Existing experimentally determined structures of 5-HT1B.  
 
The N-terminus (residues 1-40) is predicted to be disordered with high flexibility 
and glycosylation at N24 and N32. The full length, residues 1- 390, 5-HT1B receptor 
model, was generated with the I-TASSER online server240. The template used was 
PDB ID code 4IAQ leading to the creation of five models. Model three was selected as 
it was the only model that did not have the N-terminus folded into the transmembrane 
region. This criterion was used as the N-terminus's glycosylation would make the 
burring of the N-terminus into or through the membrane energetically unfavorable.  
 
2.1.5.2 Simulation setup, equilibration, and production 
 
The systems were prepared using the online CHARMM-GUI241 server and using 
the full-length 5-HT1B models as the input file. Individual models of the wild-type and 
the double mutant in the presence of known agonists were generated. The models are 
summarized in Table 2.2. To generate the wild-type glycans FA2G1 and FA2G2 





Figure 2.4. Structures of the glycans used in generating the models for MD simulations. 
 
A disulfide bond was indicated between residues Cys122 and Cys199. Lipids 
were added by selecting a rectangular box type with a water layer of 30 Å, an axis 
length of 120 Å, and POPC selected as the lipid type. These options generated a box 
with the x-y-z dimensions of 120 Å x 120 Å x 150 Å containing 194 POPC lipid 
molecules in both the upper and lower leaflets. Potassium and chloride ions were 
added to the system at a concentration of 0.15 M using the distance ion placing method 





























1 WT FA2G1 FA2G2 - 388 171/180 62587 246762 2 
2 WT FA2G1 FA2G2 5-HT 388 171/181 62562 246714 2 
3 WT FA2G1 FA2G2 SUM 388 171/181 62606 246862 2 
4 WT FA2G1 FA2G2 DHE 388 171/181 62622 246949 2 
5 AA - - - 388 172/181 62867 247151 2 
6 AA - - 5-HT 388 171/181 62822 247041 2 
7 AA - - SUM 388 171/181 62842 247117 2 
8 AA - - DHE 388 171/181 62802 247036 2 
 
Table 2.2. Simulations set-up details.  
 A single ligand was randomly placed above the lipid membrane's upper leaflet 
for simulations with a ligand. The force fields used for the ligand, lipids, and ions were 
CHARMM36f242, CHARMM General Force Field (CGenFF)243, and TIP3P244, 
respectively. The equilibrations were performed with the standard CHARMM-GUI 
protocol of multiple consecutive simulations in the NVT and NPT ensembles. 
Temperature (T) was set at 310 K, and the pressure (P) was set at 1 atm. The harmonic 
restraints on the position of the ligand, lipids, and protein atoms were gradually 
removed as the equilibration procedure progressed. The final equilibrations were 
performed for 50 ns in the NPT ensemble with no positional restraints. 
 The production simulations were performed with the Bussi-Donadio-Parrinello 
thermostat245 and the semi-isotropic Parrinello-Rahman barostat246 using the NPT 
ensemble. The time step was set to 2 fs, and H-bonds were constrained with a linear 
constraint solver for molecular simulations (LINCS)247. Van der Waals forces were 
gradually dampened at 10 Å and terminated at 12 Å. Direct electrostatic interactions 
we truncated at 12 Å and long-range interactions treated by using the particle-mesh 
Ewald method248. The sampling was accelerated with metadynamics during the 
production simulation. All of the simulations were performed using GROMACS 2020.4 
and PLUMED 2.7. 
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2.1.5.3 Metadynamics details 
 
The metadynamics (MetaD)249,250 approach utilized a newer method called 
Parallel Bias metadynamics (PBMetaD)250 that uses a greater amount of collective 
variables (CVs). An overview of metadynamics can be found in Annex II. For these 
simulations, the conformational landscape of the disordered, extracellular, N-terminal 
of 5-HT1B and the ligands' position relative to the lipid bilayer were used as the criterion 
to select the CVs. The N-terminal was defined as the first 40 residues of the receptor. 
The following 6CVs were used: 
1) The total α-helical content of the N-terminal quantified by the ALPAHARMSD 
keyword of PLUMED. The total α-helical contents were calculated by deriving a 
set of all possible regions of six consecutive residues in the system and 
comparing the root mean squared distance of each segment to an idealized α-
helical structure. 
 
2) The summation of the total parallel and anti-parallel β-sheet content within the 
N-terminal. The total parallel (anti-parallel) β-sheet contents were calculated 
using the PARABETARMSD (ANTIBETARMSD) keyword in PLUMED. The 
summations were computed by first generating all possible six residue 
groupings within the systems that can form a parallel (anti-parallel) β-sheet. 
They were then compared the root mean squared distance of each segment of 
an idealized parallel (anti-parallel) β-sheet structure. 
 
3) The radii of gyration were determined from the location of the Cα carbons of the 
N-terminal residues using the GYRATION keyword in PLUMED. 
 
4) The number of contacts in-between hydrophobic residues in the N-terminal of 
the receptor. The hydrophobic contacts were determined by counting the 
number of interactions, below 6 Å, in-between the Cβ atoms of alanines, 
isoleucines, leucines, methionines, phenylalanines, prolines, tryptophans, 
tyrosines, and valines. This calculation was achieved using the 
COORDINATION keyword in PLUMED. 
 
5) The occurrences of salt-bridges. Salt-bridges were identified by contacts within 
6 Å of the atoms of the COO- functional group of aspartic and glutamic acids 
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and the atoms of the –C(NH2)2+ functional group of arginines or the atoms of the 
NH3+ functional group of lysines in the N-terminal. These counts were 
determined using the COORDINATION keyword in PLUMED. 
 
6) Ligand location was identified in reference to the membrane. The ligands' 
positions were determined by measuring the distance, along the z-axis, 
between the geometric center of the ligands and phosphorus atoms of the upper 
leaflet of the POPC molecules of the membrane. 
 
The PBMetaD approach with the above CVs was used with a bias factor of 24, 
a deposition stride of 1 ps, and an initial Gaussian height equal to 1.2 kJ/mol. The 
Gaussian widths were set, respectively, to 0.5, 0.1, 0.1 nm, 2.0, 0.3, and 0.1 nm. The 
PBMetaD bias potentials were stored on a grid. The ligand molecules were restricted 
to the extracellular region with an upper harmonic wall added to CV #6 at 7 nm with a 
harmonic constant equal to 20,000 kJ/mol/nm2. All of the PLUMED input files and the 
GROMACS topology files were made available on PLUMED NEST (www.plummed-
nest.org)251 under the accession number plumID: 21.0YY. 
 
2.1.5.4 MD simulation data analysis 
 
MetaD trajectories do not allow one to calculate histograms or average 
quantities of desired observables directly. This limitation is due to the existence of a 
biasing potential that alters each frame's statistical weight. Removing the bias potential 
is performed by reweighting the system, achieved through various methods252–254. Our 
systems were reweighted using the MetaD bias potential calculated at the end of the 
simulation, assuming that the bias remained constant throughout the simulation 
duration. With this approximation, the weight w of each frame can be defined using the 
expression  𝑤 ∝ exp[𝑉 (𝑆, 𝑡 → ∞)/𝑘 𝑇], similarly to the umbrella-sampling reweighting 
approach255. 
The first 5 PBMetaD CVs' distributions during the first and second half of each 
simulation were calculated to check for convergence of the PBMetaD simulations and 
characterize the N-terminus' conformational states of 5-HT1B receptor. The histograms 
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were computed using the reweighted systems mentioned above. After convergence, 
the distributions of each half of the simulation should be similar to the other half. 
The minimum distance dmin between the ligand's heavy atoms and the atoms of 
the N-terminus (residues 1-40), ECL2 (residues 188-204), or present glycans were 
calculated to determine the ligand's propensity to bind to the extracellular regions of 5-
HT1B. The binding of the ligand was defined by a dmin of less than 4 Å. The MD 
simulations were filtered for frames that included the ligand in the extracellular volume. 
The binding frequencies were determined by the weighted fraction of bound versus 
unbound conformations over the total number of frames. The atoms of the receptors 
nearest to the ligands (had the lowest dmin) were used to identify the binding frequency 
at specific residues or glycan moieties. Each specific binding event to a residue or a 
glycan moiety was then calculated over the total amount of binding events for each 
system to determine their occurrence frequency. 
We measured the distance of the ligand from the binding site, to get an 
understanding of ligands activity. The dmin was calculated, as above, from the 
geometric center of the binding site and of each ligand. The binding site was defined 
as residues D129, I130, C133, T134, A216, W327, F330, and F331. 
To identify potential stabilized conformations in the extracellular domains of the 
receptor, self-organizing maps (SOMs) were generated. The SOMs were generated 
as described in Mallet et al.256. The simulations were concatenated, and the trajectories 
of the Cα of the N-terminus and the ECL2 regions were extracted. A SOM of the N-
terminus and ECL2 for each simulation was then plotted. 
 
2.2 Results and Discussion 
 
2.2.1 PRESTO-Tango of 5-HT1B agonists and antagonists 
 
2.2.1.1 Fluoxetine toxicity 
 
Fluoxetine was tested using the PRESTO-Tango assay to rule out that 
fluoxetine does not directly interact with 5-HT1B. The assay, Figure 2.5A, revealed that 
fluoxetine appears to be inhibiting the self-activation of 5-HT1B. Self-activation can be 
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identified by the relative lower RLU seen in the assay. The RLU is about four-fold less 
in this instance where the maximum RLU of the self-activating 5-HT1B was ~4,000 
versus the RLU maximum of 16,000 when the 5-HT1B expressing cells were dosed with 
5 mM 5-HT. However, upon further analysis of the negative control cells that were 
dosed and were not transfected with the 5-HT1B PRESTO-Tango plasmid, Figure 2.5B, 
showed that the perceived inhibition was caused by cell death and not by inhibition of 
the receptor. 
 It appears that fluoxetine becomes toxic to HTLA cells at 100 nM range and 
leads to complete cell death at 100 µM after 18 hours of exposure. When co-dosed 
with 5-HT, Figure 2.5C, the HEK293 cells appeared to be more resilient to the toxic 
effects of fluoxetine, showing signs of toxicity near the 10 µM concentration rage. 
Complete cell death was observed when the concentration of fluoxetine reached 10 
mM. The early decrease in the signal may have been caused by protein synthesis 
inhibition induced by cell stress, preventing luciferase synthesis, causing the reduction 
in the signal from the assay. Repetition of these experiments where the cells were 
inspected for cell death before assays and a qualitative viability assay, visually 
checking for cell survivors, showed that fluoxetine led to complete lethality at the 100 
µM concentration for HEK 293 cells after 18 hours of exposure. These observations 
are consistent with previous experiments which also note the toxicity of fluoxetine to 





Figure 2.5. Dose 5-HT1B dependency curves of fluoxetine. The 5-HT1B dosage dependency 
curve of fluoxetine A in red shows a reduction of the self-activation signal at 100 nM with a 
complete reduction of the signal at 100 µM. In panel B, the control cells, in teal, which have 
not been transfected with the 5-HT1B plasmid, show complete loss of signal at 100 µM 
fluoxetine. When co-dosed with 5 mM 5-HT, C, a reduction of the signal from the 5-HT1B 
expressing cells, in red, is first observed at 10 µM fluoxetine and is completely extinguished at 
100 µM fluoxetine. In teal, panel D of the non-transfected cells shows a loss of signal starting 
at 100 µM. The HTLA cells (derived from HEK293 cells, containing a tTA-dependent luciferase 
reporter sequence and a stably expressing a β-arrestin2-TEV fusion gene) were transiently 
transfected with a 5-HT1B-tTA fusion gene (HTR1B-Tango). The curve is a fitted four-parameter 
dosage dependence curve (the equation can be found in the methods). Median measurements 
are displayed. All error bars are the interquartile range, RLU is relative light units, and the N = 
5 experimental replicates. 
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A PRESTO-Tango experiment where the cells were co-dosed with 5 mM 5-HT 
and fluoxetine for two hours, the recommended minimum for the assay to function, 
compared to the known antagonist SB224289 was performed to determine whether 
fluoxetine has some inhibitory effect on 5-HT1B outside of toxicity to the cells. Toxicity 
was still observed in the cells, starting near 1 µM concentration of fluoxetine, Figure 
2.6C. When comparing to SB224289, Figure 2.6A, the fluoxetine data points were 
noisier, and the points mimicked the non-5-HT1B expressing cells, Figure 2.6D. 
Whereas the antagonist, while still toxic at higher concentrations, had low noise, began 




Figure 2.6. Dose 5-HT1B dependency curves of 2 hours of fluoxetine and SB224289. The 
SB224289 inhibition curve of 5-HT1B co-dosed with 5 mM 5-HT, in panel A. The signal begins 
to be inhibited near 10 nM and is completely inhibited near 30 µM SB24289. Panel B shows 
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the non-transfected cells decreasing starting at 1 µM of SB24289, indicating cell toxicity at 
higher concentrations. Cell exposed to fluoxetine for 2 hours, panel C, shows a reduced signal 
at 1 µM with a complete reduction of the signal at 3 mM. In panel D the control cells, which 
have not been transfected with the 5-HT1B plasmid, mirror the transfected cells at lower RLU 
with a complete loss of the signal at 100 µM fluoxetine. The HTLA cells (derived from HEK293 
cells, containing a tTA-dependent luciferase reporter sequence and a stably expressing a β-
arrestin2-TEV fusion gene) were transiently transfected with a 5-HT1B-tTA fusion gene 
(HTR1B-Tango). The curves are a fitted four-parameter dosage dependence curves (see 
methods). Median measurements are displayed. All error bars are the interquartile range, RLU 
is relative light units, and the N = 5 experimental replicates. 
 
These experiments and visual observations show that fluoxetine is likely toxic to HTLA 
cells, but to demonstrate this, further experiments need to be performed. It may be 
possible that the compounds themselves are quenching some of the photons as 
several of them contain cyclic aromatic compounds. Additionally, the compounds could 
be interfering with the signaling cascade within the reporter cells. These experiments 
highlight some of the limitations when interpreting results from PRESTO-Tango 
experiments. However, negative results from these assays can be useful. 
 
2.2.1.2 Propranolol negative result 
 
Propranolol is known as an antagonist of rodent 5-HT1B. The half-maximal 
inhibitory concentration of propranolol has been reported to be 50 mM13. It has been 
reported that the slight changes of amino acid residues found between the rodent and 
human 5-HT1B receptor homolog cause the receptors to react differently to agonists 
and antagonists. This variance is also true for propranolol, whose antagonistic 
properties are reduced in the human version of 5-HT1B. PRESTO-Tango experiments, 





Figure 2.7. PRESTO-Tango of 5-HT1B with propranolol.  The rodent 5-HT1B antagonist 
propranolol has no inhibitory effect on human 5-HT1B at physiologically relevant dosing 
concentration. The receptor-expressing cells, in red, show no variation other than random 
noise. The non-receptor-expressing cells, in teal, mimic the random noise seen in the 
expressing cells at a lower RLU. The HTLA cells (derived from HEK293 cells, containing a tTA-
dependent luciferase reporter sequence and a stably expressing a β-arrestin2-TEV fusion 
gene) were transiently transfected with a 5-HT1B-tTA fusion gene (HTR1B-Tango). Median 
measurements are displayed and all error bars are the interquartile range. The RLU is relative 
light units, and the N = 6 experimental replicates. 
These results correspond with the reported half-maximal inhibitory 
concentration of 3.2 M13 for human 5-HT1B. Further experimentation with co-dosage of 
5-HT and propranolol would further very this observation. PRESTO-Tango can be 
utilized outside of determining the properties of non- efficacious compounds. It can be 
utilized to study the receptors themselves. 
 
2.2.2 The N-terminus of 5-HT1B modulates the potency of serotonin 
 
2.2.2.1 The bioinformatics analysis of the 5-HT1B receptor N-terminus  
 
 The crystallization of the human 5-HT1B receptor was performed with a hybrid 
and N-terminally truncated version of the 5-HT1B receptor82. Radioligand studies on this 
construct from the same paper, with H3-LSD, concluded that the deletion of the N-
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terminus did not change the binding affinity of ergotamine and its derivatives when 
compared to the wild-type 5-HT1B receptor. However, homology alignment of the 5-
HT1B receptor between species revealed high homology in the N-terminus of the 
protein, suggesting a conserved function. The hallmark N-X-S/T glycosylation pattern 
was present in duplicate in the N-terminus of 5-HT1B receptor throughout mammals 
and was also found in species of Class Aves and Reptilia. Locations of the patterns 
can be seen in Figure 2.8. Additionally, S34, which was identified as a potential 
phosphorylation site by the Netphos 3.1, a phosphorylation prediction algorithm, was 
also highly conserved in the homologs. 
 
P28222| HUMAN         MEEPGAQCAPPPPAGSET-WVPQANLSSAPSQNCS-AKDYIY 40 
P60020| CHIMPANZEE    MEEPGAQCAPPPPAGSET-WVPQANLSSAPSQNCS-AKDYIY 40 
P49144| RABBIT        MEEPGAQCAPPLAAGSQI-AVPQANLSAAHSHNCS-AEGYIY 40 
P28334| MOUSE         MEEQGIQCAPPPPAASQT-GVPLTNL----SHNCS-ADGYIY 36 
P28564| RAT           MEEQGIQCAPPPPATSQT-GVPLANL----SHNCS-ADDYIY 36 
D3Y1H8| CHICKEN       MEPASP-----------CPAPLLPANDSYHGRNCS-AEEGIY 30 
G1KD63| AM. CHAMELEON MEQSSPLCQADQANLEVFPHQPFNASSSPSSPNCSWQESPVY 42 
B3DK14| ZEBRAFISH     MERSGYF-KPTPAHFE--------VLNSSTGTNVTLT-PKTD 32 
                      **  .                         . * :           
 
Figure 2.8. Homology alignment of the N-terminus of the 5-HT1B receptor. Shown here is the 
alignment of the 5-HT1B receptor N-terminus between humans and seven other species. The 
UniProt accession number for each species-specific protein is listed among the common 
names of the species. The conserved theoretical glycosylation sites are highlighted in yellow. 
“*” indicated full conservation of the amino acid, “:” indicates conservation of the amino acid 
with strongly similar properties, and “.” indicates conservation of the amino acid with weakly 
similar properties.  
 
To get an insight into the accessibility of the N-terminus amino acid residues 
that were identified as potentially being post-translational modification sites, a 
structural model of 5-HT1B receptor was generated with I-TASSLER240,258. Several 
models were generated using the crystalized structure of the modified hybrid BRIL- 5-
HT1B receptor (PDB 4iaq) as a template. The top-scoring model, with the highest C-
score, showed that residues N32 and S34 were freely accessible extracellularly while 
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N24 was buried in the membrane (data are not shown). C388 was also freely 
accessible intracellularly in this model. A lower scoring model showed that the 
asparagine residues at 24 and 32, the serine residue 34, and the cysteine residue 388 
to be available for transient post-translational modification (Figure 2.9). The lower 
scoring model was chosen as the top-scoring model had its N24 buried in the 
membrane, which is energetically unfavorable if the residue is glycosylated.  
 
 
Figure 2.9. Model of the 5-HT1B receptor showing the sites of point mutations. A computational 
model was generated with I-TASSER using the chimeric 5-HT1B-BRIL crystalized model (PDB 
ID: 4iaq) as a template. The N-terminus truncated in the crystallizations of 5-HT1B receptor is 
colored in cyan. The sites for glycosylation N24, and N32 are colored in green. The 
phosphorylation site at S34, the ligand recognizing aspartate at D129, and the palmitoylation 
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site at C388 are colored in orange, red, and yellow, respectively. The dashed line represents 
the edges of the cell membrane.  
 
2.2.2.2 Western blots of the mutagenic constructs 
 
To check for the successful transfection of the PRESTO-tango mutant plasmids 
and to identify electrophoretic variances between the mutations, Western blots were 
performed. Cell lysates from cells separately transfected with each of the PRESTO-
Tango alanine point mutations constructs, with a theoretical molecular weight of 84.4 
kDa, showed as bands near 80 kDa on anti-5-HT1B receptor Western blots. Both the 
N24A and the N24A/N32A mutant lysates were negative (Figure 2.10A) when 
incubated with the anti-5-HT1B receptor antibodies. A second anti-FLAG blot was 
performed to test if the negative bands resulted from a transfection issue or an antibody 
recognition problem. The anti-FLAG blot revealed bands in all of the lysates except 
D129A. Sequencing results revealed that the D129A construct had a point mutation in 
the FLAG tag sequence. The band from the double mutant lysate was found at a lower 
kDa and is sharper in resolution than all the other bands from all the other mutants 




Figure 2.10. Western blot of lysate expressing the PRESTO-Tango point mutation constructs. 
Ponceau staining and exposure images of (A) anti-5-HT1B receptor and (B) anti-FLAG blots. 
The anti-5-HT1B receptor shows bands near 80 kDa corresponding to the PRESTO-Tango 
constructs with a calculated mass of 84 kDa. No bands are present in the lysate of non-
transfected HTLA cells, N24A, and the double mutant (DM). The anti-FLAG blot shows bands 
near 80 kDa. Bands are present in all wells except the non-transfected HTLA cell lysate and 
the lysate of D129A, which has a known nullifying point mutation in its FLAG tag. The band in 





2.2.2.3 PNGase F of 5-HT1B 
 
To identify if the N-terminus of the 5-HT1B receptor is glycosylated, a PNGase F 
digest was performed on the cell lysates of HTLA cells transfected with the 5-HT1B 
receptor construct and the double mutant construct. Western blotting demonstrated a 
shift between the digested and non-digested 5-HT1B receptor construct from around 77 
kDa to around 75 kDa (Figure 2.11). Conversely, the double mutant was not sensitive 
to PNGase activity as both the digested and non-digested lysates of the double mutant 
construct appear near 75 kDa. As expected, the GAPDH loading control bands near 
40 kDa showed no difference between the digested and non-digested lysates of either 
constructs or the negative control non-transfected sample (HTLA).  
 
 
Figure 2.11. Western blot of lysates expressing the PRESTO-Tango wild-type (WT) and 
double mutation (DM) constructs digested with PNGase F. The band of the wild-type PNGase 
digested lysate “+” is downshifted from the non-digested “-” lysate and closer in line with the 
bands from the double mutant lysates (A). No shift was observed in the double mutant between 
the digested and nondigested lysates. The loading control bands of GAPDH showed no shifts 





2.2.2.4 PRESTO-Tango mutagenesis 
 
PRESTO-Tango drug dosage dependence curves for each mutant were 
performed to identify whether ligand potency was affected by the point mutations 
(Figure 2.12). The assays showed a significant difference between the EC50 values for 




Figure 2.12. PRESTO-Tango dose respond curves for the point mutants of the 5-HT1B 
receptor. The median EC50 values are listed in Table 2.3. Wild-type curves are in red and point 
mutants are in blue. The curves are fitted four-parameter dosage dependence curves (see 
methods). The HTLA cells (derived from HEK293 cells, containing a tTA-dependent luciferase 
reporter sequence and a stably expressing a β-arrestin2-TEV fusion gene) were transiently 
transfected with a 5-HT1B-tTA fusion gene (HTR1B-Tango). Median measurements are 
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displayed. All error bars are the interquartile range, and RLU is relative light units. The potency 
of serotonin in all mutants was analyzed with a minimum of N = 5 of experimental replicates. 
 
The median change was 36 nM with a p-value of 0.0070, and 38 nM with a p-
value of 0.0012 (Table 2.3), respectively. The respective fold changes were 2.4 with a 
p-value of 0.023, and 2.5 with a p-value of 0.023. Further study on the N24A/N32A 
double mutant showed an even larger shift in the EC50 values. A change in the median 
of 71 nM with a p-value of 0.017 (Table 2.4) was seen. The negative control point 
mutation D129A showed no ligand-receptor-dependent activity. The other point 
mutations S34A and C388A, showed no significant difference in the median EC50 
values (Table 2.3). The 5-HT potencies in all mutants were analyzed with a minimum 
of N = 5 of experimental replicates. The results from this assay instigated further 




[25 %, 75 %] (nM) 
Median Δ 
(nM) 
p- value Fold Change p - value 
WT 27 [12, 32] - - - - 
N24A 63 [41, 76] 36 0.007 2.4 0.023 
N32A 64 [57, 70] 38 0.0012 2.5 0.023 
S34A 37 [32, 47] 10 0.21 1.4 0.17 
D129A N.A. N.A. N.A. N.A. N.A. 
C388A 20 [15, 24] - 6 0.46 0.77 0.86 
 
Table 2.3. Changes observed in the EC50 values of point mutations of 5-HT1B receptor. 






2.2.2.5 PRESTO-Tango wild-type to double mutant comparison studies 
 
Of all of the mutants, the double mutant was identified as having the greatest 
change in the median EC50 values, equaling to 74 nM, which represents over a twenty-
fold decrease in potency (Table 2.4). Thus, the double mutant was selected for further 




Figure 2.13. The chemical structures of the 5-HT1B receptor agonists. The molecular structure 
of serotonin, dihydroergotamine, and sumatriptan are illustrated in charge states 
corresponding to physiological conditions. The serotonin pharmacophore has been highlighted 
in blue in dihydroergotamine and sumatriptan.  
 
The comparative drug assay showed that only serotonin was sensitive to the 
double mutation. Curves can be seen in (Figure 2.14). The other pharmaceuticals, 
dihydroergotamine and sumatriptan, showed no gross changes in their EC50 values 
compared to the wild-type to the double mutant (Table 2.3) assays. They had a change 






Figure 2.14. Dosage response curves for the 5-HT1B receptor agonists serotonin, 
dihydroergotamine, and sumatriptan. Serotonin (A) showed a right shift between the wild-type 
(red) and the double mutant (blue). No shift was observed between the wildtype and double 
mutant with dihydroergotamine (B) and a minor shift to the left in sumatriptan (C). The median 
EC50 values are listed in Table 2.4 for all of the compounds. The curves were fitted with four 
parameters (see methods).The HTLA cells (derived from HEK293 cells, containing a tTA-
dependent luciferase reporter sequence and a stably expressing a β-arrestin2-TEV fusion 
gene) were transiently transfected with a 5-HT1B-tTA fusion gene (HTR1B-Tango). Median 
measurements are displayed. All error bars are the interquartile range, and RLU is relative light 
units. All drug potencies were analyzed with a minimum of N = 6 of experimental replicates.  




 To understand why the 5-HT structurally similar compound sumatriptan was 
not responsive to the double mutation, the compounds bufotenine and didesmethyl 
sumatriptan were assayed (Figure 2.15). These compounds each contained a single 




Figure 2.15. The chemical structures of the 5-HT1B receptor analogs. An Illustration showing 
the structural differences between Bufotenine and didesmethyl sumatriptan with serotonin. The 
structures are illustrated with charge states observed under physiological conditions. The 
pharmacophore of serotonin within both compounds is shown in blue.  
 
The assay revealed that the intermediate didesmethyl sumatriptan, with a 
sulfonamide R group replacing the hydroxide found in serotonin, showed a large and 
significant change in the EC50 values between the wild-type and the double mutant 
(Figure 2.16B). The median EC50 values changed by 410 nM with a p - value of 0.017 
(Table 2.4). With a tertiary amine replacing the primary amine found in serotonin 
(Figure 2.16A), Bufotenine did not show a large change in the EC50 values between 
the wild-type and the double mutant (Table 2.4). All drug potencies were analyzed with 





Figure 2.16. Dosage response curves of the serotonin analogs. Bufotenine (A) showed no 
shift in dosage response curves between the wild-type (red) and the double mutant (blue). 
Didesmethyl sumatriptan (B) showed a right shift in the dosage response curve when 
comparing the wild-type (red) with the double mutant (blue). The median EC50 values are listed 
in Table 2.4 for both compounds. The curves were fitted with four parameters (see methods). 
The HTLA cells (derived from HEK293 cells, containing a tTA-dependent luciferase reporter 
sequence and a stably expressing a β-arrestin2-TEV fusion gene) were transiently transfected 
with a 5-HT1B-tTA fusion gene (HTR1B-Tango). Median measurements are displayed. All error 
bars are the interquartile range, and RLU is relative light units. All drug potencies were 
analyzed with a minimum of N = 5 of experimental replicates. 
 
Agonist 
WT Median EC50 
[25 %, 75 %] (nM) 
DM Median EC50 
[25 %, 75 %] (nM) 
Median 
Δ (nM) 
p - value 
Fold 
Change 
p - value 
5-HT  3.3 [0.91, 5.3]  74 [16, 490]  71 0.0173 23 0.043 
DHE  3.1 [2.7, 3.3]  3.8 [3.1, 6.1]  0.19 0.96 1.2 0.11  
SUM 150 [130, 170]  95 [83, 110]  - 51 0.0087 0.65 0.0065 
BUF 39 [20, 59]  32 [21, 42]  -7.1 0.59 0.82 0.57 




Table 2.4. Calculated EC50 values of agonistic compounds in the 5-HT1B wild-type receptor and 
the double mutant receptor. The p values were calculated using a two-sided hypothesis with a 
significance threshold of 0.05. DM is the double mutant N24A, N32A, WT is the unmodified 5-
HT1B PRESTO-Tango construct, DHE is Dihydroergotamine, SUM is Sumatriptan, BUF is 
Bufotenine, and DMS is Didesmethyl Sumatriptan. 
2.2.3 Molecular Dynamics simulations point to a fly-casting mechanism 
 
2.2.3.1 Characteristics of the N-terminus 
 
To understand the effects of the glycans on the N-terminus structure of the 5-
HT1B, we performed MD simulations of the entire wild-type and double mutant receptor. 
The simulations were executed in the presence of three different ligands serotonin, 
sumatriptan, and dihydroergotamine. The simulations were run until 2 μs were 
simulated. We then analyzed the simulations for the structural properties of the N-
terminus. 
We analyzed the N-terminal for secondary structural propensities, hydrophobic 
interactions, salt bridges, and the radii of gyration (Figure 2.17). The N-terminus had 
little to no alpha-helical tendencies in all simulations, except in the double mutant 
simulations with sumatriptan and dihydroergotamine. However, only a limited amount 
of alpha-helical formations were observed. The beta-sheet formations were little to 
non-existent in the N-terminus for all of the simulations. The wild-type and wild-type 
serotonin simulations showed the greatest amount of beta-sheet forming residues. 
With a count below two in these simulations, the beta-sheet formation was considered 
to be minimal.  
The radii of gyration indicated structural rearrangements. In particular, they 
showed that in the wild-type simulation, the N-terminus was extended and flexible. In 
contrast, in the double mutant simulation, the N-terminus became both less flexible 
and less extended. Additionally, in the wild-type simulation, the N-terminus’ radii of 
gyrations appeared to have a bimodal distribution and a unimodal distribution in the 
double mutant simulation. 
Interestingly, when the serotonin was included with the wild-type receptor, the 
observed radius of gyration maxima became unimodal, tightly packed. The left shift 
showed that once bound to the ligand, the N-terminus adopted a more condensed 
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ensemble of conformations. The contraction indicates that the N-terminus could be 
bringing the ligand closer to the binding site. This contraction is not observed in the 
double mutant with serotonin simulations, where the peak was slightly shifted and had 
a broader distribution. The double mutant simulation distribution appeared very similar 
to the histogram from the double mutant simulation with serotonin. Sumatriptan 
affected the radius of gyration similarly to serotonin.  
In the simulation with the wild-type, sumatriptan appeared to create a narrower 
distribution compared to the wild-type only simulation. In the double mutant with 
sumatriptan simulation, the distribution was similar to the double mutant only 
simulation distribution. Dihydroergotamine in both the wild-type and the double mutant 
simulations appeared to drive a bimodal and extended distribution of the N-terminus 
radii of gyrations. The distribution was more condensed and unimodal in the double 
mutant with dihydroergotamine simulation. 
Another indication of the compactness is the number of hydrophobic contacts. 
The number of contacts between hydrophobic residues was increased in the double 
mutant over the wild-type simulations. The higher number of contacts suggests greater 
compactness which was also seen when comparing the radii of gyration. These results 
indicated that the glycans extend the N-terminus. The extension was likely driven 
through the steric hindrance and the repulsion of hydrophobic residues by the glycans. 
With the ligands, serotonin in the wild-type receptor was similar to the wild-type 
with a narrower distribution. The more limited distribution of the number of hydrophobic 
residues interactions agreed with a reduction in the N-terminus flexibility observed in 
the radius of gyration. The opposite was seen with serotonin and the double mutation, 
where the number of hydrophobic contacts increased. The increase is in agreement 
with the lack of extensions of the N-terminus observed in this condition. 
An even more significant narrowing of the distribution of the hydrophobic contact 
was seen with sumatriptan. The narrow distribution suggested a reduced random 
motion of the N-terminus, which agreed with a reduced and narrowly distributed radius 
of gyration. In the double mutation with sumatriptan simulation, broader distribution 
and increased hydrophobic contacts were observed over the double mutant simulation.  
In the simulations with dihydroergotamine, the wild-type showed a generally 
reduced number of hydrophobic contacts. However, there was a distinct population 
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with a higher number of contacts. The two populations agreed with the bimodal 
distribution seen in the radius of gyration. In contrast, in the double mutant with 
dihydroergotamine simulation, the distribution was quite narrow and centered on ~15 
contacts, similar to the double mutant simulation. This behavior was not mirrored in the 
radius of gyration distribution, which showed an extended N-terminus. The difference 
between the two structural properties may have arisen from dihydroergotamine’s 
hydrophobicity, where the N-terminus interacted with the ligand instead of itself or 
ECL2. 
The number of salt-bridges in the wild-type simulations was bimodal with a 
distinct population devoid of salt-bridges and a population containing around three salt-
bridges. Sumatriptan was the exception where the population without salt-bridges was 
not observed, and the population with three salt-bridges was greater than in the ligand-
free simulation. Comparing the ligand-free simulation with the simulation containing 
serotonin, a distinct increase in the count of frames with around 3 salt-bridges was 
seen. In contrast to the radii of gyration and hydrophobic interactions, the number of 
salt-bridges in the N-terminus did not appear to change. Dihydroergotamine showed 
little to no difference compared to the just the wild-type simulation. The double mutation 
simulations showed minimal salt-bridge formation. The double mutation simulations 
with ligands showed a few frames with three salt-bridges, with sumatriptan containing 





Figure 2.17. N-terminus characteristics form MD simulations of 5-HT1B. Histograms of any 
neighboring six residues of the N-terminus in an alpha-helical conformation in red. No 
significant changes were seen except for sumatriptan (SUM) and dihydroergotamine (DHE) 
with the double mutant (DM-5-HT and DM-DHE), which showed more alpha-helical 
populations. Histograms of any neighboring six residues of the N-terminus in a parallel or anti-
parallel conformation in green. Minimal differences were observed between the different 
distributions. In blue, the population of radii of gyrations (Rgyr) of the N-terminus of each 
simulation is shown. The wild-type (WT) showed a bimodal distribution and was further 
extended than the unimodal double mutant (DM). Adding serotonin (5-HT) to the WT (WT-5-
HT) decreased the Rgyr and each population's amount, indicating increased flexibility. A 
decrease in the extended population was seen in DM-5-HT simulation compared to DM. SUM 
showed decreases in the Rgyr in the WT, but not the DM when compared to the respective 
ligand-free simulation. DHE showed and extended Rgyr in both the WT and DM, with the WT-
DHE showing bimodal distribution. In dark yellow, the number of hydrophobic interactions 
between hydrophobic residues. Between the WT and the DM, a slight increase of populations 
with higher hydrophobic interactions was observed. When the WT interacted with 5-HT, there 
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were similar amounts of hydrophobic contacts with a lower distribution of populations than the 
WT. In contrast, there were more hydrophobic contacts in 5-HT with the DM compared to the 
DM only simulation. With SUM, hydrophobic interactions remained the same with a lower 
distribution in both the WT and DM. DHE increased the number of hydrophobic contacts in the 
WT and had little change in the DM. In purple, the number of salt-bridges in the N-termini is 
displayed. The WT simulations showed a bimodal population with and without salt-bridges. 
Only sumatriptan with the WT was devoid of the major populations free of salt-bridges. The 
DM simulations show minimal slat-bridge activity. 
 
2.2.3.2 Ligand interactions with extracellular domains 
 
To better understand the N-terminus' role in modulating ligands' potency, we 
scanned the N-terminus areas, which interact (within 4 Å) with ligands during the MD 
simulations. In simulations of the wild-type receptor, serotonin interacted with the N-
terminus in 9.4 % of frames (Figure 2.18A) compared to less than 0.66 % of frames in 
the double mutant receptor without the glycans (Figure 2.18B). The number of 
interactions was reduced near fourteen-fold. With an interaction in 9.4 % of frames, 
serotonin exhibited weak binding. Of these frames, the majority occurred with the 
glycans and near the residues around the glycans. Without the glycans, the double 
mutant, the binding focused on the first few residues of the N-terminus and the amino 
acids of ECL2. The contrasting observations of binding frequency between the wild-





Figure 2.18. Binding events of serotonin to the extracellular domains of the wild-type and 
double mutant 5-HT1B receptor. The percentage of frames that have binding serotonin events 
with atoms of either the N-terminus of ECL2 in green. Of the bound frames, the percentage of 
frames binding at atoms of specific residues is in red. The percentage of frames with binding 
at atoms associated with glycans is in blue. About a six-fold decrease in total binding events 
was observed when the glycans are removed from the system. Binding events in the wild-type 
(A) occur in about 9.4% of frames indicating weak binding. The majority of the binding events 
occur with the glycan bound to N24. The binding events occurred in the N-terminus residues, 
mainly between residues 24-33. In the double mutant (B), the binding events that did occur 
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were concentrated in the first few residues of the N-terminus and ECL2 residues. Found on 
the figure's far-right a list of the amino acids of 5-HT1B with their corresponding positions. 
 
Sumatriptan, while structurally similar to serotonin, had very different 
interactions with the N-terminus. Sumatriptan demonstrated profound binding behavior 
in both the wild-type and the double mutant. Sumatriptan was bound to either the N-
terminus or the ECL2 in over 89 % of wild-type frames (Figure 2.19A) and over 92 % 
of the double mutant frames (Figure 2.19B). Of the bound frames in the wild-type 
simulation, sumatriptan is almost exclusively bound to the N-terminus residues 5 to 10 
and ECL2 residues 202 to 204. However, in the double mutant, most of the binding 
events occurred in residues 36 to 40 and residues 196 to 200 of ECL2. Regardless of 
the high binding rate of sumatriptan, the potency was not affected by the interactions. 





Figure 2.19. Binding events of sumatriptan to the extracellular domains of the wild-type and 
double mutant 5-HT1B receptor. In green, the percentage of frames that had binding events 
between sumatriptan and either the N-terminus or ECL2. Of the bound frames, in red, the 
percentage of frames bound to atoms of specific residues. The percentage of frames with 
binding at atoms associated with glycans is in blue. Sumatriptan bound consistently to the N-
terminus and the ECL2 in both the presence and absence of glycans, greater than 89 % for 
both systems. The binding events in the wild-type (A) occur in the N-terminus, mainly between 
residues 5 to 10 and in the ECL2 at residues 202 to 204. In the double mutant (B), the binding 
events were more frequent and appeared mostly near the base of the N –terminus at residues 
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36 to 40. The majority of binding events occurred with the ECL2 at residues 196 to 200. On 
the far right of the figure is a list of the amino acids of 5-HT1B with their corresponding positions. 
 
 Dihydroergotamine, a large polycyclic molecule with serotonin as a 
pharmacophore, showed interaction with the N-terminus or ECL2 in 21 % of the wild-
type and 15 % of the double mutant frames (Figure 2.20). Of those interactions, in the 
wild-type, the majority were with the glycans. Most interactions with the N-terminus 
occurred from residues 1 to 30, and no interaction with ECL 2 occurred. The double 
mutant differed as it had binding events with ECL2, generally between residues 188 to 
194. Interactions with the N-terminus appeared to be broad and centered on residues 




Figure 2.20. Binding events of dihydroergotamine to the extracellular domains of the wild-type 
and double mutant 5-HT1B receptor. In green, the percentage of frames that had binding events 
with dihydroergotamine and the N-terminus or ECL2. Of the bound frames, in red, the 
percentage of frames bound to atoms of specific residues. The percentage of frames with 
binding at atoms associated with glycans is in blue. Dihydroergotamine bound weakly to the 
extracellular components of the receptor in both the presence and absence of glycans. Binding 
occurred in 20 % and 15 % of frames for both the wild-type and the double mutant, respectively. 
The binding events in the wild-type (A) occur in the N-terminus mainly between residues 1 to 
30 and with the glycans. In the double mutant (B), the binding events occurred similarly, but 
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centered around residues 10 and 21, both prolines. Additionally, binding did occur in the ECL2 
for the double mutant. On the far right of the figure a list of the amino acids of 5-HT1B with their 
corresponding positions. 
 
2.2.3.3 Ligand interactions with the binding site 
 
The distance between the ligand and the binding site's geometric center (Figure 
2.21) was measured in each frame of each of the simulations to check whether glycans 
could increase the receptor's activation. 
 
 
Figure 2.21 The binding site of 5-HT1B. The residues corresponding to the binding site are 
colored in purple. On the bottom left, a zoomed-out view of the entire receptor. The binding 




For serotonin, there was a distinct population close to the binding site in the 
wild-type that was not present in the double mutant simulation (Figure 2.22). 
Additionally, a binding event that occurred during the wild-type simulation is indicated 
by the bar near zero. For sumatriptan, there were a high number of frames with the 
ligand near the binding site in both simulations. Additionally, sumatriptan found the, 
binding site and remained in it for a moderate duration. A binding event was not 
observed for dihydroergotamine in either simulation. However, in the wild-type 
simulation, a population of frames was present where dihydroergotamine was closer 
to the binding site than in the double mutant simulation. 
 
 
Figure 2.22 Histogram of the distance of the ligand from the binding site. In red, the count of 
frames with a specific distance of the ligand from the binding site's geometric mean. In the 
wild-type (WT), serotonin had the ligand in the binding site, which was not the case for the 
double mutant (DM). Sumatriptan had binding events in both simulations. Dihydroergotamine 
was closer to the binding site when the glycans were present, with the most populous distance 
from the binding site being between 1 and 2 nm. 
 
2.2.3.4 Self-organizing maps of the N-terminus and ECL2 
 
Self-organizing maps (SOMs) were utilized to determine if the glycans or the 
ligands drive formations of specific conformations in the IDPR of the N-terminus and 
ECL2. Overall, unique clusters were observed for each simulation, along with some 
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clusters that remained constant. However, no dominant specific conformation was 
identified in any simulation. The SOMs show that all of the ligands interacted with the 
extracellular domains and, along with the glycans, influenced the extracellular 
domain’s structure.  
In the wild-type simulation (Figure 2.23A), there is a clear cluster at (20, 15) that 
was absent in the double mutant. The double mutant showed small unique clusters at 
(20, 20), (25, 30), and (45, 40) that only appeared in the simulations with DM receptor, 
except for dihydroergotamine. The different clustering showed that the glycans 
affected the structure of the extracellular domains. The ligand simulations also showed 
unique clustering.  
In the serotonin simulations, there were distinct clusters at (15, 25) and at (20, 
35) in the wild-type simulation (Figure 2.23B). The double mutant had unique clusters 
at (25, 35) and near (35, 1) present in all double mutant simulations. In both simulations 
with serotonin, the interactions with ligand changed the conformational of the 
extracellular domains. This pattern continued with sumatriptan. 
In the sumatriptan simulation, there were distinct clusters. In the wild-type 
simulation (Figure 2.23C), there was a large cluster centered near (20, 45) and two 
smaller clusters at (15, 2) and (40, 2). These were not present in the double mutant 
simulation where there were distinct clusters at (30, 45) and (40, 45). Additionally, a 
small populated cluster was near (18, 18) and (26, 35). Like sumatriptan, 
dihydroergotamine also showed a stark difference between the two receptors. 
The dihydroergotamine SOMs showed a large difference between the wild-type 
and double mutant simulations. The wild-type simulation was similar to the wild-type 
with no ligand simulation. The exceptions were having a single-pixel populated cluster 
replacing the large cluster, seen in the no ligand simulation, at (20, 15) and a unique 
cluster (1, 49). The double mutant simulation showed a marked absence of clusters. 
There were three distinct populous clusters. Two small clusters at (1, 31) and (15, 30), 






Figure 2.23 Self-organizing maps (SOMs) of the wild-type (WT) and double mutant (DM) 
simulations with ligands. Simulations without ligands, in A, showed different clustering of 
conformations between the WT and DM simulation. The large cluster centered at (20, 15) in 
the WT was absent in the DM, and the DM had unique clusters at (20, 20), (25, 30), and (45, 
40). In B, SOMs of serotonin (5-HT) simulations showed a difference between WT and the DM 
simulations. Distinct clusters were seen at (15, 25) and at (20, 35) in the WT simulation. DM 
has unique clusters at (25, 35) and near (35, 1). In C, sumatriptan showed in WT a large cluster 
centered near (20, 45) and two smaller clusters at (15, 2) and (40, 2). The DM did not have 
these clusters, but had distinct clusters at (30, 45) and (40, 45), and small high count clusters 
near (18, 18) and (26, 35). In D, a single-pixel populated cluster was seen at (20, 15) and a 
unique cluster at (1, 49) in WT. The DM showed a void of clusters. Three distinct populous 
clusters were observed, two small ones at (1, 31) and (15, 30), and one large one centered 
near (35, 35). White pixels indicate no conformations were counted. 
 
2.2.3.5 Fly-casting-like mechanism of the N-terminus 
 
The above results tell us that serotonin and dihydroergotamine bound weakly to 
the glycans of the N-terminus of 5-HT1B. Additionally, sumatriptan did not show the 
same activity and had minimal interactions with the glycans. In conjunction with the 
analysis of the N-terminus structure, these observations hint towards ligand-specific 
interactions. Foremost it appears that all of the ligands caused the N-terminus to 
contract in some capacity, with serotonin having the greatest effect. Uniquely, 
dihydroergotamine caused a second extended population in the simulation, possibly 
by interacting with hydrophobic residues. 
In contrast, the ligands behaved differently on the extension of the N-terminus 
in the double mutant simulations. There were minimal differences between the no 
ligand simulations and the ligands' simulations, except for dihydroergotamine which 
again showed an extended N-terminus population. Dihydroergotamine’s observations 
may be due to the N-terminus' hydrophobic areas, especially the proline residues, 
interacting with dihydroergotamine. Dihydroergotamine is hydrophobic with a log P of 
2259. Studying if and which residues interacted with the ligands highlighted some key 
differences between the ligands.  
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Serotonin was sensitive to the presence of glycans on the N-terminus of the 
receptor. The number of binding events in the glycans' presence tells us that there 
were interactions of the N-terminus with serotonin, but their low-frequency points to 
them being weak interactions. Additionally, when the glycans were not present, binding 
events almost disappear, occurring at a near fourteen-fold lower rate. In the few 
observed binding events, serotonin is bound to different residues of the N-terminus 
and ECL2. In juxtaposition, sumatriptan did not interact with the glycans and was 
strongly bound to the N-terminus in both simulations. Sumatriptan facilitated the folding 
of the N-terminus onto itself and ECL2. In the sumatriptan double mutant simulations, 
the absence of the glycan’s steric hindrance likely favored a different N-terminus region 
to be involved in the fold reflected in other N-terminus residues interacting with the 
ligand.  
Finally, dihydroergotamine was also bound to the glycans and the N-terminus 
like serotonin. However, dihydroergotamine bound about twice as often as serotonin, 
and in the double mutation, the binding events only reduced by about 30 %. In the 
absence of the glycans, dihydroergotamine is bound to ECL2. Interestingly, the 
experimental data did not show any difference between the wild-type and the double 
mutant. The lack of a difference may be due to the ligand's preference to intercalate 
into the membrane. Through the membrane, the ligand may find access to the binding 
pocket opening, independent of the N-terminus. Further analysis on all of the 
simulations showed that the extracellular domains reacted to the ligands differently and 
were dependent on the N-terminal glycans. 
The SOMs showed unique conformational trajectories between the wild-type 
and the double mutant and between the different ligands. While unique conformations 
showed the interaction between ligand and the extracellular domains, they did not 
confer the binding activity's effect. The ligand's proximity to the binding site residues in 
the different simulations showed binding events for serotonin in wild-type simulation 
and both of the sumatriptan simulations. No binding events were observed in the 
dihydroergotamine simulation. Serotonin showed a population of frames with the ligand 
present within 2 nm of the binding site in the wild-type simulation that was not present 
in the double mutant simulation. 
This combination of data suggests a fly-casting-like260–262 mechanism of action 
for the N-terminus of 5-HT1B. Where in this mechanism, the free motioning N-terminus 
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attracts nearby floating serotonin molecules and brings them closer to the opening of 
the active site of the receptor by shuttling serotonin through the glycans and ECL2 
through weak interactions (Figure 2.25).  
 
 
Figure 2.25 MD simulations snapshots. In A, serotonin is briefly bound to residues E2 and E3 
of the N–terminus. In B, serotonin is bound to the glycan and swept toward ECL2, where it is 
bound to E198 (C). In D, serotonin moves toward the binding pocket, and the glycans behave 
as a cap, sterically hindering the escape of the ligand. The N-terminus is in cyan, ECL2 is in 





This mechanism acted to create locally increased concentration of serotonin, 
effectively increasing its potency. The weak interaction appeared to be critical. The 
stronger basic tertiary amine of sumatriptan caused the ligand to traps the N-terminus 
in a fold and eliminated its aggregation function (Figure 2.26). The glycans' presence 
changed the fold's specific residue interactions, but some folding still occurred in the 
glycan's absence. The larger hydrophobic ligand dihydroergotamine appeared to 




Figure 2.26. Folded N-terminal structure in sumatriptan simulation. In both the wild-type (WT) 
and the double mutant (DM), the N-terminal folds onto itself when interacting with sumatriptan 
and ECL2. In A, the glycans' presence altered how the fold occurs, involving residues from the 
beginning of the N-terminus. In B, the DM simulations, the residues at the base are engaged 
in the N-terminus fold. The N-terminus is in cyan, ECL2 is in dark green, the transmembrane 
helices are in grey, the glycans are in green, and sumatriptan is purple. Residues that interact 




For the first time, we have demonstrated that the sites for post-translational 
modifications found in the N-terminus of 5-HT1B receptors play a role in modulating 
serotonin's potency. Specifically, we have observed that removing the two 
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glycosylation sites at N24 and N32 decreases the potency by over twentyfold. Of 
particular interest is that these residues are not at the active site, are located 
extracellularly, and code for some transiently modified PTMs. These facts make it 
logical to conclude that physiological responses that involve enzymatic activity may 
modify serotonin's potency on the 5-HT1B receptor. Additionally, it may be that different 
cell types with varying glycosylation programs make receptors with differing 
sensitivities to serotonin. These possibilities would need experimental verifications. 
These findings may open up the ability to target specific cell types expressing the same 
receptor using structurally specific molecules or biologics if valid. Additionally, we have 
shown that potency change relies on serotonin's primary amine, possibly via a fly-
casting mechanism. When substituted with a tertiary amine, the sensitivity to the 
double mutant dissipates. 
PRESTO-Tango, an open-source GPCRs drug screening assay that utilizes 
plasmid transfected into PRESTO, a cell line stably expressing luciferase, was adapted 
to identify whether sites for post-translation modifications play a role in the potency of 
5-HT1B receptors ligands. This method was selected as it was already verified to 
function for the wild-type 5-HT1B receptor. The N-terminus of the 5-HT1B receptor was 
of particular interest because it has several potential PTMs sites highly conserved 
between species. An N-terminus truncated version of the protein was assayed for 
binding affinity by the team who crystalized the receptor, demonstrating no change in 
affinity between the wild-type and the truncated receptor. However, the group only 
investigated ergotamine and its derivatives, not the receptor's natural ligand, serotonin. 
Our studies that looked at the ligands' potencies found that the glycosylation sites 
found in the N-terminus influenced the potency of serotonin on the 5-HT1B. 
The other residues with potential for PTM were observed not to affect the 
potency of the serotonin. The D129A mutant also interrupted receptor activity in our 
assay. This point mutation, located in the binding pocket that normally interacts with 
serotonin's primary amine, is known to abolish receptor activity. However, some 
luminescence increase with concentration was still observed. This observation may be 
an artifact from induced activation of the HT1B receptor caused by heterodimerizing 
with the 5-HT1D receptor84. This receptor is endogenously expressed in the HEK293 
cell line263, the parent cell line of HTLA cells. It is important to note that the S34A 
mutation, which is part of the N-X-S pattern for the glycosylation at N32, demonstrated 
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no change in the EC50 values nor showed a band shift in the Western blot. It appears 
that in this mutant, the N32 is still glycosylated. While rare, nonconsensus N-linked 
glycosylation sequences have been reported before264. Particularly, the inverse 
sequence S-X-N within three residues of flexible residues, such as the conditions 
present around N32 in 5-HT1B, has been demonstrated265 and explains why we still 
see glycosylation in the S34 construct. Finally, C388, which is palmitoylated but not 
vital for protein translocation to the membrane266, was a selected target for mutation 
due to the transient nature of palmitoylation267, making it a candidate for receptor 
activity modulation. Our results showed that palmitoylation did not affect the potency 
of the 5-HT1B receptor. Although negative, this result is interesting when taken into 
conjunction with the demonstration that palmitoylation is not crucial for membrane 
targeting of this receptor. It begs the question of the functional purpose of this PTM on 
the 5-HT1B receptor. 
When testing other 5-HT1B receptor agonists, including dihydroergotamine, we 
observed no change in potency between the wild-type and the double mutant receptor. 
This result agrees with the affinity studies reported by Wang et al. The ligand-
dependent variance in the double mutant responses leads one to believe that the 
glycosylation’s functional role is not one of global conformational stabilization of the 
receptor. It may indicate that the sugars of the N-terminus interact with the ligand. To 
further investigate the ligand’s structural group interacting with the N-terminus, we 
tested serotonin analogs, structurally lying between serotonin and sumatriptan (Figure 
2.15). Our experiments revealed that the primary amine of serotonin appears to be the 
interacting functional group. When the primary amine is changed to a tertiary amine, 
the large change in EC50 values observed between the double mutants and the 
receptor's wild-type form is lost. Both dihydroergotamine and sumatriptan have this 
amine in tertiary constructs in their pharmacophores. The tertiary amine may explain 
why they have no significant observed change in their EC50 values when tested in the 
double mutant. Although, dihydroergotamine’s polycyclic structure may also be 
responsible. 
Evidence from the observed band shifts in our Western blot of the PNGase F 
digest of transfected HTLA cells' lysate shows that these residues are indeed N-linked 
glycosylated. The slight shift observed between the PNGase F digested wild-type band 
and the double mutation band may be explained by the lack of other post-translational 
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modifications inhibited from conjugated when the glycans are not present. The 
inhibition, however, would need to be experimentally proven. Understanding the 
different glycosylation patterns that may decorate this receptor, based on which cell 
types the receptor is being expressed in, would give us an understanding if this is a 
site for cell type-specific regulation. Finally, while homology alignments suggest it, it 
would be interesting to see whether other species, specifically the common animal 
models, also have serotonin potency modulating factors in their N-terminal residues. 
Like in 5-HT1B, the N-terminus in other GPCRs has been demonstrated to have 
various functions, and several models have been proposed based on these functions72. 
Models of extracellular allosteric modulators of GPCRs signaling have been 
proposed268. Interestingly, PTMs themselves have been identified to be allosteric 
modulators269. The glycosylation of the N-terminus of 5-HT1B may yet be another 
example of this and maybe an interesting target for pharmaceutical interventions.  
Our MD simulations gave us a better understanding of a potential mechanism 
behind the N-terminus’ modulation of the potency of 5-HT. The MD simulations showed 
that the N-terminus is dynamic, very flexible, and probes the space around its radius 
of gyration. Additionally, 5-HT weakly binds to the N-terminus, causing its contraction 
(decrease in the radius of gyration) and flexibility. These observations taken together 
suggest the N-terminus is scavenging for 5-HT molecules and bringing them closer to 
the active site of the receptor in a fly-casting-like manner. However, instead of 
anchoring chemokine ligands like described in other GPCR with this mechanistic 
action261,262, the N-terminus potentially creates a locally increased concentration of 5-
HT at the opening of the binding pocket of 5-HT1B. Thereby it increases the potency of 
5-HT on 5-HT1B.  
The other ligands did not benefit from the fly-casting mechanism as their 
interaction with the receptor's N-terminus differed. Sumatriptan, containing a tertiary 
amine functional group, bound tightly to the N-terminus. Consequentially, the radius of 
gyration of the N-terminus was nearly halved. The smaller radius of gyration indicates 
potential induced unstructured folding of the N-terminus to a non-function 
conformation. In juxtaposition, dihydroergotamine interaction with the N-terminus 
hydrophobic residues did not influence the N-terminus' behavior. Nor did the potency 
of dihydroergotamine benefit. It appears that 5-HT binding affinity, likely stemming from 
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having primary amine instead of the tertiary amine as in sumatriptan, allows it to be 
gathered by the N-terminus and enables it to be released closer to the active site of 
the receptor. The affinity of 5-HT lies in a “sweet spot,” giving a potential area for 
physiological regulatory function via PTMs. Our work shows that the N-glycosylation in 
the N-terminus of 5-HT1B has a role, but the exact mechanism needs to be proven 
experimentally, whether it is a fly-casting or another. 
  This work's logical continuation would be to identify the glycans involved in 
these interactions and confirm that the receptor’s glycans vary between different cell 
types. Additionally, seeing if the N-terminal glycosylation tempers the ligand potency 
of other GPCRs is of interest. If glycosylation varies and we see a change in potency 
based on sugar composition, it may enable increased tissue specificity when designing 
molecular or biological therapeutics. We have demonstrated that the glycosylation in 
the N-terminus of the 5-HT1B receptor adjusts serotonin's potency. Our work identifies 
that the extracellular residues of 5-HT receptors can be a factor in the potency of 
ligands of the receptors, even outside of stabilizing specific protein conformations. The 
knowledge shown in this thesis opens up the possibility of identifying new 




3 Part II 
 
Skeletal muscles are studied for multiple reasons. After the age of fifty muscle 
mass decreases at a rate of 1-2 % in humans, and this muscle loss can lead to an 
increased risk of frailty270. Additionally, skeletal muscles are involved in many 
diseases, including various myopathies and cachexia (muscle wasting) which is seen 
in up to half of all cancer patients271. From a biotechnological aspect, skeletal muscles 
are intensely studied in the pursuit of commercializing cell-cultured meat. All of the 
areas mentioned above of study look at the regenerative properties of skeletal muscle 
to better understand it and utilize them for their applications. 
 
Recently, data has shown that the serotonin pathway exists in murine skeletal 
muscles. Serotonin appeared to increase the proliferation of skeletal muscle cells in 
mouse models. However, the skeletal muscle proliferation mechanism is unclear, and 
the existence of the serotonin pathway in human skeletal muscles is unknown. 
We hypothesized that the serotonin pathway was present in precursor human 
skeletal muscle cells. Further, we believe that serotonin is involved in the proliferation 
of precursor muscle cells. We additionally wanted to understand by which receptor 
serotonin was acting to identify potential therapeutic targets. Finally, we wanted to 
know which mechanisms the serotonin receptors were regulating to understand better 
how proliferation is activated. 
With cell biological techniques, we showed that serotonin increased proliferation 
of human myoblasts. Biochemical methods showed that several serotonin receptors 
and associated proteins are present in the human myoblast. Additionally, we see that 
several cellular signaling mechanisms are effect by the presence of serotonin. 
Together we know that serotonin indeed plays a role in skeletal muscle regeneration 







3.1 Materials and Methods 
 
3.1.1 Characterizing the immortalized human myoblast cell line 
 
3.1.1.1 Measuring the doubling time of the immortalized myoblasts 
 
The immortalized cell lines were gifted from Vincent Mouly’s lab (Ref. 
AB1190C16PV). The cell line originated from a paravertebral muscle of a 16-year-old 
human male who declared not to have any neuromuscular disease at the time of 
collection. The cells were immortalized with two lentiviral vectors contain hTert and 
cdk4, as described by Machaoui et al.272. The cells were cultured in a tissue culture-
treated T75 flask in 10 mL of Skeletal Muscle Cell Growth Medium (SM), Ref. C-23060, 
from PromoCell (Heidelberg, Germany) with 1 % penicillin and streptomycin at 37 °C 
with 5 % CO2. The cells were then trypsinized with 2 mL of 0.05 % of trypsin at 37 °C 
until the cells detached from the bottom of the flask. The trypsinization was quenched 
by adding 3 mL of 4 °C DMEM with 10 % FCS and 1 % penicillin and streptomycin to 
the flask. The cells were then transferred via a serological pipette to a 15 mL conical 
centrifuge tube. The cells were pelleted by centrifugation at 300 x g for 3 minutes at 
RT. The supernatant was removed via pipetting, and the cells were resuspended in 10 
mL of 37 °C SM. The cells were counted using a KOVA cell counter slide after diluting 
the cells 1:1 with trypan blue. A new T75 flask was seeded with 1.2 x 106 myoblasts in 
10 mL of fresh 37 °C SM. The flask was then placed on top of a Cytonote 1W camera 
by iPRASENSE (Clapiers, France) inside an incubator. The cells were allowed to 
incubate at 37 °C and 5 % CO2 for 72 hours with the camera recording. The 
iPRASENSE software was set to take an image every ten minutes and count the cells 
in the image for the entire 72 hour period. The data were then exported to prism to 
generate the figure. 
 
3.1.1.2 Identifying the optimal culture medium changing protocol 
 
For the medium changing protocol experiments, three tissue culture-treated 12-
well plates were seeded with 5 x 105 myoblast in 1 mL of SM into each plate’s well. 
The cells were then allowed to incubate overnight at 37 °C and 5 % CO2. The following 
day the 0 Hr wells had their culture medium collected in a 1.5 mL centrifuge tube. The 
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wells were then gently washed with 0.5 mL of PBS and were trypsinized with 0.15 mL 
of 0.05 % trypsin for 5 minutes at 37 °C. A 0.1 mL of FBS was added to each well to 
quench the trypsin action. The previously stored cell culture medium was used to 
pipette their correlated well to collect the cells and moved them to their corresponding 
tube. The cells were then pelleted by centrifugation at 300 x g for 3 minutes. The 
supernatant was removed from the pellet, and the cells were then gently resuspended 
into 0.5 mL of RT PBS. A 10 µL aliquot of the resuspended cells was mixed with 10 µL 
of trypan blue and counted on a KOVA cell counter slide. 
For the later time point wells, the half medium volume change labeled wells had 0.5 
mL of their medium replaced with fresh SM. The full medium volume change labeled 
wells had their entire cell culture medium replaced with 1.0 mL of fresh SM. The plates 
were then placed back into the incubator and allowed to incubate as previously for 
another 24 hours. Following the counting, the media change was repeated above for 
24, 48, and 72 hours at those respective periods. The media was changed every 24 
hours, and the cells were counted once at the appropriate time point. The data were 
then aggregated in excel and moved to prism for analysis and figure generation. The 
analysis consisted of Dunnett’s multiple comparison test of each time point versus the 
“0 Hr” time point to adjust for the experimental setup’s multiplicity. Each condition was 
performed in biological triplicate, and the data graphed for visualization. 
 
3.1.1.3 Optimizing human myoblast transfections 
 
To qualify the transfection reagent, which yielded the best transfection 
efficiency, several commercial transfection reagents were tested. The TransIT®- 2020 
(Ref. MIR 5404), TransIT®- LT1 (Ref. MIR 2304), TransIT®- 293 (Ref. MIR 2704), and 
TransIT®- X2 (Ref. MIR6003) from Mirus Bio (Madison, WI, USA) and Viromer® RED 
(Ref. VR-01LB-00) from Lipocalyx (Halle, Germany) were all tested. Cells were seeded 
near 75 % confluency and allowed to incubate overnight at 37 °C and 5 % CO2. The 
following day the pcDNA3-mRFP plasmid, gift from Doug Golenbock (Addgene 
plasmid # 13032), containing the mRFP1 gene encoding for the monomeric red 
fluorescent protein (mRFP1) was transfected into the cells following the manufacturer’s 
protocol for all of the transfection reagents. The plate was then incubated for 48 hours 
at 37 °C with 5 % CO2.  
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After the incubation, the wells were imaged on an ApoTome inverted 
Microscope from Zeiss (Oberkochen, Germany). The microscope was equipped with 
a Mercury HBO 100 light source. The cells were visualized with the bright-field and 
A594-TexasRed-mCherry-HcRed filters. A PlnN 10X/0.3 objective and a Hamamatsu 
sCMOS ORCA-Flash 4.0 v3 camera were used to take the images. The images were 
acquired using ZEN blue 2012 software from Zeiss and stored for further analysis. 
Images were analyzed for scale in Icy 1.9.10.0273, and figures were finalized in 
Inkscape. 
 
3.1.1.4 Opera proliferation analysis 
 
To screen multiple conditions at once, an Opera High-Content Screening 
System (Opera HCS) from PerkinElmer (Waltham, MA, USA) was used for the 
proliferation assay. Two black with clear flat bottom tissue treated plates were coated 
with Matrigel Matrix, Ref. 354248 from Corning (Corning, NY, USA). For the treatment, 
50 µL of Matrigel was pipetted into each utilized well. The plates were gently shaken 
to ensure that the Matrigel was evenly distributed through the bottom of each well. The 
Matrigel was removed, and the plates were placed in an incubator for 30 minutes at 37 
°C. The wells were then seeded with 4,000 myoblasts per utilized well, which were 
acquired via trypsinization, as described previously, from a maintained cell culture 
restarted after the 8th passage. The plates were then incubated overnight at 37 °C and 
5 % CO2. 
The following day the medium was removed. Cells were dosed with various 
combinations of drugs at various concentration per drug (depending on the 
experiment) and their corresponding controls in fresh medium. Each condition was 
performed in triplicate, and both plates were dosed identically. The plates were then 
allowed to incubate overnight at 37 °C and 5 % CO2. The following day, after 24 hours 
had elapsed from the dosing of the cells, the plates were removed from the incubator 
for further processing. Both plates had the media from their wells removed via pipetting. 
The wells in the Day 2 plate had freshly dosed media with the corresponding drug(s) 
or control media pipetted into them. The Day 2 plate was then placed back into the 
incubator for another 24 hours.  
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The Day 1 plate had its wells washed once with 50 µL of PBS per well via gentle 
pipetting. Once the PBS was removed, the cells were fixed using 50 µL of 4 % 
paraformaldehyde (PFA), made from 16 % PFA in ddH2O, Ref. 15710, from Electron 
Microscopy Science (Hatfield, PA, USA) in PBS. The cells were incubated with the 
PFA solution for 15 minutes at room temperature. Each of the wells with cells were 
then washed again with 50 µL of PBS. The cells were then stained with 50 µL of 1 
µg/mL Hoechst staining solution (made from bisBenzimide H 33342 trihydrochloride, 
Ref. 14533, from Sigma-Aldrich diluted in PBS) for one hour at RT and protected from 
light. The wells with cells were then washed two times as described previously, then 
had 100 µL of PBS added to them, and were stored at 4 °C protected from light. The 
following day the same fixing and staining procedure was performed for the Day 2 
plate.  
The plates were then imaged using the Opera HCS. The images were acquired 
after autofocusing, alignment, and plate pattern input using the software. The images 
were then analyzed by detecting nuclei and counting the number of cells and their 
associated parameters per well using the Columbus software by PerkinElmer. The 
nuclei were found using the following parameter: a common threshold of 0.4, an area 
greater than 20 µm2, a split factor of 7, an individual threshold of 0.45, and a contrast 
greater than 0.4. The population was selected by using the common filter to remove 
border objects and setting the region to nucleus. The intensity was calculated by using 
the standard mean. The cell counts and their associated parameters were then 
exported to Excel and Prism for further analysis. Each triplicate data set were tested 
for a significant change compared to the corresponding Day control using a Mann-
Whitney test. No adjustment for multiplicity was performed. 
 
3.1.1.5 Protein production for Western blot analysis 
 
For each condition, a 100 mm cell culture treated petri dish was seeded with 4 
x 106 myoblasts, from a previously amplified cell culture, in 7 mL of SM and allowed to 
incubate overnight at 37 °C and 5 % CO2. The following day, if cells were treated with 
a drug, the supernatant was removed from each Petri dish and placed in 15 mL conical 
centrifuge tube. A corresponding amount of stock drug solution was added to each 
correlating centrifuge tube to attain the desired final drug concentration. The media in 
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the tube was then returned to the original Petri dish, and the cells were then incubated 
overnight under the same conditions. If there was no drug treatment, the cells were 
allowed to incubate until near 90 % confluency.  
When the cells were ready for harvesting, one of two procedures was utilized: 
trypsinization or cell scraping. If intracellular proteins that were not sensitive to trypsin 
activity were desired, then the plates would be trypsinized and cells pelleted as 
described before. Afterward, the cells would be washed with 10 mL of ice-cold PBS 
and spun at 300 x g for 3 minutes to pellet the cell. The supernatant would be 
discarded, and the cells would be placed at 0 °C, ready for lysing. If the desired protein 
was sensitive to trypsinization, then the cell scraping method was used. After the 
medium was removed, the Petri dish was placed on ice, and the cells were gently 
washed with 5 mL of 0 °C PBS. Once the wash was removed, 1 mL of 0 °C PBS was 
added, and the dishes were scrapped. Using a pipette, the scrapped suspension was 
pipetted and dispensed back onto the dish to try and collect as many of the cells as 
possible. The cells were then transferred to a 0 °C pre-chilled 1.5 mL centrifuge tube. 
The cells were then pop-spun at 6708 x g for 10 seconds to pellet them. 
Once pelleted, the cells were treated with ≤ 150 µL lysing buffer (less if the pellet 
was smaller than usual) and processed as described before. The protein solutions 
were then quantified using a Pierce BCA Protein Assay. The samples were diluted 10 
and 20 fold in lysis buffer. The assay standard concentration gradient and the samples 
were prepared and loaded in duplicate for each quantification assay. The assay 
reading and analysis were performed as described before. 
If the protein quantity concentration was low, below 1 µg / µL, the protein 
extracts were concentrated. Acetone that was chilled to -20 °C was added at a fourfold 
higher volume (e.g., 600 µL to 150 µL of protein extract) to each protein sample. The 
samples were then vortexed and placed at -20 °C for 1 hour. The samples were then 
centrifuged at 21,000 x g for 10 minutes. The supernatant was then carefully discarded, 
and the pellets were allowed to air dry for another 30 minutes with the tube top open 
at RT. The pellets were then resuspended in lysis buffer to the desired concentration. 






The SDS-PAGEs were performed as described previously. Care was taken to 
flush out the storage buffer from each well of the gels with the MES running buffer. For 
the 15 well NUPAGE, 4-12 % Bis-Tris (Ref. NP0323) from ThermoFisher 25 µg of each 
sample was loaded (15 µL) into each well while 30 µg of each sample was loaded (20 
µL) into the ten well gels. If multiple separate Western blots were to be run on the gel, 
the sample groups were divided by 2 µL of PageRuler™ Prestained Protein Ladder 
(Ref. 26616) from ThermoFisher. 
 
3.1.1.7 Western blots 
 
After SDS-PAGE separation, the gels were transferred to the membranes as 
described previously. Once transferred and labeled, the membranes were blocked, as 
mentioned before. After Ponceau S staining and milk blocking, the membranes were 
carefully cut down the middle of the ladder. The separate pieces of the blot were placed 
into individual 50 mL conical centrifuge tubes and incubated with the primary antibody. 
The antibodies are listed below in Table 3.1. All incubations, washings, and imaging 
procedures for the Western blots were performed as previously stated. 
 
  
 Table 3.1. A list of anti-human antibodies used. The target, host, reference, manufacturer, 
the concentration used, and clonality of all of the antibodies used in the Western blots. 
 
3.1.1.8 Proteomic profile analysis 
 
Myoblasts were expanded and allowed to grow to near confluence in two tissue 
cultured treated T150 flask in an incubator set at 37 °C with 5 % CO2 to perform the 
Target Host Species Reference Manufacturer [ ] (µg/mL)Clonality 
5-HT2A Mouse MABN1595 Merck Mono 
5-HT1B Rabbit NB100-56350 R & D Systems Poly 
5-HT2B Rabbit NBP1-55429 R & D Systems Poly 
5-HT7 Rabbit PA1-41122 Invitrogen Poly 
SERT Rabbit AMT-004 Alomone Labs 0.8Poly 
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proteomic profile. The cells were then trypsinized as described before, rescued with 6 
mL of culture medium, and collected into a single 50 mL centrifuge tube. The cells were 
spun down, resuspended, and counted as before. Four separate 60 mm tissue culture 
treated Petri dishes were incubated with 2 x 106 myoblasts in 3 mL of SM. The dishes 
were then allowed to incubate overnight as previously described.  
The following day, the supernatant of three of the Petri dish were collected and 
pooled into a 15 mL centrifuge tube, and the other dishes were put on ice. The medium 
was then treated with 5-HT to a final concentration of 10 µM. The dosed medium was 
then returned to the three Petri dishes in equal volumes, and the dishes were each 
placed back in the incubator for either 15, 30, or 45 minutes. After incubation, the 
dishes were placed on ice, and the instructions for the Proteome Profiler Human 
Phospho-Kinase Array Kit from R&D Systems (Ref. ARY003B) were followed. Lysis 
was performed using 500 µL of the kit’s Lysis buffer. After lysis, the lysate’s protein 
concentration was quantified using a Pierce BCA kit as described above. The array 
was loaded with 300 µg of protein from each Petri dish. The blots were imaged as 
described before for Western blots. The digital images were quantified for intensity 
corresponding to each blot from the array using FIJI. An ROI mask over the blots was 
created, and the mean intensity of each blot was measured and exported into an array. 
The data were then exported to Excel, where ratios based on the blots’ internal controls 
were used to calculate the phosphorylation change for each target. The information 
was moved to PRISM for figure generation.  
 
3.2 Results and Discussion 
 
3.2.1 Characterizing the immortalized human myoblast cell line 
 
To understand how this cell line behaves under our culturing conditions, several 
experiments characterizing this cell line were performed. 
 
3.2.1.1 Measuring cell doubling time 
 
The cell doubling time was computed from videographic analysis of a culture. 
The myoblast culture in SM was allowed to grow undisturbed at 37 °C with 5 % CO2 
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for 72 hours. An image was taken every 10 minutes, and the population doubling time 
was determined from the iPRASENSE software to be 29 hours with a plateau period 
of about 24 hours. The growth curve of the cell culture can be seen in Figure 3.1. It is 
important to note that the myoblasts were observed to be very motile during the time 
period, which may have added variation to the cell counts. 
 
Figure 3.1. Doubling time of immortalized human myoblast cell line. Cell counts were 
taken over 72 hours of an immortalized human myoblast culture at 37 °C with 5 % CO2. The 
doubling time was 29 hours, after an initial lag phase of >24 hours. 
 
Generally, the cells presented morphologically as elongated cells, and under 
video observation, were very mobile. As cell density increased, the cells started to align 
and pack closer together while still maintaining the same morphology. At near 
confluence, the cells reduced in size and packed tightly together. At lower 
magnification, striation patterns appeared in the culture as the cell aligned in partial 
unison. This cell line did not differentiate into myotubes without changing the cell 
medium to the differentiating cell medium. The differentiating medium consisted of 
DMEM, 50 µg / mL gentamycin, and 10 µg / mL of insulin. The cells started to form 
myotubes at about four days in this culture and were left in this culture for up to 8 days. 
After 8 days, the culture was changed. Note that the culture flask was coated with 
Matrigel if the cells were differentiated to prevent the myotubes from detaching. The 





3.2.1.2 Optimal cell culture medium change procedure 
 
An experiment comparing fractional medium replacement was performed to 
understand how cell culture changes influence cell line survival. Near confluent 
cultures of the myoblast were exposed to three culturing conditions over 72 hours in 
biological triplicates in a single experiment. For the conditions, one set of culture had 
no medium changes, one had half volume medium changes every 24 hours, and the 
third had full volume medium changes every 24 hours. The cell cultures appeared to 
proliferate the best under half volume changes showing a linear increase in 
proliferation over the 72-hour culturing period. The absence of medium changes 
appeared to be slightly detrimental to cell survival, and the full volume medium change 
showed an increase over 48 hours, which leveled off at 72 hours. However, none of 
these trends were statistically significant. This experiment did not allow one to conclude 
whether how the medium is changed modified the proliferation of myoblasts over a 72 
hour incubation period (Figure 3.2). 
 
Figure 3.2. The proliferation of immortalized human myoblasts under different culture 
medium changing conditions. The proliferation of the myoblasts does not significantly 
change by varying the volume of the medium’s changing over a 72 hour culture period. The 




3.2.1.3 Optimizing transfections of human myoblast  
 
Several commercially available cell transfection reagents were tested to 
determine how to transfect the myoblasts efficiently. The TransIt-2020, TransIt-L1, 
TransIT-X2, and TransIT-293 reagents kits from Mirus and the Viromer RED kit from 
Lypocalyx were tested. The kits were used to transfect the myoblast cell line with a 
plasmid encoding for the mRFP1 protein. From these tests, qualitatively, it was 
determined that TransIT-X2 works best for transfecting myoblast from the group of 
reagents tested. All of the regents were able to transfect the myoblast with variable 
efficiency. The TransIT-293 and TransIT-X2 appeared to have the best performance, 
having the highest number of red glowing cells after the 48 hour incubation period. The 
Viromer RED reagent appeared to work the least effectively. The complete results from 




Figure 3.3. Transfection of the immortalized human myoblast cell line. The human 
immortalized myoblast cell line 48 hours after transfecting with a plasmid encoding for 
mRFP1. There is no auto-fluorescence visible in the control cells. Cells marked in red were 
considered to be positive for the expression of mRFP1. The reagent with the highest 
transfection efficiency was TransIT-X2, followed by TransIT-293, TransIT-2020, TransIT-LT1, 
and Viromer RED. The scale bars were set to 100 µm. 
 
3.2.2 5-HT increases proliferation in muscle 
 
Experimental data from the Experimental Pathology lab indicated that mice 
treated with 18 mg/kg/day (equivalent to serum levels of ~500 ng/mL274) of the 5-HT 
reuptake inhibitor fluoxetine were able to recover faster from induced muscle injury. 
Under the hypothesis that 5-HT was the instigator of this effect, its influence was 
measured in murine skeletal muscle stem cells, also known as satellite cells. The data 
from these experiments showed that satellite cells proliferated and differentiated more 
in the presence of 5-HT (data not shown). Due to the clear clinical relevance, we 
wanted to reproduce these results in a human-based system. The technical challenges 
of acquiring human satellite cells led us to use an immortalized myoblast cell line, which 
is down the differential pathway of satellite cells. 
Several concentrations ranging from 0.1 to 30 µM of 5-HT were incubated with 
cells and allowed to incubate for 3 days to identify if 5-HT had a similar effect on the 
human immortalized myoblasts. In addition to 5-HT, the myoblasts were incubated with 
0.3 to 30 µM fluoxetine to observe if there was a direct influence on the cells from this 
SSRI. The experiment was done using an Opera HCS so that multiple conditions could 
be tested at once. The cells were stained with Hoechst dye to facilitate automated 
counting. The proliferation assay showed that starting at 10 µM, 5-HT had a positive 
effect on the cell count when compared to untreated cells after one day of incubation 
(Figure 3.4A). Whether 5-HT increased proliferation or inhibited cell death after 24 
hours is unclear and warrants further experimentation. While there was a significant 
positive increase in the cell count, the samples from days two and three treated with 
5-HT had a diminutive increase in their cell counts (Figure 3.4B and 3.4C). Additionally, 
fluoxetine appeared to be toxic to the cells even at the lowest concentration. The 





Figure 3.4. Myoblast proliferation changes with various doses of 5-HT. Myoblasts were 
incubated with different concentrations of 5-HT and fluoxetine (Flx.) for 3 days and counted 
every 24 hours. The assay was performed with biological triplicates in one experiment. 
Concentrations of 5-HT at 10 and 30 µM had a significant increase in cell yield when compared 
to the control, with a 2.7 and 3.1 fold increase over the control, respectively, after one day of 
incubation (A). An increase compared to the control cells was only seen for the 10 µM 5-HT 
dosed cells at day two, and a decrease was seen in the fluoxetine-treated cells (B). After three 
days, an increase over the control cells was seen for the 10 and 30 µM samples, and a 
decrease was seen in the fluoxetine-treated samples. The asterisk indicates significant change 




3.2.3 Identification of 5-HT receptors 
 
Lysates of the cells were probed with various antibodies to identify which 
receptors are present in the immortalized myoblast cell lines. As data from the murine 
experiments indicated that 5-HT1B might be a receptor involved in the observed 
proliferation of satellite cells, this receptor’s presence was probed for in the human 
myoblast cell line. Western blot analysis showed the lysates from this cell line were 
negative for the presence of 5-HT1B regardless of the presence of 5-HT or fluoxetine 
(Figure 3.5). The control bands ran smaller than the theoretical size of 87 kDa at 
around 79kDa. A second band appears at around 72 kDa which can be attributed as 
an artifact from the trypsin cleavage of the cells, as there is an extracellular terminus 
of the construct with a trypsin cleavage site. To investigate the presence of other 
possible 5-HT receptors that could be involved in the phenotypic observation, the 5-
HT2A, 5-HT2B, and 5-HT7 receptors were probed.  
 
 
Figure 3.5. Western blot probed for 5-HT1B. Ponceau S staining is shown on the left in red, 
and the Western blot exposure is shown on the right in grey and white. The only bands present 
are at about 79 kDa and 72 kDa from the positive control, labeled PT 5-HT1B, from lysates of 
HTLA cells transfected with the PRESTO-tango 5-HTR1B construct. Where hMb is human 
myoblast cell lysate from a stock sample. Control, 5-HT, and Flx. represent lysates from hMb 





The Western blots showed that the 5-HT receptors 5-HT2A and 5-HT2B were 
present in the myoblast cell line and that the 5-HT7 receptor was not present in the 
myoblast cell line. These results were independent of whether the cells were culture in 
the presence of 5-HT or fluoxetine (Figure 3.5). The anti- 5-HT2A blot (Figure 3.6A right) 
had bands present at about 53 kDa, right at the 52.6 kDa theoretical mass of the 
receptor. Dosing with 10 µM 5-HT and 10 µM fluoxetine appears to reduce the 
expression of the receptor slightly. A similar result was seen when blotting for 5-HT2B. 
The anti- 5-HT2B blot (Figure 3.6B right) had bands at 52 kDa in the immortalized 
human myoblast cell line samples. That size corresponded well with the theoretical 
weight of 54 kDa of the 5-HT2B receptor. Dosing with 10 µM 5-HT increased the band’s 
intensity, and dosing with 10 µM fluoxetine decreased the band’s intensity. The final 
four wells containing whole skeletal muscle extracts (mSK. Mus. 1-6) showed either 
smear bands or no bands indicating poor quality of the samples. Ponceau S staining 
in red and white shows no great variation in loading between those samples. Finally, 
the anti-5-HT7 blot (Figure 3.6C right) was negative for bands in all samples except for 
a band present in the murine brain sample, which had a band near 45 kDa in size 







Figure 3.6. Western blot probed for other 5-HT receptors. On the left side, in red, Ponceau 
S stainings and Western blots analysis in grey and white on the right side. In the anti-5-HT2A 
blot (part A), bands were present in the immortalized human myoblasts (hMb.), in the C2C12 
murine immortalized myoblasts (C12), the murine skeletal muscle (mSk. Mus.), and the 
positive control murine brain extract (mBrain). The bands presented at about 53 kDa. Where 
C12 5-HT and hMb. 5-HT are cell lysates from cells dosed with 10 µM 5-HT, and C12 Flx. and 
hMb. Flx. are lysates from cells dosed with 10 µM fluoxetine. C12 Cntrl and hMb. Cntrl are the 
lysates of C2C12 cells and immortalized human myoblast samples, respectively, with only 
water added to their culture medium. In part B, the blot on the right show bands around 52 kDa 
in the human myoblast samples. The lanes corresponding to the C2C12 samples were 
negative for bands. The final four wells containing whole skeletal muscle extracts (mSK. Mus. 
1-6) showed either smear bands or no bands. In part C, all lanes except for the control of 
murine brain lysate (mBrain) were negative for the 5-HT7 receptor. The mBrain band appears 
near 45 kDa, where 48 kDa is the theoretical mass of 5-HT7. 
 
The presence of 5-HT2A and 5-HT2B is interesting as these receptors have been 
described to be expressed, in conjunction along with 5-HT1B, during the induced 
differentiation of the murine 1C11 neuroectodermal cell line275. That cell line 
differentiates in the presence of butyryl-cAMP, which permeates the cell membrane 
and activates cAMP-dependent kinases. As 5-HT2A and 5-HT2B are present in the 
myoblast cell line and are involved in cAMP regulation, it would be of interest to 
investigate if they are also involved in the differentiation of myoblasts. Additionally, it 
begs the question of whether the myoblasts express 5-HT1B under certain conditions. 
Additionally, the presence of SERT was confirmed to be present in the human 
myoblast cell line (on the right in Figure 3.7). Bands at near 78 kDa in the C2C12 and 
human myoblast cell lines correlated well with the theoretical weight of SERT of 70 
kDa for isoform 1 and 74 kDa for isoform 2. The addition of 10 µM 5-HT to the 
incubation medium of C2C12 cells (C12 5-HT), when comparing to the loading of the 
sample seen in the Ponceau S staining (on the left in red), did not appear to change 
the level of SERT. The band that appears to be expressed highest was seen in the 
human myoblast cell line (hMb). The incubating peptide (Peptide) was too small at 1.4 
kDa to visualize on this Western blot analysis, and the murine brain lysate (mBrain) did 






Figure 3.7. Western blot analysis against SERT. The anti-SERT antibody incubation on the 
right in grey and white, and the Ponceau S staining on the left in red. The blot showed bands 
at near 78 kDa in the wells with lysates from C2C12 control (C12 Cntrl), C2C12 cells exposed 
to 5-HT (C12 5-HT), and human myoblast cell lines (hMb.). The strongest band appears in the 
well corresponding to the human myoblast cell line. The incubating peptide (Peptide) and the 
murine brain lysate (mBrain) were negative for bands. 
 
With the presence of SERT in myoblasts, the non-receptor mediated function of 
5-HT or the intracellular reception of 5-HT may be in play during the promotion of 
proliferation in these myoblasts. Serotonylation has been reported to affect histones 
and increase proliferation276 making this an interesting possibility of a mode of action 
of 5-HT. Additionally, with the discovery of 5-HT receptors on the mitochondrial 
membranes74, intracellular levels of 5-HT may also be correlated to our observed 
phenomenon. Both of these two possibilities warrant further experimental exploration. 
 
3.2.4 Cellular mechanism modulated by 5-HT 
 
 A proteome profiler human phospho-kinase array assay was performed using 
the myoblasts to investigate the mechanism behind the increase in the human 
myoblasts’ cellular yield under the in vitro exposure of 5-HT. The assay probed for the 
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phosphorylation of 43 kinases and the expression of two other related proteins. The 
assay was performed as a time series with exposure to 5-HT over 15, 30, and 45 
minutes to understand the potential kinetics involved in the myoblast’s response to 5-
HT. The assay revealed several kinases whose phosphorylation were up-regulated 
during the exposure of 5-HT, showed others whose phosphorylation was repressed, 
and some kinases that had dynamic phosphorylation events over the time course. 
Generally, changes in phosphorylation peaked after 30 minutes of exposure to 5-HT. 
The kinases with the greatest increase in phosphorylation were mitogen-activated 
protein kinase 3 /1 (ERK1/2), glycogen synthase kinase-3 alpha/beta (GSK-3α/β), and 
lysine deficient protein kinase 1 (WNK1). All three showed a near threefold increase in 
phosphorylation over the time 0-minute time point. 
Interestingly, ERK1/2 and GSK-3α/β showed this increase after 15 minutes, 
while WNK1 phosphorylation peaked after 30 minutes of 5-HT exposure. Of the kinase 
targets, only heat shock protein beta-1 (HSP27) phosphorylation was markedly 
repressed throughout the entire time series. Data from the assay revealed 14 targets 
that had over a 1.5 fold increase in observed phosphorylation over the 0 minute time 
point.  
Several of these targets were members of known pathways involved in 
proliferation. The signaling pathways whose components’ phosphorylation appeared 
to be up-regulated the greatest in the assay were the classical MAP kinase pathway 
along with the sub branched mitogen-activated protein kinase 14 (p38α) pathway 
(Figure 3.8), the mammalian target of rapamycin (mTOR) pathway, and parts of the 
Wnt pathway (Figure 3.9). 
It can be seen that multiple parts of the p38α pathway had an increase in 
phosphorylation, leading to the activation of this cascade ending with the cyclic AMP-
responsive element-binding protein 1 (CREB) upregulating cell proliferation (Figure 
3.8A). Correspondingly, other p38α mediated phosphorylation events showed a 
change in phosphorylation. Notably, the HSP27 protein showed a prolonged decrease 
in phosphorylation (Figure 3.8B), allowing for its oligomerization and action as its 
capacity as a chaperone. HSP27 oligomerization is contradictory to the canonical 
activity of phosphorylated p38α and would be an interesting area for further 
experimentation after validation of this observation. For this pathway, the effect of 5-
HT appears to be temporal, with most of the peak phosphorylation events appearing 
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at 30 minutes and dissipating at 45 minutes. In the greater MAP kinase pathway, 
ERK1/2 showed a 3 fold increase in phosphorylation within the first 15 minutes of being 
exposed to 5-HT (Figure 3.8D). ERK1/2 phosphorylation may be additive or the main 
driver of the downstream phosphorylation of CREB (Figure 3.8C). Temporally, ERK1/2 
increased phosphorylation is maintained throughout the time series, while CREB’s, as 
mentioned above, peaks at 30 minutes of exposure (Figure 3.8D). The other activated 
pathways had similar behaviors. 
Both the mTOR and the Wnt pathway showed an increase in phosphorylation 
events. In the mTOR kinase pathway, two AKT-regulated cascades showed an 
increase in phosphorylation (Figure 3.9A). Interestingly, the WNK1 protein showed a 
high phosphorylation increase, about 2.5 fold, peaking at 30 minutes. WNK1 has been 
linked to cell proliferation via dual specificity mitogen-activated protein kinase 5 (MEK5) 
activation of mitogen-activated protein kinase 7 (ERK5)277 and C2C12 cell hypertrophy 
via forkhead box protein O4 (FOXO4)278. While the phosphorylation of WNK1 had been 
linked to RAC-alpha serine/threonine-protein kinase (AKT)279, the vast difference 
between the changes in phosphorylation between the two may be due to other 
mechanism acting on it, or it may simply be a reflection of the high kinase efficiency of 
AKT on WNK1. Follow-up studies probing by which mechanism WNK1 is acting on the 
cell when stimulated by 5-HT exposure is needed to understand WNK1’s role under 






Figure 3.8. Proteomic profiler results of p38 and MAP kinase pathways. The mapped out 
changes in phosphorylation of proteins in the p38α (A) and MAP (C) kinase pathways at the 
30 minute time point. In the pathway, p38α phosphorylation leads to phosphorylation of p53 
and MSK1/2, and mediated phosphorylation of HSP27. MSK1/2 catalyzed the phosphorylation 
of CREB, which can lead to the activation of proliferating genes. In the p38α pathway, there 
was a marked increase of over 1.5 fold in the phosphorylation of p38α (T180/Y182), MSK 1/2 
(S376/S360), and CREB (S133) shown in dark green. A noted increase in p53 (S392) 
phosphorylation in light green and a noted decrease in HSP27 phosphorylation in light red. In 
the time course (B), there was increased phosphorylation through 15” (purple), 30” (red), and 
45” (blue) exposure to 10 µM 5-HT in the medium for p38α and p53. MSK1/2 and CREB 
showed increases after 15”, peaking at 30”, and with ebbing increases in phosphorylation after 
45” exposures. HSP27 showed a sustained decrease throughout the time series. In the MAP 
kinase pathway, cAMP can stimulate PKA mediated ERK1/2 (T202, Y204/T185, Y187) 
phosphorylation via Rap1 and RafA phosphorylation of MEK1/2. DAG may do the same via a 
PKC mediated RafB phosphorylation of MEK1/2. Phosphorylated ERK1/2 mediates CREB 
phosphorylation via the phosphorylation of RSK1/2/3. ERK1/2 and CREB were markedly 
increased, with ERK1/2 showing a 3 fold increase seen in dark green. RSK1/2/3 showed a 
moderate increase in phosphorylation. Temporally (D), the increased phosphorylation of 
ERK1/2 was maintained throughout the time series. 
 
Aside from WNK1, all of the proteins phosphorylated via AKT mediated 
regulated ribosomal protein S6 (RPSS6) protein synthesis, represented in the assay, 
showed an increase in phosphorylation after exposure to 5-HT. However, the increase 
in phosphorylation is not very strong being below 1.5 fold. The exception being the 
mTORC1 repressor 5'-AMP-activated protein kinase subunit alpha 2 (cAMPK α2), 
which had increased phosphorylation of 1.5 fold (Figure 3.9B). When looking at the 
temporal aspect of this pathway, it is visible that AKT1/2/3 phosphorylation increases 
modestly after 15 minutes. The inhibiting enzyme proline-rich AKT1 substrate 1 
(PRAS40), regulated by AKT1/2/3, also shows a modest increase in phosphorylation, 
decreasing its inhibitory effect on mammalian target of rapamycin complex 1 
(mTORC1). However, mTORC1 shows the opposite effect than expected, with a 
decrease in phosphorylation after 15 minutes. 
Interestingly the downstream player ribosomal protein S6 kinase beta-1 (p70s) 
already showed an increase at that period. The negative regulation may result from 
not catching the increase in phosphorylation in this assay, or it may be due to an over-
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response from the increase in AMPKα2 phosphorylation, which also occurred at that 
time point. Further increasing the complexity of these results is that at 30 minutes, 
mTORC1 shows an increase in phosphorylation, as do its downstream constituencies. 
However, after 45 minutes of exposure, all pathway members except WNK1 returned 
to their hemostatic phosphorylation levels. The fluctuations of phosphorylation of 
mTORC1 bring an interesting question of regulation and, if verified, merits extra 
consideration. 
The Wnt pathway, known to be involved in embryonic development, also had 
members of its pathway show strong changes with exposure to 5-HT (Figure 3.9C). 
The phosphorylation of GSK3-α/β increased 3 fold and stayed highly phosphorylated 
over the entire time series (Figure 3.9D). β-catenin showed an increase in the amount 
of phosphorylation, which peaked after 15 minutes of exposure to 5-HT and remained 
elevated, to a lesser extent, over the time series. The β-catenin observations are 
consistent with GSK-3α/β phosphorylation leading to the inhibition of the 
phosphorylation and subsequent destruction of β-catenin. Of note, β-catenin has been 
linked to transcription factor (TCF) / lymphoid enhancer-binding factor (LEF) based 
regulation of proliferation280 and shown to directly interacting with myoblast 
determination protein (MYOD) when promoting differentiation in myoblast281. With 
GSK-3α/β having been demonstrated to be a target of phosphorylation by PKA282, a 
direct link between the 5-HT4,6,7 may exist. Whether any of these receptors are present 
in myoblasts and cause an increase of cAMP with 5-HT exposure is worth exploring. 






Figure 3.9. Proteomic profiler results of mTOR and Wnt kinase pathways. The mapped 
out changes in phosphorylation of kinases in the mTOR (A) and Wnt (C) kinase pathways at 
the 30 minute time point. In the pathway AKT1/2/3 (T308) phosphorylation leads to 
phosphorylation of WNK1 (T60), which leads to a phosphorylating cascade that leads to ERK5 
mediated proliferation. AKT1/2/3 phosphorylation of PRAS40 (T246) inhibits the negative 
regulation of mTORC1 (Y1086), leading to protein synthesis via the phosphorylation of p70S6 
(T421/S424), which activates RPS6. mTORC1 is also negatively regulated by a 
phosphorylated AMPKα2. After 30 minute incubation with 10 µM 5-HT, WNK1 showed an 
increase in phosphorylation of about 2.5 fold, and AMPKα2 showed a 1.5 fold increase, seen 
in dark green. AKT1/2/3, PRAS40, mTORC1, and p70S6 showed a moderate increase in 
phosphorylation, seen in light green. During the time series (B), only WNK1 phosphorylation 
was sustained through 45” of exposure. The mTORC protein showed a dynamic change in 
phosphorylation fluctuation with an initial decrease at 15”, an increase at 30”, and a return to 
homeostatic condition at 45”. All other pathway members showed an increase at 15” and 30” 
and a return to or near to homeostatic levels at 45”. In the Wnt pathway (C), the β-catenin 
inhibitor GSK3α/β can be inhibited by cAMP via PKA phosphorylation. Active β-catenin can 
drive proliferation via TCF/LEF or differentiation with directly interacting with MYOD. The 
GSK3α/β protein showed a near 3 fold increase in phosphorylation, and β-catenin showed an 
increase of over 1.5 fold after 30” 5-HT treatment, seen in dark green. Over the time series, 
both showed increased phosphorylation throughout the time series with a tapering of the effect 
seen at 45” (D). 
 
Of the kinases that showed increased phosphorylation the Src, which stands for 
sarcoma, family kinases Lck/Yes novel tyrosine kinase (LYN) and lymphocyte-specific 
protein tyrosine kinase (LCK) showed greater than a 1.5 fold increase in 
phosphorylation along with the signal transducer and activator of transcription (STAT)s 
2,3,5a/b, and 6 (Figure S1 located in Annex I). The LYN kinase located at the plasma 
membrane is activated via various surface receptors and has been linked to PI3K 
mediated AKT phosphorylation in cancer283. Thus, it may be involved in the mTOR 
pathway during 5-HT exposure. The LCK kinase is known to phosphorylate PI3K and 
PLC, potentially linking the kinase to the MAP kinase pathway and the mTOR pathway, 
respectively, to the corresponding 5-HT receptors. If the 5-HT receptors or other 
receptor causes LYN and LCK activation in this assay needs further study. Regarding 
the activated STATs in this pathway, STAT2, STAT3284,285, and STAT5286 have been 
linked to myoblast proliferation where STAT3 phosphorylation has already been 
associated with 5-HT2A receptor activity150 in rat fetal myoblasts. STAT 6 has been 
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connected with IL-4 stimulated myoblast fusion287. How STAT2, 5, and 6 are related to 
5-HT remains to be discovered. 
 
Overall from this preliminary data, it appears that 5-HT has an active role in the 
proliferation of myoblasts and may play a role in differentiation. We have seen that 
there is indeed an increase of myoblast numbers when they are exposed to moderate 
concentrations (10-30 µM) of 5-HT. The cause of the higher cell count, which may stem 
from 5-HT interacting with its receptor, the intracellular metabolism of 5-HT, 
serotonylation, or another undefined mechanism, warrants further experimentation. It 
appears from the western blot information that we have the 5-HT2A and 5-HT2B 
receptors and SERT present in the cells during homeostasis, in the human 
immortalized myoblast cell line. Data from the proteome profiler assay indicates that 
5-HT has at least an acute effect on cell signaling, and it could be interesting to 
understand the signaling modifications of longer 5-HT exposure. Additionally, based 
on the proteome information, it would not be surprising to find either 5-HT4,6,7 to be 
present in the myoblast. 
Interestingly, there are hints that 5-HT1B should also be present. However, the 
preliminary data was not successful in proving 5-HT1B was expressed in the myoblast. 
This receptor may be expressed during specific conditions not reproduced in these in 
vivo conditions. It may be that the receptor is expressed during hypoxia, the 
inflammatory response, or other specific physiological conditions. Regarding the 
mechanistic action of 5-HT in the proliferation of myoblast, it appears to be multi-
fronted. There is a strong hint that CREB via ERK1/2, β-catenin via GSK3α/β, and 
WNK1 mediate proliferation in myoblasts that have been treated 5-HT. However, 
further experimentation would need to be performed to verify this data, figure out the 
primary pathway, and determine if some of the pathways are redundant. The picture 
of proliferation around the action of 5-HT is forming and may be exploited to develop 






4 Conclusion and Perspectives 
 
The molecule 5-HT has been mostly associated with being a neurotransmitter. 
The connection of 5-HT as a neurotransmitter hides the fact that 5-HT acts in a greater 
capacity. It can be found throughout the kingdoms of life, where it has a variety of 
actions. Within the human body, 5-HT has a plethora of purposes that we do not yet 
fully understand. We do know that the molecule is found throughout the body, including 
but not limited to: the gut, nervous system, liver, bones, smooth muscle, and skeletal 
muscles. Due to its broad distribution, it is not surprising that 5-HT is involved in several 
pathologies. 
Interestingly, along with 5-HT’s multiple functional capacities, the mechanism 
by which it acts is also very diverse. In the traditional canonical function, 5-HT interacts 
with an entire family of receptors, with each subfamily of the receptors perform a variety 
of tasks. In conjunction, 5-HT has non-canonical activities. It can be added to proteins 
as a post-translational modification, acts as a radical scavenger, and influences 
melatonin metabolism. While much about 5-HT’s functions have been elucidated, other 
duties of this molecule will likely be discovered in the future. 
In this body of work, two frontiers of 5-HT were probed: the role of the N-
terminus of the 5-HT1B receptor in interacting with 5-HT was determined, and the role 
of 5-HT in skeletal muscle regeneration was explored. Through point mutation studies, 
it was determined that the two putative N-glycosylation residues N24 and N32 of the 
5-HT1B receptor modulated the potency of 5-HT. The potency of 5-HT was reduced 
twenty-fold in the double mutant, which removed the two glycosylation sites. 
Fascinatingly, other orthosteric agonists did not show a strong change in modulation 
in the double mutant. This observation's interest was compounded by the structural 
homology of one of these agonists, sumatriptan, with 5-HT. When we probed into the 
observed discrepancy, we discovered that the primary amine of 5-HT, which is not 
present in sumatriptan, is the responsible functional group that interacts with the N-
terminus of the 5-HT1B receptor. MD simulations suggested that both 5-HT and 
sumatriptan do interact with the N-terminus. From the data, we propose that the N-
terminus interacts with 5-HT in a fly-casting-like manner. This mechanism generates a 
higher local concentration of 5-HT and thereby increasing the observed potency of 5-
HT. However, sumatriptan’s robust interaction causes the ligand to interfere with this 
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mechanism, negating any observable potency increase. Beyond this work, the 
physiological role of 5-HT in skeletal muscle was also considered.  
From the Experimental Pathology lab, previous work in mice hinted at 5-HT 
having regenerative properties in injured skeletal muscle. To understand if this was a 
translational property, we looked for signs of 5-HT in a human skeletal muscle model 
system. Culturing of 5-HT treated cells showed an increase in cell counts compared to 
untreated cells, and the serotonin receptors 5-HT2A and 5-HT2B, along with the 5-HT 
transporter SERT, were discovered in human myoblasts. Interestingly, 5-HT2A has 
been found in erythroid progenitor cells, where its expression is upregulated during 
differentiation288. Additionally, it has been found in hepatic stellate cells, where its 
expression is upregulated during senescence172. Along with our discovery of 5-HT2A in 
myoblasts, it appears that 5-HT and the 5-HT2A receptor have a fundamental role in 
stem cell biology. Further work probing proliferation and differentiation with 5-HT2A 
inhibitors and a 5-HT2A knockout cell line could corroborate our observation. 
Further, we looked into the causative mechanistic role of 5-HT in increasing the 
cell count. A kinase phosphorylation assay showed that the MAP kinase, mTOR, and 
Wnt pathways, which signal proliferation and differentiation, showed increased 
phosphorylation when cells were exposed to 5-HT. The assay also demonstrated an 
acute effect of 5-HT, which appears to peak at 30 minutes of exposure. In all, it is clear 
that a 5-HT regulatory pathway is present in human myoblasts, and it appears that they 
are involved in promoting proliferation. 
This work is another example of the ever-expanding discovery of the utilization 
of 5-HT by living organisms. Understanding that extracellular domains of a 5-HT 
receptor, with transient post-translational modifications, can modulate the potency of 
its ligand, the possibility of regulatory mechanism changing the local effect of 5-HT 
based on the physiological need of the tissues has been revealed. For example, during 
muscle injury, it may be the case that the immune system response releases enzymes 
that cause transient modification to the N-terminal glycans and changes the sensitivity 
of the receptors, and thus the cells, to 5-HT. As for the functional and mechanistic 
actions of 5-HT, our evidence points to the promotion of an increase in myoblast 
proliferation seen both through proliferation assays and proteomic pathway analysis. 
However, the increase in myoblast numbers in our assays may also reflect 5-HT 
promoting cell survival, which is an avenue that needs to be further explored. In reality, 
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5-HT likely has a mix of proliferative, protective, and differentiative properties. To better 
understand the scope of the action of 5-HT on skeletal muscle, more work is required. 
The work presented has some limitations. The studies on the 5-HT1B receptor 
were done in vitro, and the change in potency may not translate into living systems. 
Additionally, the assays were performed in cells derived from HEK293 cells. Since 
glycans’ constituency reflects which cell produces them, it is unclear whether the 
observed effect is universal through all cell types. Additionally, the nature of the 
interaction of 5-HT with the N-terminus needs to be confirmed experimentally. 
Understanding if the modulation in potency holds between species is also a limitation. 
As for the 5-HT pathway, work identifying the receptors in primary samples and 
confirming the proteomic profiler information would give greater weight to the role of 5-
HT in skeletal muscle regulation. While this work has its limitations, it does present 
various interesting future outlooks. 
The first half of the thesis identified that the primary amine of 5-HT is the moiety 
that interacts with the N-terminus. This information can be useful to drug designers in 
synthesizing potent agonists of the 5-HT1B receptor. Continuing with the notion of drug 
design, if the receptor’s glycosylation varies per cell type and this variation is identified, 
it may be possible to generate pharmacologics that selectively target the same receptor 
in a specific cell type. It would also be of use to identify the constituency of the glycans 
of this receptor in other species to see what part of the glycan tree is conserved and 
fundamental to the action of the receptor. Finally, as N-terminal glycosylation is 
conserved through the 5-HT family receptors, it would be prudent to understand their 
functions for each of these receptors to design pharmaceuticals specific for each 
receptor type. 
In the second half of the thesis, we began to understand what 5-HT modulates 
in human myoblasts. This work’s natural continuation would be to verify the 
observations from the proteome profiler in primary samples. Next, it would be useful to 
pharmacologically inhibit the proliferation by disrupting the identified pathways and 
then confirming the observed results with genetic knockout cell lines. Understanding 
the pathways involved in myoblast proliferation and being able to manipulate them has 
multiple applications. This knowledge may lead to the development of new 
pharmaceuticals to aid in muscle healing from trauma or regular exercise. It may also 
be utilized to help grow muscle tissue for cultured “clean” meat applications. In all, this 
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N24A N32A Used the N32A primers on the N24A mutant 
Table 1. Primes for the mutagenesis of the PRESTO-Tango 5-HT1B constructs. Primers 
are displayed with point mutations causing changes highlighted in red text. 
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GPCR Drug Name 
Atypical chemokine receptor 3 Plerixafor 
Adhesion G protein-coupled receptor G3 Beclometasone dipropionate 
Adenosine receptor A1 Adenosine 
Adenosine receptor A2a Regadenoson 
Adenosine receptor A2b Theophylline 
Adenosine receptor A3 Nicardipine 
Alpha-1A adrenergic receptor Oxymetazoline 
Alpha-1B adrenergic receptor Prazosin 
Alpha-1D adrenergic receptor Prazosin 
Alpha-2A adrenergic receptor Apraclonidine 
Alpha-2B adrenergic receptor Dexmedetomidine 
Alpha-2C adrenergic receptor Dexmedetomidine 
Beta-1 adrenergic receptor Acebutolol 
Beta-2 adrenergic receptor Pindolol 
Beta-3 adrenergic receptor Mirabegron 
Type-1 angiotensin II receptor Candesartan 
Vasopressin V1a receptor Vasopressin 
Vasopressin V1b receptor Vasopressin 
Vasopressin V2 receptor Vasopressin 
B1 bradykinin receptor Icatibant 
B2 bradykinin receptor Icatibant 
Calcitonin receptor Calcitonin 
Extracellular calcium-sensing receptor Etelcalcetide 
Cholecystokinin receptor type A Ceruletide 
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GPCR Drug Name 
Gastrin/cholecystokinin type B receptor Pentagastrin 
C-C chemokine receptor type 4 Plerixafor 
C-C chemokine receptor type 5 Maraviroc 
Muscarinic acetylcholine receptor M1 Biperiden 
Muscarinic acetylcholine receptor M2 Propantheline 
Muscarinic acetylcholine receptor M3 Umeclidinium 
Muscarinic acetylcholine receptor M4 Acetylcholine 
Muscarinic acetylcholine receptor M5 Acetylcholine 
Cannabinoid receptor 1 Nabilone 
Cannabinoid receptor 2 Nabilone 
Corticotropin-releasing factor receptor 1 Corticorelin ovine triflutate 
C-X-C chemokine receptor type 4 Plerixafor 
Cysteinyl leukotriene receptor 1 Zafirlukast 
Cysteinyl leukotriene receptor 2 Zafirlukast 
D(1A) dopamine receptor  Dopamine 
D(2) dopamine receptor  Dopamine 
D(3) dopamine receptor Dopamine 
D(4) dopamine receptor Dopamine 
D(1B) dopamine receptor  Dopamine 
Endothelin-1 receptor Ambrisentan 
Endothelin receptor type B Bosentan 
Proteinase-activated receptor 1 Vorapaxar 
Free fatty acid receptor 1 Rosiglitazone 
fMet-Leu-Phe receptor  Cyclosporine 
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GPCR Drug Name 
Follicle-stimulating hormone receptor Human follicle stimulating hormone 
Gamma-aminobutyric acid type B receptor subunit 1 Baclofen 
Gamma-aminobutyric acid type B receptor subunit 2 Baclofen 
Glucagon receptor Glucagon 
Growth hormone-releasing hormone receptor Sermorelin 
Glucagon-like peptide 1 receptor Lixisenatide 
Glucagon-like peptide 2 receptor Teduglutide 
Gonadotropin-releasing hormone receptor Abarelix 
G-protein coupled bile acid receptor 1 Deoxycholic acid 
G-protein coupled estrogen receptor 1 Estradiol 
G-protein coupled receptor 143 Levodopa 
N-arachidonyl glycine receptor Dronabinol 
G-protein coupled receptor 35 Bumetanide 
G-protein coupled receptor 55 Dronabinol 
Ovarian cancer G-protein coupled receptor 1 Lorazepam 
Hydroxycarboxylic acid receptor 1 Sodium oxybate 
Hydroxycarboxylic acid receptor 2 Acipimox 1 
Hydroxycarboxylic acid receptor 3 Nicotinic acid 
Orexin receptor type 1 Suvorexant 
Orexin receptor type 2 Suvorexant 
Histamine H1 receptor Cetirizine 
Histamine H2 receptor Betazole 
Histamine H3 receptor Pitolisant* 
Histamine H4 receptor Clozapine 
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GPCR Drug Name 
5-hydroxytryptamine receptor 1A Vilazodone 
5-hydroxytryptamine receptor 1B Sumatriptan 
5-hydroxytryptamine receptor 1D Frovatriptan 
5-hydroxytryptamine receptor 1E Asenapine 
5-hydroxytryptamine receptor 1F Eletriptan 
5-hydroxytryptamine receptor 2A Asenapine 
5-hydroxytryptamine receptor 2B Methysergide 
5-hydroxytryptamine receptor 2C Methysergide 
5-hydroxytryptamine receptor 4 Cisapride 
5-hydroxytryptamine receptor 5A Ergotamine 
5-hydroxytryptamine receptor 6 Amoxapine 
5-hydroxytryptamine receptor 7 Lurasidone 
Lutropin-choriogonadotropic hormone receptor Choriogonadotropin alfa 
Melanocyte-stimulating hormone receptor Corticotropin 
Adrenocorticotropic hormone receptor Corticotropin 
Melanocortin receptor 3 Corticotropin 
Melanocortin receptor 4 Corticotropin 
Melanocortin receptor 5 Corticotropin 
Motilin receptor Erythromycin 
Mas-related G-protein coupled receptor member X1 Chloroquine 
Melatonin receptor type 1A Ramelteon 
Melatonin receptor type 1B Tasimelteon 
Neuropeptide Y receptor type 4 Niclosamide 
Neurotensin receptor type 2 Levocabastine 
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GPCR Drug Name 
Delta-type opioid receptor Naltrexone 
Kappa-type opioid receptor Anileridine 
Mu-type opioid receptor Alfentanil 
Oxytocin receptor Oxytocin 
P2Y purinoceptor 1 Suramin 2 
P2Y purinoceptor 11 Suramin 2 
P2Y purinoceptor 12 Cangrelor 
P2Y purinoceptor 13 Cangrelor 
P2Y purinoceptor 2 Suramin 2 
P2Y purinoceptor 6 Suramin 2 
Prostaglandin D2 receptor Treprostinil 
Prostaglandin D2 receptor 2 Indomethacin 
Prostaglandin E2 receptor EP1 subtype Prostaglandin E1 
Prostaglandin E2 receptor EP2 subtype Prostaglandin E2 
Prostaglandin E2 receptor EP3 subtype Misoprostol 
Prostaglandin E2 receptor EP4 subtype Treprostinil 
Prostaglandin F2-alpha receptor Latanoprost 
Prostacyclin receptor Epoprostenol 
Parathyroid hormone 1 receptor Teriparatide 
Parathyroid hormone 2 receptor Teriparatide 
Sphingosine 1-phosphate receptor 1 Fingolimod 
Sphingosine 1-phosphate receptor 2 Fingolimod 
Sphingosine 1-phosphate receptor 3 Fingolimod 
Sphingosine 1-phosphate receptor 4 Fingolimod 
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GPCR Drug Name 
Sphingosine 1-phosphate receptor 5 Fingolimod 
Secretin receptor Secretin 
Smoothened homolog Sonidegib 
Somatostatin receptor type 1 Pasireotide 
Somatostatin receptor type 2 Lanreotide 
Somatostatin receptor type 3 Pasireotide 
Somatostatin receptor type 4 Octreotide 
Somatostatin receptor type 5 Lanreotide 
Succinate receptor 1 Sodium succinate 
Trace amine-associated receptor 1 Dexamfetamine 
Substance-P receptor Aprepitant 
Thromboxane A2 receptor Iloprost 
Thyrotropin-releasing hormone receptor Protirelin 
Thyrotropin receptor Thyrotropin 
 
Table 2. Table of drugs that target GPCR. A list of GPCRs with an example of an FDA 




Figure S1. Proteome profiler time-series results of human immortalized myoblast 
exposed to 5-HT. Fold change compared to the internal controls of phosphorylation for each 
time point. Time exposed to 10 µM 5-HT time point 0” is in green, time point 15” is in purple, 
time point 30” is in red, and time point 45” is in blue. “p-” in front of the protein name indicates 
recognition of phosphorylated kinase. Where AMPKα1 (T308) is 5'-AMP-activated protein 
kinase catalytic subunit alpha-1; Chk-2 (T68) is checkpoint kinase 2; c-Jun (S63) is 
transcription factor AP-1; EGF R (Y1086) is epidermal growth factor receptor; eNOS (S1177) 
is endothelial nitric oxide; FAK (Y397) is focal adhesion kinase 1; Fgr (Y412) is fibroblast 
growth factor receptor 1; Fyn (Y420) is the tyrosine-protein kinase Fyn; Hck (Y411) is the 
tyrosine-protein kinase HCK; Hsp60 is 60 kDa heat shock protein; JNK1/2/3 (T183/Y185, 
T221/Y223) are mitogen-activated protein kinase 8/9/10; Lyn (Y397) is the tyrosine-protein 
kinase, Lyn; p27 (T198) cyclin-dependent kinase inhibitor 1B; p531 (S15) and p532 (S46) are 
cellular  tumor antigen p53; PDGF Rβ (Y751) is platelet-derived growth factor receptors beta; 
PLC-γ1 (Y783) is phospholipase C, gamma 1; PYK2 (Y402) is protein tyrosine kinase 2-beta; 
Src (Y419) is the C-terminal Src kinase; STAT2 (Y689) is signal transducer and activator of 
transcription 2; STAT31 (S705) and STAT3 (Y727)2 are signal transducer and activator of 
transcription 3; STAT5a/b (Y699) is signal transducer and activator of transcription 5a/b; 
STAT5b (Y699) is signal transducer and activator of transcription 5b; STAT6 (Y641) is signal 
transducer and activator of transcription 6; and Yes (Y426) is the proto-oncogene tyrosine-







An overview of metadynamics 
 Entrapment in local free energy minima is a common occurrence when 
performing MD simulations of complex biological systems. This entrapment hinders 
MD simulations’ ability to fully explore all of the conformational landscape during the 
simulations’ typical duration, typically several microseconds. We utilized 
metadynamics (MetaD)249,250 to overcome this issue in our production simulations.  
MetaD is an enhanced sampling technique that introduces a bias potential that 
discourages systems from retracing areas of the conformational landscape that have 
already been explored during the simulation. The MetaD history-dependent bias 
potential 𝑉  is composed of several specific collective variables (CVs). The CVs are 
functions 𝑆 of the microscopic coordinates 𝑹 of the system 𝑆(𝑹) =  𝑆 (𝑹), . . . , 𝑆 (𝑹) . 
CVs are coarse-grain descriptors of the system that can discriminate between the most 
relevant free-energy minima and encode the system’s slowest modes. The modes are 
composed of high free-energy barriers and benefit the greatest from the acceleration 
stemming from the bias potential. The MetaD bias potential is expressed as a sum of 
Gaussians deposited along the trajectory in the CVs space: 
𝑉 (𝑆, 𝑡)= 𝑑𝑡
𝒕
𝟎
 𝜔(𝑡 )∙ exp −
𝑆 (𝑹)−𝑆 𝑹(𝑡 )
2𝜎
    (1) 
 
where 𝑡 is the simulation time, 𝜎  is the Gaussian width of the i-th CV, and 𝜔 is the 
deposition rate of the bias potential. Usually, Gaussians are added to the simulation 
with a discrete and constant deposition stride 𝜏. Therefore, the deposition rate 𝜔 is 
expressed as the ratio between the Gaussian height 𝑊 and the deposition stride 𝜏.  
In the well-tempered variant289, the Gaussian height decreases with the simulation time 
as: 
𝑊(𝑡) = 𝑊 ∙ exp −
𝑉 (𝑆, 𝑡)
𝑘 𝛥𝑇




where 𝑘  is the Boltzmann constant, 𝑊  is the initial Gaussian height, and 𝛥𝑇 is an 
input parameter with the dimension of a temperature. 𝛥𝑇 can be used to limit the 
exploration to the relevant regions of the CV space and thus limiting the visitation to 
excessively high free-energy areas. This parameter is often expressed in terms of the 




     (3) 
 
where 𝑇 is the temperature of the system. MetaD has two advantages: it accelerates 
the sampling, and it enables the direct reconstruction of the equilibrium free-energies 
from the bias potential simultaneously, following: 
 
𝑉 (𝑆, 𝑡 → ∞) =  −
𝛥𝑇
𝑇 + 𝛥𝑇
∙ 𝐹(𝑆) + 𝐶     (4) 
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